TITLE PAGE 
 
Clinical Trial Protocol  747-207 
OBETICHOLIC ACID  
 
A Phase 2, Randomized, Double-Blind, Placebo-Controlled,  Dose-Finding, 
Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in 
Subjects with P rimary Sclerosing Cholangitis  
 
Version 5:  [ADDRESS_21045] Number:  2014-002205-38 
 
Sponsor 
Intercept Pharmaceuticals, Inc.  
4760 Eastgate Mall  
San Diego, CA [ZIP_CODE] 
[LOCATION_003] 
 
TEL:  +[PHONE_349]  
FAX:  +[PHONE_350] 
 
CONFIDENTIAL  
The information contained herein is the property of Intercept Pharmaceuticals, Inc. and may not 
be reproduced, published, or disclosed to others without written authorization of Intercept 
Pharmaceuticals, Inc.  
 

Protocol741-2O7 Version 5: l8 Mar 2016
Page 2
SPONSOR'S APPROVAL OF THE PROTOCOL
Reviewed and Approved by:
[CONTACT_22051], PhD
Vice President, Clinical Development
Intercept Pharmaceuticals, lnc.6n*u,
Confi dential and Proprietary
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 3 
Confidential and Proprietary    INVESTIGATOR â€™S AGREEMENT 
 
I have received and read the current version of the Investigator â€™s Brochure (IB) for obeticholic 
acid (OCA) and this Protocol 747-207.  Having fully considered all the information available, I 
agree that it is ethically justifiable to give OCA to selected subject s according to this protocol. 
I understand that all information concerning OCA supplied to me by [CONTACT_1034] , Intercept 
Pharmaceuticals, Inc., and/or its agents in connection with this trial and not previously published 
is confidential information.  This i ncludes the IB, Clinical Trial Protocol, Case Report Forms 
(CRF) and any other non clinical and clinical data provided by [CONTACT_1034]. 
I understand that no data are to be made public or published without prior knowledge and written approval by [CONTACT_1034]. 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read, understood and agreed to abide by [CONTACT_18983], instructions and restrictions contained in Protocol 747-207 and in accordance with Good Clinical Practice (CPMP/ICH/135/95), the Declaration of H elsinki, and all regulatory 
requirements for protection of human subjects in clinical studies and privacy requirements for the protection of individual and company data. 
I acknowledge that the Sponsor of the trial has the right to discontinue the trial at any time. 
  
 
   
Investigatorâ€™s Name (Printed)    
 
  
 
Investigatorâ€™s Signature   [CONTACT_22166] 747-207 Version 5:  [ADDRESS_21046]: Barbara Scholz, MD, MPH  
Telephone:  + [PHONE_351] (Pacific Time Zone) 
Email: [EMAIL_379]  
SAE Fax: +[PHONE_352]  
SAE Email:  [EMAIL_380]  
 
Clinical Operations and Project Management  
Contact: [CONTACT_22053] -Jones BSc (Hons)  
VP, Head of Clinical Operations, EU  
Telephone:  
Mobile: 
Email: [PHONE_355] (GMT)  
[PHONE_356] (GMT)  
[EMAIL_381]  
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 5 
Confidential and Proprietary    1. SYNOPSIS  
Name [CONTACT_790]/Company:  Intercept Pharmaceuticals, Inc.  
Name [CONTACT_791]:  Obeticholic Acid (OCA)  
Name [CONTACT_3261]:   OCA; 6Î± -ethyl chenodeoxycholic acid (6- ECDCA) 
Title of Trial:  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose -Finding, 
Clinical Trial Evaluating the Efficacy and Safety  of Obeticholic Acid in Subjects with Primary 
Sclerosing Cholangitis  
Trial Number:   747-207 
Number of Subjects :  Approximately 75 
Planned Number of Trial Sites :  Approximately 35 (Europe and [LOCATION_002] [US])  
Trial Period (Months) : Approximately 50 months  (first subject consented to last subject 
completing last study visit)   
Phase of Trial:  Phase 2 
Objectives:  
Primary 
To evaluate the effects of OCA on  the following in subjects with primary sclerosing cholangitis 
(PSC): 
â€¢ Serum alkaline phosphatase (ALP)  
â€¢ Safety 
Secondary 
To evaluate the effects of OCA on the following in subjects with PSC:  
â€¢ Hepatic biochemistry and indices of function  
â€¢ Markers of:  
âˆ’ Hepatic fibrosis and GI inflammation and disease  
âˆ’ Farnesoid X receptor (FXR) activity  
âˆ’ Inflammatory bowel disease (IBD)  
â€¢ Pharmacokinetics (PK) of OCA and other bile ac ids  
â€¢ Exposure response of total OCA (OCA and its conjugates) to biomarkers (eg, ALP 
and bile acids) 
â€¢ Long-term efficacy and safety of OCA  
â€¢ Disease-specific symptoms.  
 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 6 
Confidential and Proprietary    Methodology:  
Double-blind Phase (DB)  
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding evaluation of the 
efficacy and safety of OCA in subjects with PSC.  Approximately 75 subjects who provide 
written informed consent and meet all of the inclusion and none of the exclusion criteria will be 
randomized to 1 of 3 treatment groups as follows:  1.5 mg titrating to 3 mg OCA, 5 mg titrating 
to 10 mg OCA, or placebo, in a 1:1:[ADDRESS_21047]â€™s dose will be 1.[ADDRESS_21048]â€™s  dose will be titrated  as follows, providing there are no limiting safety or 
tolerability concerns in the opi[INVESTIGATOR_689], whil e maintaining the trial blind:  the 
1.5 mg OCA treatment group will titrate to 3 mg , the 5 mg OCA treatment group will titrate to 
10 mg OCA, and the placebo group will remain on placebo.  DB treatment will continue for a  
further 12 weeks at that dose .   
Any subjects whose dose is not titrated, due to safety or tolerability concerns, will remain on their starting treatment (1.5 mg OCA, 5 mg OCA, or placebo) for the remainder of the DB phase to Week 24. 
Randomization will be stratified by [CONTACT_22054] 
(UDCA) use  and total bilirubin level (â‰¤1.5x upper limit of normal [ULN] or >1.5x ULN but 
<2.5x ULN). 
Long-Term Safety Extension  Phase (LTSE)  
Following completion of participation in the DB phase, subjects will be asked  to reconfirm their 
consent for participation in the open- label long- term safety extension (LTSE) phase (a further 
24 months).   
Upon a subjectâ€™s completion of the DB phase, the trial blind will be broken in order to assign the 
starting OCA dose for the LTSE phase.  It is intended t hat subjects will commence treatment at 
5 mg OCA, except those subjects who completed treatment in the DB phase with 10 mg OCA who will continue at 10 mg OCA unless safety and tolerability warrant a dose reduction to 5 mg.   
â€¢ Placebo at end of DB ïƒ   5 mg OCA in LTSE 
â€¢ 3 mg OCA at end of DB ïƒ  5 mg OCA in LTSE  
â€¢ 10 mg OCA at end of DB ïƒ   [ADDRESS_21049] to be titrated in line with the above schedules, this may be discussed with the Medical Monitor. 
During the LTSE phase, subjects may titrate to higher doses of OCA, at a frequency not greater than 3 monthly (ie, at each of the scheduled LTSE visits), up to a maximum dose of 10 mg daily.  The guideline for an increase in the dose of OCA is based on tolerability and the goal of 
achieving an ALP level <[ADDRESS_21050].  Doses of OCA should be titrated as follows, unless 
clinically indicated:  1.5 mg to 3 mg, 3 mg to 5 mg, and 5 mg to 10 mg.  Intermediate doses 
3URWRFRO 9HUVLRQ0DU
 3DJH
&RQILGHQWLDODQG3URSULHWDU\HJPJPD\EHFRQVLGHUHGDVGHHPHGDSSURSULDWHE\WKH,QY HVWLJDWRU'RVHVKRXOGQRW
H[FHHGPJ
7KH,QYHVWLJDWRUPD\GHFUHDVHWKHGRVHRI2&$RUGRVLQJIUHTXH QF\LQOLQHZLWKVDIHW\DQG
WROHUDELOLW\DVUHTXLUHGIRUWKD WVXEMHFW)ROORZLQJDFKDQJH LQ2&$GRVHRUGRVHIUHTXHQF\DQ
,QYHVWLJDWRUPD\EHSHUPLWWHGWRUHWXUQWKHVXEMHFWWRDSULRU GRVHRUGRVLQJIUHTXHQF\DQGWKLV
VKRXOGEHGLVFXVVHGZLWKWKH,QWHUFHSW0HGLFDO0RQLWRULQDGYDQ FH
7ULDO'HVLJQ6FKHPDWLF

'LDJQRVLVDQG0DLQ&ULWHULDIRU,QFOXVLRQ
6XEMHFWVPXVWPHHWDOORIWKHI ROORZLQJWREHHOLJLEOHWRSDUWL FLSDWH
0DOHRUIHPDOHDJHGWR\HDUV
0XVWSURYLGHZULWWHQLQIRUPHGF RQVHQWDQGDJUHHWRFRPSO\ZLWK WKHWULDOSURWRFRO
0XVWKDYHDGLDJQRVLVRI36&EDVHGRQFKRODQJLRJUDSK\DWDQ\S RLQWLQWLPH
$/3DW6FUHHQLQJÂ•[8/1
7RWDOELOLUXELQDW6FUHHQLQJ[8/1
1RWH6XEMHFWVZLOOEHVWUDWLILHGDFF RUGLQJWRWRWDOELOLUXELQOHYH ODQGQRPRUHWKDQ
RIVXEMHFWVUHFUXLWHGZLOOKDYH DWRWDOELOLUXELQ![8/1DQG [8/1DW6FUHHQLQJ
)RUVXEMHFWVZLWKFRQFRPLWDQW,%'
D&RORQRVFRS\LIWKHVXEMHFWKDV DFRORQRURWKHUDSSURSULDWHH QGRVFRSLFSURFHGXUH
ZLWKLQPRQWKVRI'D\FRQILUPLQJQRG\VSODVLDRUFRORUHFWDO FDQFHU
E6XEMHFWVZLWK&URKQÂ¶V'LVHDVH&' PXVWEHLQUHPLVVLRQDVGHIL QHGE\D&URKQÂ¶V
'LVHDVH$FWLYLW\,QGH[&'$,

Protocol 747-207 Version 5:  18 Mar  2016 
 Page 8 
Confidential and Proprietary    c. Subjects with ulcerative colitis (UC) must either be in remission or have mild disease. 
Remission is defined as a partial Mayo score of â‰¤2 with no individual sub- score 
exceeding 1.  Mild disease is defined as a partial Mayo score â‰¤[ADDRESS_21051] been stable for â‰¥[ADDRESS_21052] 
exceeded 20 mg/kg/day during this time.  
Note 2:  Subjects not taking UDCA at  Day [ADDRESS_21053] taken UDCA for â‰¥[ADDRESS_21054] not take UDCA during the DB period.  Subjects 
will be stratified according to UDCA use , and no more than 50% of subjects 
administering UDCA at Day 0 will be enrolled. 
8. Subjects being administered biologic treatments (eg , anti-TNF or anti -integrin 
monoclonal antibodies), immunosuppressants , systemic corticosteroids, or statins,  must 
have been on a stable dose for â‰¥3 months prior to, and including, Day 0 and should plan 
to remain on a stable dose throughout the trial.  
9. Contraception:  female subjects of childbearing potential must use â‰¥1 effective method (â‰¤1% failure rate) of contraception during the trial and until [ADDRESS_21055] (in cluding LTSE doses).  Effective methods of 
contraception are considered to be those listed below:  
â€¢ Barrier method, ie, (a) condom (male or female) with spermicide or (b) diaphragm 
with spermicide; or  
â€¢ Intrauterine device; or  
â€¢ Vasectomy (partner), or  
â€¢ Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch,  intramuscular implant or injection ); or 
â€¢ Abstinence, if in line with the preferred and usual l ifestyle of the subject  [where 
abstinence is defined as refraining from heterosexual intercourse during the trial duration ( from first administration of investigational product until [ADDRESS_21056] )] 
Exclusion Criteria  
Subjects will be excluded from trial participation if they meet any of the following:  
1. Evidence of a secondary cause of sclerosing cholangitis at Screening  
2. Immunoglobulin G4 ( IgG4) >4x ULN at Screening or evidence of IgG4 sclerosing 
cholangitis 
3. Small duct cholangitis in the absence of large duct disease  
4. Presence of clinical complications of chronic liver disease or clinically sign ificant hepatic 
decompensation, including:  
â€¢ Current Child-Pugh classification B or C 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 9 
Confidential and Proprietary    â€¢ History of, or current diagnosis or suspi[INVESTIGATOR_1884], cholangiocarcinoma or other 
hepatobiliary malignancy, or biliary tract dysplasia 
â€¢ History of liver transplantation, or cur rent model of end stage liver disease (MELD) 
score â‰¥12  
â€¢ History of, or current, cirrhosis with complications, including history or presence of 
spontaneous bacterial peritonitis , hepatocellular carcinoma or hepatic encephalopathy 
(as assessed by [CONTACT_737])  
â€¢ Current known portal hypertension with complications, including known gastric or large esophageal varices, poorly controlled or diuretic resistant ascites, history of 
variceal bleeds, or related therapeutic or prophylactic interventions (eg, beta blo ckers, 
insertion of variceal bands, or transjugular intrahepatic portosystemic shunt [TIPS]) 
â€¢ History of, or current, hepatorenal syndrome (type I or II) or Screening serum creatinine >2 mg/dL (178 Î¼mol/L) 
â€¢ Platelet count <50  x10
9/L 
5. Current clinical evidence of dominant strictures that are considered clinically relevant in 
the opi[INVESTIGATOR_21991] 
6. Current cholecystitis or evidence of current biliary obstruction due to gallstones. 
Asymptomatic gallstones that are not considered a safety risk in the opi[INVESTIGATOR_21992]  
7. Colonic dysplasia within â‰¤5 years prior to Day 0 
8. History of small bowel resection  
9. History of other chronic liver diseases , including, but not limited to, primary biliary 
cirrhosis (PBC), alcoholic liver disease, non -alcoholic fatty liver disease (N AFLD), 
autoimmune hepatitis, hepatitis B virus (unless seroconverted and no positive Hepatitis B 
Virus DNA), hepatitis C virus, and overlap syndrome 
10. Known Gilbertâ€™s syndrome or histo ry of elevations in unconjugated (indirect) bilirubin 
>ULN or unconjugated (indirect) bilirubin >ULN at Screening. 
11. Known history of human immunodeficiency virus (HIV) infection 
12. Currently experiencing, or experienced within â‰¤3 months of Screening, pruritus requiring systemic or enteral treatment . 
13. Known or suspected acute cholangi tis in the 3 months  prior to, and including, Day 0 
including cholangitis treated with antibiotics.  
14. Administration of antibiotics is prohibited â‰¤1 month of Day 0 (unless subject is on a stable prophylaxis dose for at least 3 months prior to Day 0 ). 
15. Administration of the following medications is prohibited â‰¤6 months of Day 0 and 
throughout the  trial:  fenofibrate or other fibrates and potentially hepatotoxic medications 
(including Î±-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin). 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 10 
Confidential and Proprietary    16. IBD flare  during Screening (up to and including Day 0) , where â€œflareâ€ is defined as 
follows: 
â€¢ UC flare:  partial Mayo Score â‰¥5, and  
â€¢ CD flare:  CDAI â‰¥250 
17. Evidence of deleterious effects of alcohol abuse (as assessed by [CONTACT_737]) or 
excessive alcohol consumpt ion (>4 units/day for males, >2 units/day for females) 
18. Known or suspected use of illicit drugs or drugs of abuse (allowed if medically 
prescribed or indicated) within 3 months of Day 0 
19. If female:  known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating  
20. Other concomitant disease, malignancy, or condition likely to significantly decrease life 
expectancy to less than the duration of the trial (eg, moderate to severe congestive heart 
failure) 
21. Participation in another investigational drug, biologic, or medical device trial within 
[ADDRESS_21057], Dosage and Mode of Administration:  OCA, 1.5 mg tablet and 
matching placebo and OCA 5 mg tablet and matching placebo. 
Doses will be 1.5 mg, 3mg, 5mg, 10 mg OCA or matching placebos, as follows:  
DB phase:  2 tablets administered once daily during weeks 0 through 12 and 4 tablets 
administered once daily during weeks 12 through 24 
LTSE Phase:  All subjects will receive open -label OCA at a starting dose that is dependent upon 
their dose at completion of DB phase, as well as safety and tolerability.  Doses may be 1.5 mg, 
3 mg, 5 mg, or 10 mg, ie, 1 or 2 tablets, once daily.  Intermediate doses (eg, 6.5 mg) may be considered as deemed appropriate by [CONTACT_737].  Dose should not exceed 10 mg. 
Duration of Treatment:  30 months (6 month DB  period followed by a 24 month, open- label 
LTSE) 
Duration of Subject Participation: up to 32 months (up to 30 day Screening period, 6 month 
DB period, followed by a 24 month open- label LTSE period, and a 1 month follow-up period) 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 11 
Confidential and Proprietary    Criteria for Evaluation:  
Primary Objectives  Assessments  
Serum ALP  ALP   
Safety Adverse events (AE s) 
Clinical findings and laboratory values  
Secondary Objectives   
Hepatic biochemistry and indices of 
function ALP  
Albumin, alanine transaminase (ALT), aspartate aminotransferase (AST), bilirubin, gamma -glutamyl transferase (GGT), 
international normalized ratio  (INR)  
Markers of hepatic and GI inflammation, disease , and fibrosis  Autotaxin and its metabolites, calprotectin, C -reactive protein 
(CRP), Cytokeratin -18 (CK-18), Enhanced liver fibrosis (ELF) 
markers, Immunoglobulin A (IgA), IgG, Immunoglobulin M (IgM), Interleukin -6 (IL-6), 
Interleukin -12 (IL-12), Interleukin-23 (IL -23),  
Transient elastography (TE ; at participating sites), Transforming 
growth factor -beta (TGF -Î²), Tumor necrosis factor -alpha (TNF -Î±) 
Markers of farnesoid X receptor (FXR) activity  Fibroblast growth factor -19 (FGF -19) 
PK of OCA and other bile acids  Plasma OCA bile acids and conjugates including  7Î±-hydroxy-4-
cholesten -3-one (C4) 
Exposure response of total OCA to biomarkers Relationship of total OCA (OCA and its conjugates) to biomarkers such as change in ALP and change in bile acids.  
Long-term efficacy and safety  As above 
Disease-specific symptoms  Pruritus Visual Analogue Scale (VAS)  
Pruritus 5 -D questionnaire  
Partial Mayo scoring system for assessment of ulcerative colitis activity (partial Mayo score) 
Crohnâ€™s disease activity index (CDAI)  
Statistical Methods:  
Efficacy Analyses 
The primary efficacy endpoint is the Week 24 change from Baseline in ALP.  The primary 
efficacy analysis will compare the Week  24 change from Baseline in ALP between the OCA 
10 mg treatment group and placebo using an analysis of covariance ( ANCOVA) model with 
fixed effects for treatment group and randomization strata, and Baseline as a covariate.   
Secondary efficacy analyses of hepatic biochemistry and function parameters will use the same 
ANCOVA models as the primary endpoints.  A hierarchical approach will be used for 
multiplicity adjustments.  If the primary efficacy analysis is statistically significant (p <0.05), the 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 12 
Confidential and Proprietary    following order will be used in the testing procedure to compare the change from Baseline in 
ALP between OCA and placebo:  
â€¢ Week 12:  OCA 5 mg treatment group (randomized to 5 mg for the initial 12 weeks followed by 10 mg for the latter 12 weeks) vs. placebo  
â€¢ Week 24:  OCA 3 mg treatment group (randomized to 1.5 mg for the initial 12 weeks 
followed by 3 mg for the latter 12 weeks) vs. placebo  
â€¢ Week 12:  OCA 1.5 mg treatment group (randomized to 1.5 mg for the initial 
12 weeks f ollowed by 3 mg for the latter 12 weeks) vs. placebo 
If at any step the comparison is not statistically significant, then all subsequent comparisons will be exploratory rather than confirmatory.   
In addition, secondary efficacy analyses of ALP response ra tes, defined as ALP to <1.5x ULN, 
will compare OCA treatment groups vs. placebo at Week [ADDRESS_21058] stratified by [CONTACT_22055].  Missing 
values will be considered a non -response.  
Safety Analyses 
The incidence of treatment emergent adverse events ( TEAEs) and serious adverse events ( SAEs) 
will be tabulated by [CONTACT_20623], and 
similarly by [CONTACT_22056].  
Laboratory parameters and vital signs will be summarized by [CONTACT_22057] -Baseline visit.  The change from Baseline will 
also be summarized .  Electrocardiograms (ECGs) will be summarized by [CONTACT_22058] t group using 
frequency at each visit.  The shift from baseline will also be summarized.   Baseline is defined as 
the mean of all available evaluations prior to treatment (except for lipoprotein assessments where 
Baseline will be Day 0).    
Pharmacokinetic and Pharmacodynamic Analyses 
The pharmacokinetics (PK) of OCA and other bile acids will be evaluated, including AUC
t, 
Cmax, and tmax.  An exposure response analysis of total plasma OCA (OCA and its conjugates) to 
biomarkers, such as change in ALP and change in bile acids, will be performed to help identify 
optimal doses for this patient population.   
Full details of the statistical methodology, analyses, and outputs will be detailed in the statistical 
analysis plan (SAP).  
Interim Analysis  
An unblinded interim analysis for planning purposes will be conducted after approximately 50% of subjects have completed the initial 12 -weeks of blinded treatment.  The trial will not be 
terminated early for futility.  The interim analysis will compare at Week 12, the same variable as 
will be analyzed for the primary endpoint:  the change from Baseline in ALP, between OCA treatment groups (1.5 mg and 5 mg) and placebo using an analysis of covariance (ANCOVA) model with fixed effects for treatment group and randomization stra ta and Baseline as a 
covariate.  No adjustments to the alpha level will be made.  
Protocol 747-207 Version 5:  [ADDRESS_21059] 
90% power to detect a treatment difference for change in ALP assuming the mean absolute 
change in ALP for OCA and placebo treatment groups are approximately -20% and -5%, 
respectively, with a pooled standard deviation of 16, based on a 2- sided independent [ADDRESS_21060] at an alpha level of 0.05. 
Protocol 747-207 Version 5:  [ADDRESS_21061] ..............................28  
4.6.1.  Rationale for Trial Design  ..........................................................................................28  
4.6.2.  Rationale for Doses  .....................................................................................................29  
5. TRIAL OBJECTIVES AND PURPOSE  ....................................................................30  
5.1. Primary Objective  .......................................................................................................30  
5.2. Secondary Objectives  .................................................................................................30  
6. INVESTIGATIONAL PLAN  .....................................................................................31  
6.1. Overall Trial Design  ...................................................................................................31  
6.1.1.  Trial Design Diagram  .................................................................................................32  
6.1.2.  Trial Duration  .............................................................................................................39  
6.2. Number of Subjects ....................................................................................................39  
6.3. Treatment Assignment  ................................................................................................39  
6.4. Dose Adjustment Criteria and Dose Titration  ............................................................39  
6.4.1.  Double-Blind Phase ....................................................................................................39  
6.4.2.  LTSE Phase  ................................................................................................................40  
6.4.3.  Safety Criteria for Adjustment or Stoppi[INVESTIGATOR_21993]  .....................................................40  
6.5. Criteria for Trial Termination  .....................................................................................41  
Protocol 747-207 Version 5:  [ADDRESS_21062] Treatment Regimen  ..............................................................48  
8.2. Concomitant Medications ...........................................................................................49  
8.2.1.  Ursodeoxycholic Acid ................................................................................................49  
8.2.2.  Bile Acid Sequestrants  ................................................................................................49  
8.2.3.  Prohibited Medications  ...............................................................................................50  
8.3. Treatment Compliance  ................................................................................................50  
8.4. Randomization and Blinding ......................................................................................51  
8.4.1.  Stratification  ...............................................................................................................51  
8.4.2.  Unblinding Procedures â€“ Emergency Unblinding ......................................................[ADDRESS_21063] Numbers .........................................................................................................52  
8.6. Visit Procedures  ..........................................................................................................52  
8.6.1.  Visit Windows  ............................................................................................................52  
8.6.2.  Informed Consent Procedures .....................................................................................52  
8.6.3.  Screening Procedures (Within 30 Days of Day 0) ......................................................53  
8.6.4.  Day 0 Procedures ........................................................................................................54  
8.6.5.  Week 2 Procedures .....................................................................................................55  
8.6.6.  Week 6 Procedures .....................................................................................................56  
8.6.7.  Week 12 (Titration Visit) Procedures  .........................................................................57  
8.6.8.  Week 14 Procedures ...................................................................................................58  
8.6.9.  Week 18 Procedures ...................................................................................................59  
8.6.10.  Week 24/LTSE Day 1 Procedures ..............................................................................60  
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 16 
Confidential and Proprietary    8.6.11.  Early Discontinuation and/or Early Termination Procedures:  Double-Blind 
Phase ...........................................................................................................................62  
8.6.12.  Follow-Up Visit:  Double -Blind Phase .......................................................................63  
8.6.13.  Long-Term Safety  Extension Visits ...........................................................................64  
8.6.14.  LTSE Day 1 (DB Week 24) Procedures .....................................................................64  
8.6.15.  LTSE Week 2 Procedures  ...........................................................................................64  
8.6.16.  LTSE Month 3, 9, 15, and 21 Procedures ...................................................................64  
8.6.17.  LTSE Month 6 Procedures .........................................................................................65  
8.6.18.  LTSE Month 12 Procedures .......................................................................................66  
8.6.19.  LTSE Month 18 Procedures .......................................................................................67  
8.6.20.  LTSE Month 24 Procedures .......................................................................................68  
8.6.21.  Early Discontinuation and/or Early Termination Procedures:  LTSE Phase ..............69  
8.6.22.  Follow-Up Visit:  LTSE  .............................................................................................[ADDRESS_21064] Accountability and Disposal .................................................73  
10. ASSESSMENTS OF EFFIC ACY ..............................................................................73  
10.1.  Sample Collection  .......................................................................................................73  
10.2.  Primary Efficacy Assessments  ...................................................................................73  
10.3.  Secondary Assessments ..............................................................................................74  
10.4.  Additional Exploratory Assessments  ..........................................................................75  
10.5.  Pharmacokinetics and Bile Acid Assessments ...........................................................76  
11. ASSESSMENT OF SAFETY  .....................................................................................76  
11.1.  Adverse Events and Serious Adverse Events .............................................................76  
11.1.1.  Definitions  ..................................................................................................................76  
[IP_ADDRESS].  Adverse Event .............................................................................................................76  
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 17 
Confidential and Proprietary    [IP_ADDRESS].  Serious Adverse Event  ................................................................................................77  
[IP_ADDRESS].  Treatment Emergent Adverse Event  ...........................................................................[ADDRESS_21065]  ......................................................................77  
11.1.3.  Recording Adverse Event Severity .............................................................................78  
[IP_ADDRESS].  Severity of Pruritus (as  an AE) ...................................................................................78  
11.1.4.  Reporting of Adverse Events and Serious Adverse Events ........................................80  
[IP_ADDRESS].  Reporting of Adverse Events ......................................................................................80  
[IP_ADDRESS].  Reporting of Serious Adverse Events .........................................................................[ADDRESS_21066] -Trial SAEs  ..................................................................................82  
11.1.8.  Follow-Up of AEs  and SAEs  ......................................................................................82  
11.1.9.  Pregnancy and Follow- Up ..........................................................................................83  
11.2.  Other Safety Parameters  .............................................................................................83  
11.2.1.  Medical History/Demographics  ..................................................................................83  
11.2.2.  Physical Examination  .................................................................................................83  
11.2.3.  Vital Signs  ..................................................................................................................84  
11.2.4.  Electrocardiogram  .......................................................................................................84  
11.2.5.  Laboratory Assessments .............................................................................................84  
12. STATISTICS ..............................................................................................................85  
12.1.  Analysis Populations ..................................................................................................85  
12.2.  Determination of Sample Size ....................................................................................86  
12.3.  Efficacy Analysis  ........................................................................................................86  
12.3.1.  Primary Efficacy Analysis  ..........................................................................................86  
12.3.2.  Secondary Efficacy Analysis ......................................................................................86  
12.4.  Pharmacokinetics ........................................................................................................87  
12.5.  Safety Analysis  ...........................................................................................................87  
12.5.1.  Adverse Events ...........................................................................................................87  
12.5.2.  Clinical Laboratory Evaluations  .................................................................................88  
12.5.3.  Additional Safety Analysis .........................................................................................88  
12.6.  Interim Analyses and Data Monitoring ......................................................................88  
12.6.1.  Interim Analysis  ..........................................................................................................88  
12.6.2.  Data and Safety Monitoring Committee  .....................................................................88  
Protocol 747-207 Version 5:  [ADDRESS_21067] ACCESS TO SOURCE DATA/DOCUMENTS  .........................................[ADDRESS_21068] RESEARCH QUESTIONNAIRE .............................................103  
APPENDIX  F. CROHNâ€™S DISEASE ACTI VITY INDEX  ................................................104  
APPENDIX  G. PROTOCOL VERSION 2 â€“ SUMMARY OF CHANGES  .......................105  
APPENDIX  H. PROTOCOL VERSION 3 â€“ SUMMARY OF CHANGES  .......................140  
APPENDIX  I. PROTOCOL VERSION 4 â€“ SUMMARY OF CHANGES  .......................178  
APPENDIX  J. PROTOCOL VERSION 5 â€“ SUMMARY OF CHANGES  .......................181  
 
Protocol 747-207 Version 5:  [ADDRESS_21069] OF TABLES  
Table 1: Schedule of Trial Procedures:  Double-Blind Phase ..................................................33  
Table 2: Schedule of Trial Procedures:  LTSE Phase ...............................................................36  
Table 3: Planned Duration of Trial Phases ...............................................................................39  
Table 4: Initial LTSE Doses of OCA  ........................................................................................40  
Table 5: Initial LTSE Doses of OCA for Non- Titrating Subjects  ............................................40  
Table 6: Daily Tablet Regimen by [CONTACT_22059] ...............................................................49  
Table 7: Relationship of AEs to Invest igational Product  ..........................................................78  
Table 8: Severity of AEs ...........................................................................................................78  
Table 9: Severity of Pruritus  .....................................................................................................[ADDRESS_21070] OF FIGURES  
Figure 1:  Trial Design Schematic  ...............................................................................................32  
  
Protocol 747-207 Version 5:  [ADDRESS_21071]  area under the concentration time curve  
Î²- hCG beta human chorionic gonadotrophin  
BAS Bile acid sequestrants  
BP blood pressure  
BUN blood urea nitrogen  
C4 7Î±-hydroxy-4-cholesten -3-one 
CCA cholangiocarcinoma  
CCl4 carbon tetrachloride  
CD Crohnâ€™s disease  
CDAI Crohnâ€™s disease activity index  
CDCA chenodeoxycholic acid 
CFR Code of Federal Regulations  
CK-18 cytokeratin 18  
Cmax maximum concentration observed  
CRA Clinical Research Associate 
CRF case report form  
CRP C-reactive protein  
Css steady state concentration  
CYP7A1 cholesterol 7 -Î± hydroxylase ;  
DB double-blind 
D/d day/days 
dL deciliter 
DSMC Data Safety Monitoring Committee  
Protocol 747-207 Version 5:  [ADDRESS_21072] growth factor  
FU follow-up 
FXR farnesoid X receptor 
GCP Good Clinical Practice  
GGT gamma-glutamyl transferase  
GI gastrointestinal 
Glyco-OCA glyco-obeticholic acid  
GMP good manufacturing practice 
HA hyaluronic acid  
HDL high density lipoprotein  
HEENT head, eyes, ears, nose and throat  
HIV human immunodeficiency virus  
HR heart rate  
HSC hepatic stellate cells  
IB investigatorâ€™s brochure  
IBD inflammatory bowel disease 
ICF informed consent form  
ICH International Conference on Harmoni sation 
ICMJE International Committee of Medical Journal Editors  
ID identification  
IEC Independent Ethics Committee  
IgA Immunoglobulin A  
IgG4 Immunoglobulin G4  
IgM Immunoglobulin M  
IL interleukin  
Protocol 747-207 Version 5:  [ADDRESS_21073]  
ITT intent-to-treat 
IWRS interactive web response system  
L liter 
LCA lithocholic acid 
LDL low density lipoprotein  
LTSE long-term safety extension  
MedDRA  medical dictionary of regulatory activities  
MELD model of end stage liver disease  
Î¼mol/L micromoles per liter  
mg milligram  
mRNA messenger ribonucleic acid  
NAFLD nonalcoholic fatty liver disease  
NASH nonalcoholic steatohepatitis  
NMR nuclear magnetic resonance 
OCA obeticholic acid  
P3NP procollagen-3 N -terminal peptide  
PBC primary biliary cirrhosis  
PD pharmacodynamic 
PIS patient information sheet  
PK pharmacokinetic 
PSC primary sclerosing cholangitis 
RBC red blood cell  
RNA ribonucleic acid  
RSI Reference Safety Information  
SAE serious adverse event  
SAP statistical analysis plan  
SAR serious adverse reaction  
S[LOCATION_003]R suspected unexpected serious adverse reaction 
TAA thioacetamide  
Protocol 747-207 Version 5:  [ADDRESS_21074] Term  Explanation  
Tauro-OCA tauro-obeticholic acid  
TE transient elastography  
TEAE treatment emergent adverse event  
TG triglycerides 
TGF-Î²1 transforming growth factor â€“ beta 1 
TIMP-1 tissue inhibitor of metalloproteinase 1 
TIPS transjugular intrahepatic portosystemic shunt  
tmax time to C max 
TNF-Î± tumor necrosis factor - alpha 
UC ulcerative colitis  
UDCA ursodeoxycholic acid  
U/L units per liter 
ULN upper limit of normal  
VAS visual analogue scale  
VLDL very low density lipoprotein 
W/wk week 
WBC white blood cell  
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 24 
Confidential and Proprietary    4. INTRODUCTION  
4.1. Overview of Primary Sclerosing Cholangitis and Obeticholic Acid 
Primary sclerosing cholangitis (PSC) is a rare, life -threatening, chronic cholestatic liver disease 
characterized by [CONTACT_22060].  Despi[INVESTIGATOR_21994], liver transplant is currently the only 
treatment shown to improve clinical outcome.  
PSC is usually diagnosed by [CONTACT_22061], with or without 
reported symptoms, and confirmed by [CONTACT_22062], typi[INVESTIGATOR_21995] (ERCP).  
Alkaline phosphatase (ALP) is elevated in most PSC patients, consistent with cholestasis; alanine aminotransferase (ALT) and gamma- glutamyltransferase (GGT) are typi[INVESTIGATOR_897] e levated as 
well, but not in all cases.  Bilirubin is often normal in early stage PSC but increases with progression of the disease.  The mean age at diagnosis is 40 years, and men are affected twice as often as women.   
PSC is a serious and life- threatenin g condition.  Median survival for PSC patients has been 
previously estimated as 8 to 12 years from diagnosis in symptomatic patients, depending upon 
stage of the disease at the time of diagnosis (Levy 2006, Worthington 2006, Lee  1995).  
Complications involving the biliary tree are common and include cholangitis as well as ductal strictures and gallstones, both of which may require frequent endoscopic or surgical 
interventions.  PSC is often complicated by [CONTACT_22063] , with 
cholangiocarcinoma ( CCA) being the most common .  CCA drastically worsens mortality 
(Fevery 2007, Lazaridis 2006 ).  In a large Swedish trial, the 5-year survival rate for patients 
diagnosed with either CCA or gallbladder cancer was approximately 5% compared to 
>85% survival in PSC patients without hepatobiliary cancer ( Bergquist 2002).   
Obeticholic acid  (OCA) is a modified bile acid and is a potent agonist of the farnesoid X receptor 
(FXR).  OCA has marked anti-fibrotic and anti- inflammatory properties in animal models of 
liver disease.  In addition, the safety and tolerability of OCA has been evaluated in clin ical trials 
in the â€˜sisterâ€™ cholestatic liver disease, primary biliary cirrhosis (PBC).  Phase [ADDRESS_21075] shown that treatment with OCA resulted in highly statistically significant improvements in liver biochemistry associate d with cholestasis and was generally 
well tolerated.  These findings render OCA potentially useful for the treatment of PSC.   OCA has 
received orphan drug designation for the treatment of PSC in Europe and the [LOCATION_003]. 
4.2. Mechanism of Action of Obeticholic Acid 
For a detailed description of OCAâ€™s mechanism of action please refer to the current OCA 
Investigator â€™s Brochure (IB).   FXR is an essential  and pleiotropic regulator of a variety of 
activities involved in bile acid homeostasis ( Lefebvre 2009) .  Its activation affects genes that 
control bile salt synthesis and transport  (Makishima 1999, Wang 1999) ; activation of FXR 
reduces the expression of messenger ribonucleic acid (mRNA) for cholesterol 7-Î± hydroxylase 
(CYP7A1 ; the rate-limiting enzyme of bile salt synthesis) and the sinusoidal bile salt uptake 
pump, while inducing the bile salt export pump.  Activation of FXR in the ileum leads to 
increased release of fibroblast growth factor  19 (FGF-19) into the portal vein, transporting it to 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 25 
Confidential and Proprietary    the liver where it also acts as a brake on endogenous bile acid production by [CONTACT_22064]7A1 
(Cipriani 2011, Pols 2011).  In addition to being the key regulatory gatekeeper for bile acid 
synthesis, FXR has also been implicated as having a role in modulating immune response, 
decreasing portal hypertension, and potentially being anti-atherogenic ( Lefebvre 2009).  
Chenodeoxycholic acid (CDCA) is the principal natural ligand of FXR in humans.  When 
cellular levels are already high , the negative feedback pathway inhibits the further synthesis of 
bile.  CDCA, and its epi[INVESTIGATOR_21996] ( UDCA), have a long history of use in of the 
dissolution of  cholesterol gallstones (although currently laparoscopic surgery is more typi[INVESTIGATOR_21997]).  In cholestasis, the primary mode of action of UDCA is thought to be choleretic, ie , 
facilitating bile flow  to relieve cholestasis rather than suppressing its synthesis and buffering the 
bile (Beuers 2006).  UDCA has no FXR agonist properties.  
OCA is structurally related to  CDCA and differs by [CONTACT_1121] a single ethyl group.  The 
chemical name [CONTACT_22167] 3Î±,7Î±-dihydroxy-6Î±-ethyl-5Î²cholan-24- oic acid.  It is also referred to 
as 6Î±-ethylchenodeoxycholic acid, or 6- ECDCA, and as an agonist it is approximately 100-fold 
more potent than CDCA in vitro (Pellicciari 2002 ).  OCA is also highly selective for FXR and 
does not bind other nuclear receptors, and with the exception of weakly activating the dedicated 
bile acid receptor TGR5, it does not activate any G- protein coupled receptors ( CEREP 2008 ).  
OCA is in clinical development in a series of chronic liver and metabolic disease indications in 
which the functions regulated by [CONTACT_22065].    
4.3. Nonclinical Experience with Obeticholic Acid 
Administration of OCA to rats (f or 6 months) and dogs (for 9 months) in repeat dose toxicity 
trials resulted primarily in adverse effects on the liver and gastrointestinal (GI) tract at only the highest dose levels.  OCA was not genotoxic in a battery of 3 genotoxicity studies.  Reproduc tive 
and developmental toxicity studies in rats and rabbits demonstrated no adverse effects on fertility and embryo/fetal development at doses where OCA caused maternal toxicity.  
A summary of the toxicology studies is provided in the IB.  The nonclinical pharmacology 
experience with OCA is summarized below.  For more information on the nonclinical data for 
OCA, please refer to the current IB.  
4.3.1. Nonclinical Anti- fibrotic and Anti -inflammatory Properties  
In vitro exposure of both murine and human hepatic stellate cells (HSC) to OCA represses 
fibrogenic Î±1(I) collagen and transforming growth factor- beta 1 (TGF -Î²1) expression by 60% to 
70%, indicating that OCA is a potent regulator of HSC mediated fibrogenesis.   
OCA significantly inhibits fibrogenesis and r everses liver cirrhosis, as determined by [CONTACT_22066] a thioacetamide (TAA)- induced liver injury model 
(Albanis 2005).  In addition, OCA inhibits NF ÎºBâ€“regulated pro-inflammatory genes in 
hepatocytes and in vascular cells, inhibiting induction of pro-inflammatory cytokines, such as 
tumor necrosis factor (TNF -Î±), and inflammatory mediators, such as cyclooxygenase- 2 (COX-2) 
and inducible nitric oxide synthase ( Li 2007, Wang 2008).  OCA also inhibits production of 
TNF-Î± by [CONTACT_22067], and inhibits 
differentiation of human monocytes into dendritic cells ( Gadaleta 2011).  Furthe rmore, OCA 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 26 
Confidential and Proprietary    inhibits production of TNF-Î±, interleukin (IL)-17, and interferon-Î³ in lymphocyte-enriched 
human lamina propria cells ( Gadaleta 2011).  
4.3.2. Nonclinical Effects on Cholestasis  
The results of trials performed in rodent models of cholestasis involving the administration of 
chemical agents that severely injure bile ducts (such as carbon tetrachloride [CCl 4] or lithocholic 
acid [LCA]) provide evidence that OCA is effective in preventing or reducing cholestasis in vivo .  
In the LCA model, co-infusion of OCA fully reversed the impairment of bile flow and protected against liver cell injury (Pellicciari 2002 ). 
Results of other trials  have demonstrated that OCA significantly reduces fibrotic collagen 
synthesis in vitro and in various rodent models of chronic liver injury that involve fibrosis and 
eventual cirrhosis, consistent with the progression of PSC ( Albanis 2005, Mookerjee 2015).   
4.4. Clinical Experience with Obeticholic Acid 
To date, OCA has been evaluated in the clinic in a total of 25 completed and 8 ongoing trials , 
including patients with PBC and  other chronic liver diseases ( eg, portal hypertension and 
nonalcoholic steatohepatitis [ NASH]) and healthy volunteers.  Additional trials are also planned 
to further chara cterize the pharmacokinetic (PK) and pharmacodynamic (PD)  properties of OCA 
as well as the safety and efficacy of OCA in subjects with PBC and  other chronic liver diseases . 
As of [ADDRESS_21076] one dose of OCA in 
completed or ongoing trials.  Overall, the PK profile of OCA is consistent with that expected of a 
bile acid.  Phase 1 PK trials demonstrated that OCA was rapi[INVESTIGATOR_21998]- OCA and tauro -OCA, respectively.  OCA and 
its conjugates were primarily eliminated via biliary excretion and plasma concentration -time 
profiles demonstrated multiple peaking with prolonged exposure, indicative of enterohepatic 
circulation.  Plasma concentrations of OCA and its conjugates peaked shortly after meals, 
consistent with gall bladder emptying into the duodenum as expected of a bile acid.   
Phase 2 Trial  747-201 evaluated 2 doses of OCA (10 mg and 50 mg) given as monotherapy 
versus placebo  in subjects with PBC.  S ignificant relative and absolute reductions in ALP were 
achieved with both doses of OCA versus placebo (p <0.0001).  Mean relative ALP reductions 
were 44.5% (OCA 10 mg) and 37.6% (OCA 50 mg) compared to + 0.4% with placebo.  Absolute ALP reductions were -233.5 U/L and -161.3 U/L with OCA doses of 10 mg and 50 mg, 
respectively compared to +11 U/L with placebo.  Further, significant improvements in GGT and in conjugated bilirubin were observed with both doses compared with placebo (p <0.05).  OCA doses of 10 mg and 50 mg resulted in decreased alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) but the change did not achie ve statistical significance.  
Phase 2 trial  747-202 evaluated 3 doses of OCA (10 mg, 25 mg, and 50 mg) versus placebo in 
subjects with PBC on a stable therapeutic dose of UDCA.  Overall, the data from 747 -202 were 
consistent with the monotherapy trial.  Statistically significant relative and absolute reductions in 
ALP were achieved with all 3 d oses of OCA versus placebo (p <0.0001).  Mean ALP reductions 
ranged from 21% to 25% compared to 3% with placebo.  Absolute ALP reductions ranged from approximately 65 U/L to 75 U/L versus 5 U/L for placebo.  Significant improvements were also 
Protocol 747-207 Version 5:  [ADDRESS_21077] at 10 mg and 25 mg, and in conjugated 
bilirubin (% change) at 25 mg and 50 mg. 
The long term safety extension ( LTSE) phases of both trials  (completed LTSE phase from 
Trial 747-202 providing exposures out to one year and ongoing LTSE phase of Trial 747-201 
providing exposures up to approximately 4.5 years to date ) support the long -term safety of OCA 
and demonstrate a durable therapeutic response.  
Phase 3 Trial 747-301 evaluated 2 OCA treatment arms (10 mg and 5 mg titrating to 10 mg based on efficacy and tolerability) versus placebo in subjects with PBC on a stable therapeutic 
dose of UDCA or who could not tolerate UDCA.  The primary efficacy endpoint was the 
proportion of subjects who achieved an ALP <1.67x upper limit of normal (ULN) with a minimum 15% reduction in ALP and a normal bilirubin after 12 months of treatment.  Both 
OCA treatment groups showed statistically significant d ifferences (p <0.0001) versus placebo for 
the composite endpoint at all post-baseline timepoints with 47%, and 46% achieved the endpoint 
at 12 months in the 10 mg and titration groups compared to 10% with placebo.  Consistent with 
the Phase 2 trials, statistically significant relative and absolute reductions in ALP were achieved 
in both treatment groups (p <0.0001).  Mean ALP reductions were 39% and 33% compared to 5% with placebo.  
Overall, OCA has been demonstrated to be safe and generally well tolerated in PBC patients.   
The primary adverse event (AE) shown to be related to OCA is pruritus.  This reflects a drug and 
dose related exacerbation of the most common symptom of PBC and is thought to be due to the 
choleretic effect of OCA that increases bile flow  and hepatic clearance, but may also increase 
exposure to a pruritogen present in the bile that can induce pruritus in susceptible patients.  Of 
note, UDCA therapy initiation also can induce pruritus in patients, which can be ameliorated by 
[CONTACT_22068].   Pruritus has also been observed in clinical trials with OCA in other indications, 
but with a much lower frequency than that observed in subjects with PBC.  Other potential risks 
identified include liver toxicity at high doses.  Detailed clinical information can be found in the 
OCA IB.  
4.5. Summary of Known Potential Risks with Investigational Product 
Investigators are referred to the current IB for a thorough presentation of the safety data associated with OCA.  An overview is as follows:  
Pruritus is a common symptom of chronic cholestatic diseases such as PBC and PSC.  In subjects 
with PBC, treatment with OCA has been shown to cause a dose-dependent exacerbation of this 
common symptom and similar results can be expected in subjects with PS C.  Pruritus has also 
been observed in clinical trials  with OCA in other indications and in healthy volunteers, but at  a 
lower frequency and at higher doses than that observed in subjects with chronic cholestasis.  Investigator guidance for pruritus manage ment strategies are outlined in Section [IP_ADDRESS] of the 
protocol. 
Other potential risks include liver toxicity , especially at higher doses of OCA, which is 
consistent with nonclinical findings and the chemical characteristics of OC A as a bile acid and 
detergent.  An increase in liver function tests and hepat obiliary AEs, including jaundice, ascites 
and acute cholecystitis were observed in subjects with PBC and NASH who were treated at 
doses that are several fold higher (primarily 20 mg to 50 mg daily) than those studied in this 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 28 
Confidential and Proprietary    protocol (1.5 mg, 3 mg, 5 mg, and 10 mg) doses.  This is an important potential risk in subjects 
with PSC, where there is the possibility of dominant strictures of intra - and extra-hepatic bile 
ducts that could restrict bile flow.  In order to monitor bile duct patency, the trial protocol requires that sites perform an ultrasound at Screening, at the end of the DB phase, and annually in the LTSE.  Consistent with this potential risk, the present trial excludes subjects who have 
had, or who are suspected of having, a recent dominant stricture ( Section 7.3).  In addition, the 
trial calls for mandatory discontinuation of investigational product in those subjects whose liver 
chemistry (AST , ALT and or bilirubin) di splay clinically significant increases following the 
initiation of therapy ( Section 7.4.1).  The doses used in the present trial (1.5 mg to 10 mg) are 
amongst the lowest doses of OCA tested to date in a clinical set ting. 
Lipoprotein changes have also been observed with OCA dosing in s ubjects with PBC (including 
a decrease in high -density lipoprotein [HDL]).  The clinical significance of these lipid findings 
remains unclear and is being studied further.  Notably, despi[INVESTIGATOR_21999], they generally remained within normal limits.  The relevance of these findings to subjects 
with PSC is unclear  and will be investigated further in this trial.  
In addition, the Data Safety Monitoring Committee (DSMC) will review safety data from the 
present trial as well as other ongoing OCA trials  at approximately quarterly intervals but at least 
every [ADDRESS_21078]  
4.6.1. Rationale for Trial Design 
Rationale for Treatment Indication  
PSC is a rare, chronic cholestatic liver disease characterized by [CONTACT_22069], 
fibrosis, and destruction of the intrahepatic and extra- hepatic bile ducts with no identifiable cause 
(Eaton 2013 , Hirschfield 2013).  PSC disease progression can vary, but typi[INVESTIGATOR_22000]; fibro sis and commensurate inflammatory responses induce a progressive spread of the 
fibrotic condition.  No treatment to  date, aside from liver transplant, has been associated with an 
improvement in clinical outcome.  As such, the unmet medical need for PSC is very high. 
Drugs that can improve bile acid flow (reducing toxic bile acid concentrations in hepatocytes) 
and have anti -inflammatory and anti- apoptotic effects should have beneficial effects in PSC.  
UDCA, which is an epi[INVESTIGATOR_22001], is often used for the 
treatment of PSC due to improvements in liver biochemistry following initiation of ther apy. 
Despi[INVESTIGATOR_22002], UDCA has not been shown to improve transplant 
free survival and, at high doses, has been associated with increased risk for serious complications (Lindor 2009).  Consequently, The Eu ropean Association for the Study of the Liver ( EASL) does 
not provide a recommendation for the use of UDCA for the treatment of PSC, and The American 
Association for the Study of Liver Diseases ( AASLD) recommends against its use ( EASL 2009, 
Chapman 2010).  However, as there are no approved drugs for the treatment of PSC, some 
physicians treat patients with UDCA, typi[INVESTIGATOR_22003] a dose of 13 to 15 mg/kg/day. 
FXR has been shown to be an essential regulator of bile acid homeostasis with its activation 
being associated with decreased bile acid synthesis (Lefebvre 2009) .  FXR is the nuclear receptor 
Protocol 747-207 Version 5:  [ADDRESS_21079] anti-fibrotic and anti- inflammatory properties as well 
as being effective at reducing cholestasis ( Section 4.3).  Clinical data from trials in PBC showing 
marked reductions in liver biochemistry associated with cholestasis further support the rationale for evaluating OCA as a treatment for PSC ( Section 4.4). 
Rationale for Primary Efficacy Endpoint  
The cholestatic conditions of PSC and PBC are both characterized by [CONTACT_22070].  While UDCA did not show a treatment effect on clinical outcomes ( Lindor 1997, 
Olsson 2005), follow up analyses showed that robust improvements in ALP, the achievement of 
normalized ALP levels or levels <1.5x ULN were associated with improved prognosis 
(Lindstrom 2013, Al Mamari 2013, Talwalkar 2013).  Evaluation of OCA in PBC subjects has 
shown OCA to be associated with a clinically and statistically significant reduction in ALP.  As 
such, this first trial of OCA in subjects with PSC will evaluate therapeutic response in terms of 
change from Baseline in ALP .  Categorical improvements (ie, normalization or <1.5x ULN) will 
also be evaluated as secondary endpoints.  
4.6.2. Rationale for Doses 
This trial is intended to evaluate the safety, tolerability, and efficacy of a range of doses of OCA in subjects with PSC with an overall goal of identifying doses that are therapeutic and generally well tolerated.  Patients will be randomized to 1 of 3 dose groups:  1.[ADDRESS_21080] been established in healthy subjects and subjects with PBC (another 
cholestatic liver disease), at doses up to 50  mg once daily, and in subjects with alcoholic 
cirrhosis and portal hypertension at doses up to 25 mg.  In healthy subjects, 12 days dosing of up 
to 100 mg per day was safe and well tolerated.   
As demonstrated in the Phase 2 PBC trials, OCA can significantly reduce ALP levels at doses of 
10 mg, 25 mg, and 50 mg, but with an increase in the incidence and severity of pruritus at higher dose levels.  The Phase 3 PBC trial evaluated the safety and efficacy of OCA at lower doses of 
5 mg (titrated to 10 mg after 6 months based on efficacy and tolerability) and 10 mg; both 
treatment groups exhibited clinically meaningful improvements in liver biochemistry and were safe and generally well -tolerated.  Starting patients on 5mg OCA and titrating to 10mg based on 
the clinical response appears to be an appropriate dosing strategy in patients with PBC.  
Building on these data from patients with PBC, we plan to use the same titration dosing strategy for patients with PSC.  This considered approach provides a means for the treating physician to 
carefully manage tolerability issues while still providing an opportunity for efficacy.  The 
titration arm of 5 mg to 10 mg OCA is well-within the range shown to be safe and effective in PBC patients and in healthy volunteers.  However, given the detergent properties of OCA and 
the potential for dominant intra - and extra- hepatic strictures that could lead to bile acid retention 
in subjects with PSC (Section  4.5), evaluation of additional titration arm with 1.5 mg titrating to 
3 mg OCA (ie, â‰¤10 mg daily) is warranted.   
Protocol 747-207 Version 5:  [ADDRESS_21081] of the trial design targets doses known to be therapeutic for PBC (5 mg 
and 10 mg), another cholestatic liver disease, but also incorporates lower doses to 1) Allow 
identification of the minimally safe and effective dose, and 2) Further characterize the 
exposure-response relationship in this patient population.  The nested dose-rising approach allows for a more  robust characterization of the value of titration to address potential tolerability 
concerns and the exposure- response relationship by [CONTACT_22071] -subject variability.  The 
nested dose- rising approach also limits the needed number to treat which is important given the 
rarity of the disease and limited pool of patients from which to recruit, and minimizes the 
number of patients unnecessarily exposed to study medication. 
Rationale for P lacebo 
There are no approved therapi[INVESTIGATOR_22004]. 
As such, the use of a placebo control is warranted to maintain the study blind and scientific 
validity of the trial.  UDCA is used by [CONTACT_22072].  However, EASL does not provide a recommendation regarding UDCA use in 
PSC, and AASLD recommends against its use ( EASL 2009 , Chapman 2010).  Based on this 
guidance, UDCA would not be an appropriate active control.  However, the Sponsor does 
recognize that UDCA is used in this orphan disease, and patients who are currently taking 
UDCA may be eligible to participate in the trial ( Section 7.2).  Subjects will be stratified by [CONTACT_22073], then randomized, in equal proportions, to each of the 
treatment groups ( Section 8.4.1).  
Rationale for Duration of D osing 
In the Phase 2 PBC trials with OCA, the double-blind (DB) evaluation of the reduction in ALP associated with OCA treatment was evaluated over 85 days.  Significant reductions in ALP were 
observed as early as 2 to 4 weeks with maximal reductions (at a single dose level) apparent by 
8 weeks.  Due to similarities in the cholestatic etiology of PSC and PBC, it is anticipated that a similar evaluation period will be sufficient to evaluate OCA in PSC.  As such, the present trial 
will evaluate each dose over 12 week periods. 
5. TRIAL OBJECTIVES AND  PURPOSE  
5.1. Primary Objective 
To evaluate the effects of OCA on the following in subjects with PSC: 
â€¢ Serum ALP  
â€¢ Safety 
5.2. Secondary Objectives  
The secondary objectives are  to evaluate the effects of OCA on the following in subjects with 
PSC: 
Protocol 747-207 Version 5:  18 Mar  2016 
 Page 31 
Confidential and Proprietary    â€¢ Hepatic biochemistry and indices of function  
â€¢ Markers of:  
âˆ’ Hepatic fibrosis and GI inflammation and disease  
âˆ’ FXR activity  
âˆ’ Inflammatory bowel disease (IBD)  
â€¢ PK of OCA and oth er bile acids  
â€¢ Exposure response of total OCA (OCA and its conjugates) to biomarkers eg, ALP and 
bile acids  
â€¢ Long-term efficacy and safety of OCA  
â€¢ Disease-specific symptoms 
6. INVESTIGATIONAL P LAN 
6.1. Overall Trial Design  
Double-blind phase  (DB) 
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding evaluation of the 
efficacy and safety of OCA in subjects with PSC.  The trial design is shown in Figure 1 and the 
schedule of trial procedures for the DB phase is presented in Table 1.  Approxi mately 75 subjects 
who provide written informed consent and meet all of the inclusion and none of the exclusion 
criteria will be randomized to 1 of 3 treatment groups as follows:  1.5 mg titrating to 3.0 mg 
OCA, 5 mg titrating to 10 mg OCA, or placebo in a 1:1:[ADDRESS_21082]â€™s dose will be 1.[ADDRESS_21083]â€™s dose will be titrated  as detailed in Section 6.4.1 and 
DB treatment will continue for a  further 12 weeks at that dose.   
Randomization will be strat ified by [CONTACT_22074] (â‰¤1.5x ULN or >1.5x ULN but <2.5x ULN). 
Long-Term Safety Extension  Phase (LTSE)  
Following completion of participation in the DB phase, subjects will be asked to reconfirm their 
consent for participation in the LTSE phase (a further 24 months).  The schedule of trial 
procedures for the LTSE is shown in Table 2. 
Upon a subjectâ€™s completion of the DB phase, the trial blind will be broken in order to assign the starting OCA dose for the LTSE phase.  It is intended that subjects will commence treatment at [ADDRESS_21084] to be titrated in line with Table  4, this may be discussed 
with the Medical Monitor. 
3URWRFRO 9HUVLRQ0DU
 3DJH
&RQILGHQWLDODQG3URSULHWDU\ 7ULDO'HVLJQ'LDJUDP
)LJXUH 7ULDO'HVLJQ6FKHPDWLF

Protocol 747-207 Version 5:  18 Mar 2016 
 Page 33 
Confidential and Proprietary    Table 1: Schedule of Trial Procedures:  Double -Blind Phase  
Visit Typea Screening  
(Day -30 to 
Day -1) Day 0b Visit  
W2 Visit  
W6 Visit 
W12c Visit  
W14 Visit  
W18 Visit W24d/ 
LTSE D1/ 
EOTe FU  
(4 wks)f 
Visit Windo wg â‰¤30d  Â±3d Â±1wk Â±1wk Â±1wk Â±1wk Â±1wk Â±1wk 
Informed Consent X         
Medical History  X         
Concomitant Medication 
Review X X X X X X X X X 
Inclusion/Exclusion  X X        
Physical Exam  Xh       X  
Vital Signsi X X X X X X X X X 
12-Lead ECG X       X  
Transient Elastographyj  X      X  
Hepatic Ultrasoundk X       X  
Partial Mayo Scorel,m  X X X X X X X X X 
CDAIm,n X X X X X X X X X 
Pruritus VAS and [ADDRESS_21085] Research 
Questionnaireo        X  
Adverse Events   Xp X X X X X X X 
Randomization   X        
Protocol 747-207 Version 5:  18 Mar 2016 
 Page 34 
Confidential and Proprietary    Table 1: Schedule of Trial Procedures:  Double -Blind Phase (Continued)  
Visit Typea Screening  
(Day -30 to 
Day -1) Day 0b Visit  
W2 Visit  
W6 Visit 
W12c Visit  
W14 Visit  
W18 Visit W24d/ 
LTSE D1/ 
EOTe FU  
(4 wks)f 
Visit Windowg â‰¤30d  Â±3d Â±1wk Â±1wk Â±1wk Â±1wk Â±1wk Â±1wk 
Dispense Investigational 
Product  Xq   X   Xr  
Investigational Product  
Accountability/ 
Compliances   X X X X X X  
Laboratory Evaluationst 
Serum Chemistry , 
Hematology , & Coagulation 
Parameters  Xu X X X X X X X X 
FGF-19  X   X   X  
CRP  X   X   X  
ELF Markers & Other 
Analytesv  X   X   X  
Plasma Bile Acids   X   X   X  
C4  X   X   X  
PKw     X   X  
Apolipoprotein & NMR 
Lipoprotein Panel   X   X   X  
Dipstick Urinalysis  X X   X   X  
Urine Pregnancy Testx X X   X   X X 
Fecal Sampley  X   X   X  
Genetics Studyz  X      X  
 
Protocol 747-207 Version 5:  [ADDRESS_21086] be fasted prior to all clinic visits (except Screening) and investigational product should not be administered prior to clinic visits (see Section 8.1). 
b Day [ADDRESS_21087] to be eligible to continue in the trial.  
c Week 12 is the Dose Titration visit. 
d The Week 24 visit is the final visit during the DB treatment period.  For subjects who continue into the LTSE, the Week 24 visit is also Day 1 of the LTSE , and 
unblinding occurs after the Week 24/LTSE Day [ADDRESS_21088] been completed (except dispensing of open- label investigational product).  
e End of treatment (EOT) visit is completed for any randomized subject who discontinues the study prior to reaching Week 24 of the DB phase; this should occur 
as close as possible to the final dose of investigational product .  If a subject discontinues on th e day of a scheduled trial visit, the procedures from the scheduled 
visit will be recorded as EOT in the CRF.  
f Follow-Up visit: If a subject discontinues the study prior to the end of Week 24 or does not proceed into the LTSE, he/she returns to th e site for a Follow -Up 
visit, which should occur 4 weeks (Â±1 week) after her/his last dose of investigational product . 
g Timing of all visits is relative to Day 0.  
h Height is measured at the Screening visit only. 
i Vital signs:  oral temperature, sitting heart r ate (HR), respi[INVESTIGATOR_697], and sitting blood pressure ([BP] systolic and diastolic).  When taking HR, respi[INVESTIGATOR_862], and BP readings, subjects should be seated quietly for a minimum of 3 minutes before the readings are taken.  
j TE: at trial sites where  the FibroscanÂ® TE device is available.   TE has a 5 -day visit window.  For the Day 0 assessment, TE should occur either on Day 0 or 
within 5 days prior to Day 0.  For the Week 24 assessment, the TE should occur within Â±5 days of the onsite visit if it is n ot possible to schedule the TE on the 
same day as that visit, but the visit(s) should remain within the overall visit window . 
k Hepatic ultrasound has a Â±5-day visit window (ie, if it is not possible to schedule the ultrasound on the same day as the onsite  visit, it may occur within 5 days 
on either side of the visit, but the visit(s) should remain within the overall visit window).  
l Partial Mayo score completed only for subjects with UC.  
m Subjects with UC will be asked to complete a diary  the day prior to their next trial visit,  recording details since their last scheduled visit.  Subjects with CD 
should complete the diary in the [ADDRESS_21089] on Day 1 and at approximately the same time of day for the duration of the trial 
(see Section 8.1). 
r Investigational product is dispensed only for sub jects who continue into the LTSE.  (Dispensing of open -label investigational produc t occurs after completion 
of the Week 24/LTSE Day [ADDRESS_21090]â€™s treatment allocation .) 
s Investigational product accountability /compliance will include review of tablets and bottles dispensed and returned at each clinic visit  
t All laboratory samples (except urine and serum pregnancy test, if applicable) are analyzed by [CONTACT_15622].  
u IgG4 is included in the assessment  panel at Screening only.  
v Other analytes includes an additional blood sample for exploratory analysis.  
w PK samples will be collected from those subjects who have consented for PK sampling procedures.  Please refer to Section 10.[ADDRESS_21091] whose pregnancy is early terminated and wishes to continue in the trial.  
y Fecal sample:  for measurement of calprotectin and gut fecal microbiome; provision of a fecal sample by [CONTACT_22075].  The subject should be instructed to collect a fecal sample within 2 days of the scheduled vis it, as described in the laboratory manual.  
z Genetics study:  blood samples will be collected from those subjects who have consented for RNA sampling procedures.  
Protocol 747-207 Version 5:  18 Mar 2016 
 Page 36 
Confidential and Proprietary    Table 2: Schedule of Trial Procedures:  LTSE Phase  
Visit Typea,b LTSE D1/DB 
Visit W24c Contact 
W2 Visit 
M3 Visit 
M6 Visit 
M9 Visit 
M12 Visit 
M15 Visit 
M18 Visit 
M21 Visit M24/ 
EOTd FUe 
(4 wks) 
Visit Windowf Â±1wk Â±3 d Â±2wk Â±2wk Â±2wk Â±2wk Â±2wk Â±2wk Â±2wk Â±2wk Â±1wk 
Safety Contactg  X          
Concomitant Medication  
Review X  X X X X X X X X X 
Physical Exam  X         X  
Vital Signsh X  X X X X X X X X X 
12-Lead ECG  X         X  
Transient Elastographyi X     X    X  
Hepatic Ultrasoundj X     X    X  
Partial Mayo Scorek,l X  X X X X X X X X X 
CDAIl,m X  X X X X X X X X X 
Pruritus VAS and [ADDRESS_21092] 
Accountability/ Compliance
p X  X X X X X X X X  
Protocol 747-207 Version 5:  18 Mar 2016 
 Page 37 
Confidential and Proprietary    Table 2: Schedule of Trial Procedures:  LTSE Phase (Continued)  
Visit Typea,b LTSE D1/DB 
Visit W24c Contact 
W2 Visit 
M3 Visit 
M6 Visit 
M9 Visit 
M12 Visit 
M15 Visit 
M18 Visit 
M21 Visit M24/ 
EOTd FUe 
(4 wks) 
Visit Windowf Â±1wk Â±3 d Â±2wk Â±2wk Â±2wk Â±2wk Â±2wk Â±2wk Â±2wk Â±2wk Â±1wk 
Laboratory Evaluationsq 
Serum Chemistry , 
Hematology , & 
Coagulation Parameters  X  X X X X X X X X X 
FGF-19 X     X    X  
CRP X   X  X  X  X  
ELF Markers & Other 
Analytesr X     X    X  
Plasma Bile Acids & C4  X   X  X    X  
PKs X           
Apolipoprotein & NMR 
Lipoprotein Panel  X           
Dipstick Urinalysis  X   X  X  X  X  
Urine Pregnancy Testt X  X X X X X X X X X 
Fecal Sampleu X     X    X  
Genetics Studyv X     X    X  
a Subjects must be fasted prior to all clinic visits and investigational product  should not be administered prior to clinic visits (see Section 8.1). 
b If the Investigator is planning on up -titrating a subject at an LTSE visit, the subject needs to return for an additional Pre -Titration visit, approximately [ADDRESS_21093] then attends for the scheduled 3 month visit.  Subjects 
experiencing significant AEs (eg, severe pruritus) or other symptoms that are not tolerated, may not be eligible for tit ration.  After any increase in OCA dose, 
the Investigator or designee should contact [CONTACT_22076] [ADDRESS_21094] is 
dosing as directed.  
c The LTSE D1 is also the final visit (Week 24) of the DB treatment period.   For subjects continuing into the LTSE, unblinding occurs after the Week 24/LTSE 
Day [ADDRESS_21095] been completed (except dispensing of open- label investigational product).  
d End of treatment (EOT) visit is completed for any randomized subject who discontinues the LTSE prior to reaching Month 24; this should occur as close as 
possible to the f inal dose of investigational product.  If a subject discontinues on the day of a scheduled trial visit, the procedures from the scheduled visit will 
be recorded as EOT in the CRF.  
Protocol 747-207 Version 5:  18 Mar 2016 
 Page 38 
Confidential and Proprietary    e Follow-Up visit:  If a subject discontinues the LTSE prior to the end of Month 24, he/she returns to the site for a Follow -Up visit, which should occur 4 weeks 
(Â±1 week) after his/her last dose of investigational product .  
f Timing of all visits is relative to LTSE Day 1.  
g The Safety Contact [CONTACT_22077], and does not require an onsite visit.  
h Vital signs: oral temperature, sitting HR, respi[INVESTIGATOR_697], and sitting BP (systolic and diastolic).  When taking HR, respi[INVESTIGATOR_697], and BP readings, subjects 
should be seated quietly for a minimum of 3 minutes before the readings are taken.   
i TE:  at trial sites where the FibroscanÂ® TE device is available.  The TE should occur within Â±5 days of the onsite visit if it is not possible to schedule the TE on 
the same day as that visit, but the visit(s) should remain within the overall visit window.  
j Hepatic ultrasound has a Â±5-day visit window (ie, if it is not possible to schedule the ultrasound on the same day as the onsite visit, it may occur within 5 days 
on either side of the visit, but the visit(s) should remain within the overall visit window).  
k Partial Mayo score completed only for subjects with UC. 
l Subjects with UC will be asked to complete a diary the day prior to their next trial visit, recording details since their last scheduled visit.  Subjects with CD 
should complete the diary in the [ADDRESS_21096] is dispensed only for subjects who continue into the LTSE.  (Dispensing of open -label investigational product occurs after completion 
of the Week 24/LTSE Day [ADDRESS_21097]â€™s treatment allocation .)  
p Investigational product accountability / compliance will include review of tablets and bottles dispensed and returned at each clinic visit.  
q All laboratory s amples (except urine and serum pregnancy test, if applicable) are analyzed by [CONTACT_15622].  
r Other analytes includes an additional blood sample for exploratory analysis.  
s PK samples will be collected from those subjects who have consented for P K sampling procedures.  Please refer to Section 10.[ADDRESS_21098] whose pregnancy is early terminated and wishes to continue in the trial.  
u Fecal sample:  for measurement of calprotectin and gut fecal microbiome; provision of a fecal sample by [CONTACT_22075].  The subject should be 
instructed to collect a fecal sample within 2 days of the scheduled visit, as described in the laboratory manual.  
v Genetics study:  blood samples will be collected from those subjects who have consented for RNA sampling procedures.  
 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 39 
Confidential and Proprietary    6.1.2. Trial Duration 
Table 3: Planned Duration of Trial Phases  
DB Phase 
Time expected for all subjects to be enrolled Approximately [ADDRESS_21099] participation  Up to 7 months (including screening)  
LTSE 
Duration of individual subject participation  Up to 24 months  
DB Phase & LTSE  
Total duration of the trial ( first subject consented to 
last subject completing last study visit) Approximately [ADDRESS_21100]/Independent Ethics Committee (IRB/IEC) review and 
approval. 
6.2. Number of Subjects  
Approximately 75 subjects who meet eligibility criteria will be included in the trial.  
6.3. Treatment Assignment 
Eligible subjects will be randomized to 1 of 3 treatment groups and will initiate treatment with  
1.5 mg OCA, 5 mg OCA, or matching placebo.  Randomization will be in accordance to  a 
1:1:1 ratio (ie , 25 subjects/group).   
Subjects will be stratified by [CONTACT_22078], according to defined stratification criteria (Section  8.4.1) an d then 
randomized in equal proportions  to each of the treatment  groups.  
6.4. Dose Adjustment Criteria and Dose Titration  
6.4.1. Double-Blind Phase  
Following randomization, subjects will administer the assigned, blinded treatment once daily for 
[ADDRESS_21101]â€™s dose will be titrated  as follows, providing there are no limiting 
safety or tolerability concerns in the opi[INVESTIGATOR_689], while maintaining the trial blind:   
the 1.5 mg OCA treatment group will titrate to 3 mg , the 5 mg OCA treatment group will titrate 
to 10 mg OCA, and the placebo group will remain on placebo.  DB treatment will continue for a  
further 12 weeks at that dose .   
Any subjects whose dose is not titrated, due to safety or tolerability concerns, will remain on 
their starting treatment (1.5  mg OCA, 5 mg OCA, or placebo) for the remainder of the DB phase 
to Week 24. 
Protocol 747-207 Version 5:   [ADDRESS_21102]â€™s completion of the Week 24 visit, at the end of the DB phase, the trial blind will 
be broken in order to assign the starting OCA dose for the LTSE phase.  It is intended that 
subjects will commence treatment at 5 mg OCA, except those subjec ts who completed treatment 
in the DB phase with 10 mg OCA who will continue at 10 mg OCA ( Table 4) unless safety and 
tolerability warrant a dose reduction to 5 mg.    
Table 4: Initial LTSE Doses of OCA  
Investigational P roduct at End of DB Phase 
(once daily)  Investigational P roduct at Start of LTSE  
(once daily)  
Placebo 5 mg OCA  
3 mg OCA  5 mg OCA  
10 mg OCA  10 mg OCA 
Those subjects who did not up- titrate their dose at Week 12 in the DB phase can remain on their 
DB dose as indicated in  Table 5, or commence at 5 mg at the decision of the Investigator based 
on safety and tolerability of the DB dose at Week 24. 
Table 5: Initial LTSE Doses of OCA for Non -Titrating Subjects  
Investigational P roduct at End of DB Phase 
(once daily)  Investigational P roduct at Start of LTSE  
(once daily)  
1.[ADDRESS_21103] to be titrated in line with the above schedules, this 
may be discussed with the Medical Monitor.    
During the LTSE phase subjects may titrate to higher doses of OCA, at a frequency not greater 
than 3 monthly (ie, at each of the scheduled visits), up to a maximum dose of 10 mg daily.  The 
guideline for an increase in the dose of open- label OCA is based o n the goal of achieving 
ALP <1.5x ULN and tolerability.  Doses of OCA should be titrated as follows, unless clinically 
indicated:  1.5 mg to 3 mg, 3 mg to 5 mg, and 5 mg to 10 mg.  Intermediate doses (eg, 6.5 mg) may be considered as deemed appropriate by [CONTACT_737].  Dose should not exceed [ADDRESS_21104] to a prior dose or dosing frequency and this 
should be discussed with th e Intercept Medical Monitor in advance.  
6.4.3. Safety Criteria for Adjustment or Stoppi[INVESTIGATOR_22005] (DSMC) will review safety data from this  trial as well as 
other ongoing OCA trials at approximately quarterly intervals but at least every 6 months.  
Adjustments to or stoppi[INVESTIGATOR_22006]-defined doses may be considered based on DSMC 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 41 
Confidential and Proprietary    evaluation of OCA safety and tolerability .  At a minimum, the occurrence of 2 life threatening 
serious adverse events (SAEs) or an SAE resulting in death will trigger an unscheduled and 
unblinded review of the data by [CONTACT_22079].  Section 6.5 
details the criteria for trial termination.  Reasons for discontinuation of individual subjects are 
noted in Section  7.4.1 and Section 7.4.2. 
6.5. Criteria for Trial Termination 
The Sponsor r eserves the right to terminate the trial at any time.  Additionally, it is agreed that, 
for reasonable cause, the Investigator may terminate the trial at his/her site at any time.  
It is normal procedure to review the emerging safety data.  As a result of such a review or a recommendation by [CONTACT_6802], it may be necessary to stop the trial before all subjects have 
completed the trial.  In addition, the Sponsor may terminate the trial at an investigational site at 
any time (eg, due to the quality of data) , as determined by [CONTACT_22080] . 
The Investigator and/or Sponsor (or designee) must notify the IRB /IEC of discontinuation of a 
site or the trial and the reason for doing so.  Local requirements for not ification of trial 
termination will be adhered to.  
7. SELECTION AND WITHDR AWAL OF S UBJECTS  
7.1. Subject Population  
Approximately 75 subjects with PSC will be randomly assigned to treatment groups using an 
interactive web response system (IWRS).  Up to 50% of the trial population may be taking 
concomitant UDCA.  Once this cap is reached, only those subjects who have not been treated 
with UDCA for at least  3 months prior to and including Day 0 may be enrolled.  In addition, a 
maximum of 25% of enrolled subjects will have a total bilirubin between >1.5x ULN and <2.5x ULN  
at Screening.  Prospective subjects will be identified primarily from the hospi[INVESTIGATOR_3491]/or 
physicianâ€™s database of PSC subjects, or may be referred from other physicians.  Subjects may self-refer themselves to an Investigator if they become aware of the trial through local, national 
or international PSC patient societies, forums and networks or websites (eg, www.clinicaltrials.gov).  
7.2. Subject Inclusion Criteria  
Subjects must meet all of the following to be eligible to participate:  
1. Male or female aged [ADDRESS_21105] a diagnosis of PSC (based on cholangiography at any point in time) 
4. ALP at Screening â‰¥2x ULN.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 42 
Confidential and Proprietary    5. Total bilirubin at Screening <2.5x ULN.  
Note 1:  Subjects will be stratified according to total bilirubin level and no more than 
25% of subjects recruited will have a total bilirubin >1.5x ULN and <2.5x ULN a t 
Screening.  
6. For subjects with concomitant IBD:  
a. Colonoscopy (if subject has a colon) or other appropriate endoscopic procedure 
within 12 months of Day 0 confirming no dysplasia or colorectal cancer 
b. Subjects with Crohnâ€™s Disease (CD) must be in remission as defined by a Crohnâ€™s 
Disease Activity Index (CDAI) <150.   
c. Subjects with ulcerative colitis (UC) must either be in remission or have mild disease. Remission is defined as a partial Mayo score of â‰¤2 with no individual sub- score 
exceeding 1.  Mild disease is defined as a partial Mayo score â‰¤[ADDRESS_21106] been stable for â‰¥[ADDRESS_21107] 
exceeded 20 mg/kg/day during this time.  
Note 2:  Subjects not taking UDCA at Day [ADDRESS_21108] taken UDCA for â‰¥[ADDRESS_21109] not take UDCA during the DB period.  Subjects 
will be stratified according  to UDCA use, and no more than 50% of subjects 
administering UDCA at Day 0 will be enrolled.  
8. Subjects being administered biologic treatments (eg , anti-TNF or anti -integrin 
monoclonal antibodies), immunosuppressants , systemic corticosteroids , or statins, must 
have been on a stable dose for â‰¥3 months prior to, and including, Day 0  and should plan 
to remain on a stable dose throughout the trial.  
9. Contraception:  f emale subjects of childbearing potential  must use â‰¥1 effective method 
(â‰¤1% failure rate) of contraception during the trial and until [ADDRESS_21110] (including LTSE doses).  Effective  methods of 
contraception are considered to be those listed below : 
â€¢ Barrier method, ie , (a) condom (male or female) with spermicide or (b) diaphragm 
with spermicide; or  
â€¢ Intrauterine device ; or 
â€¢ Vasectomy (partner), or  
â€¢ Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, intramuscular implant or injection ) 
â€¢ Abstinence, if in line with the preferred and usual l ifestyle of the subject  [where 
abstinence is defined as refraining from heterosexual intercourse during the trial duration ( from first administration of investigational product until [ADDRESS_21111] )] 
Protocol 747-207 Version 5:   [ADDRESS_21112] Exclusion Criteria 
Subjects will be excluded from trial participation if they meet any of the following:  
1. Evidence of a secondary cause of sclerosing cholangitis at Screening  
2. Immunoglobulin G4 ( IgG4) >4x ULN at Screening or evidence of IgG4 sclerosing 
cholangitis 
3. Small duct cholangitis in the  absence of large duct disease  
4. Presence of clinical complications of chronic liver disease or clinically significant hepatic 
decompensation, including:  
â€¢ Current Child-Pugh classification B or C 
â€¢ History of, or current diagnosis or suspi[INVESTIGATOR_1884], CCA or other hepatobiliary 
malignancy, or biliary tract dysplasia. 
â€¢ History of liver transplantation, or current model of end stage liver disease ( MELD) 
score â‰¥12  
â€¢ History of, or current, cirrhosis with complications, including history or presence of 
spontaneous bacteri al peritonitis,  hepatocellular carcinoma, or hepatic 
encephalopathy (as assessed by [CONTACT_737]) 
â€¢ Current known portal hypertension with complications, including known gastric or large esophageal varices, poorly controlled or diuretic resistant ascites , history of 
variceal bleeds, or related therapeutic or prophylactic interventions (eg, beta blockers, 
insertion of variceal bands or transjugular intrahepa tic portosystemic shunt [TIPS])  
â€¢ History of, or current, hepatorenal syndrome (type I or II) or Scree ning serum 
creatinine >2 mg/dL (178 Î¼mol/L) 
â€¢ Platelet count <50  x10
9/L 
5. Current clinical evidence of dominant strictures that are considered clinically relevant in 
the opi[INVESTIGATOR_2511] I nvestigator or current biliary stent at Screening 
6. Current cholecystitis or evidence of current biliary obstruction due to gallstones. 
Asymptomatic gallstones that are not considered a safety risk in the opi[INVESTIGATOR_21992] 
7. Colonic dysplasia within â‰¤5 years prior to Day 0  
8. History of any small bowel resection.  
9. History of other chronic liver diseases , including, but not limited to, PBC, alcoholic liver 
disease, non -alcoholic fatty liver disease (NAFLD), autoimmune hepati tis, hepatitis B 
virus (unless seroconverted and no positive Hepatitis B Virus DNA), hepatitis C virus, 
and overlap syndrome  
10. Known Gilbertâ€™s syndrome or history of elevations in unconjugated (indirect) bilirubin >ULN or unconjugated (indirect) bilirubin >U LN at Screening 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 44 
Confidential and Proprietary    11. Known history of human immunodeficiency virus (HIV) infection 
12. Currently experiencing , or experienced within â‰¤3 months of Screening , pruritus requiring 
systemic or enteral treatment . 
13. Known or suspected acute cholangitis in the 3 months prior to, and including, Day 0  
including cholangitis treated with antibiotics  
14. Administration of antibiotics is prohibited â‰¤1 month of Day 0 (unless subject is on a 
stable prophylaxis dose for at least 3 months prior to Day 0 ). 
15. Administration of the following medications is prohibited â‰¤6 months of Day 0 and 
throughout the trial:  fenofibrate or other fibrates and potentially hepatotoxic medications 
(including Î±-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin) 
16. IBD flare during Screening (up to and including Day 0) , where â€œflareâ€ is defined as 
follows: 
â€¢ UC flare:  partial Mayo Score â‰¥5, and  
â€¢ CD flare:  CDAI â‰¥250 
17. Evidence of deleterious effects of alcohol abuse (as assessed by [CONTACT_737]) or 
excessive alcohol consumption (>4 units/day for males, >2 units/day for females)  
18. Known or suspected use of illicit drugs or drugs of abuse (allowed if medically 
prescribed or indicated) within 3 months of Day 0 
19. If female:  known pregnancy, or has a positive urine pregnancy test (confirmed by a 
positive serum pregnancy test), or lactating  
20. Other concomitant disease, malignancy, or condition likely to significantly decrease life expectancy to less than the duration of the trial (eg, moderate to severe congestive heart failure) 
21. Participation in another investigational drug, biologic, or medical device trial within [ADDRESS_21113] be followed by [CONTACT_22081].  The mother and infant will be follow ed as considered 
appropriate by [CONTACT_22082].   
Protocol 747-207 Version 5:   [ADDRESS_21114] to restart dosing is documentation of a negative 
serum beta human chorionic gonadotrophin (Î²-hCG) test.  However, this is not in and of itself a guarantee for being allowed to continue in t he study.  For reporting purposes, pregnancy is not 
considered a SAE but is reported on the Pregnancy Notification Form (see Section 11.1.9). 
Clinical Laboratory Values 
Development of the following clinical laboratory values, without explanation, during the course 
of the DB and LTSE phases of the trial mandates investigational product discontinuation: 
â€¢ AST and/or ALT >3x ULN AND 2x the Baseline value OR 
â€¢ Two consecutive measurements of total  bilirubin > ULN AND >2x the Baseline value 
in the absence of evidence of new biliary obstruction.  
The term â€œBaselineâ€ within this protocol, unl ess otherwise specified, is intended to mean, 
â€œpretrialâ€ or â€œ pretreatmentâ€ (of investigational product ).  It refers to values obtained 
during the Screening, retests, or Day [ADDRESS_21115]â€™s first dose of 
investigational product. 
If a subject is required to discontinue investigational product due to an increase in AST , ALT, or 
bilirubin, the subject must be followed at appropriate intervals until these parameters have 
returned to within the normal range or pretrial values , and/or are stable or there is are stable, or 
there is no ongoing clinical concern.  
IBD Flares 
Subjects who experience 3 or more IBD flare -ups in one year during the study will be 
discontinued, where â€œflareâ€ is defined as follows:  
â€¢ For UC flare:  as a partial Mayo Sco re â‰¥5, and  
â€¢ For CD flare:  as a CDAI â‰¥[ADDRESS_21116] should be discontinued from the study if:  
â€¢ The subject decides that it is in his/her best interest.  It is fully understood that all 
subjects volunteer for the trial and that they may withdraw their consent to continue 
in the trial at any time.  
â€¢ The Investigator considers that it is advisable or in the best interest of the subject.  
â€¢ There is a major violation of the clinical trial protocol for the subject  that would 
jeopardize the subjectâ€™s safety and/or data quality.  
â€¢ There is significant n oncompliance of the subject that would jeopardize the subjectâ€™s 
safety and/or data quality . 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 46 
Confidential and Proprietary    â€¢ The development of any exclusion criteria (see Section  7.3) that would jeopardize the 
subjectâ€™s safety and/or data quality . 
â€¢ The subject is consistently unable to provide blood or urine samples. 
â€¢ There is an occurrence of clinical or laboratory AEs considered by [CONTACT_941] I nvestigator to 
be clinically important, such that they would jeopardize the subjectâ€™s safety. 
A reasonable effort must be made to determine the reason(s) why a subject fails to return for 
his/her final visit or is discontinued from the trial.  This information and date must be recorded 
on the appropriate case report form ( CRF). 
Bacterial Cholangitis  
It is anticipated that 10% to15% of subjects may experience bacterial cholangitis at some point during participation in the trial ( Lee 2002).  Bacterial cholangitis is generally associated with 
elevation of serum bilirubin, ALP, and transaminases in conjunction with clinical signs and symptoms and positive diagnostic imaging tests.  Local guidelines should be followed for the management of pa tients with acute bacterial cholangitis.  In the absence of such local guidelines, 
the following guidelines should be followed if acute cholangitis is suspected:  
â€¢ Diagnosis of acute cholangitis should be established based on a combination of typi[INVESTIGATOR_22007], laboratory data, and imaging findings.  Subsequent to an 
intervention to relieve biliary obstruction ac ute cholangitis may occur with typi[INVESTIGATOR_22008], right upper quadrant pain, and jaundice (also known as the Charcot triad).  Further confirmation of the 
diagnosis should then be made via laboratory data (eg, elevated C- reactive protein 
levels and/or leukocytosis) and abdominal imaging tests (magnetic resonance 
cholangiopancreatography).   
â€¢ Treatment of acute cholangitis should be directed towards treatment of the biliary 
infection and relieving obstruction.  Therefore, treatment is comprised of systemic 
antibiotic therapy and biliary drainage procedures, with appropriate supportive care.  
â€¢ Antibiotic agents should be administered empi[INVESTIGATOR_22009].   Blood and 
bile cultures should also be performed at the earliest opportunity and prior to initiating antibiotic treatment, if possible. 
â€¢ The selection of an antibiotic agent should be based on likely infecting bacteria, the severity of the disease, and the presence of comorbidities.  Empi[INVESTIGATOR_22010].   The use of amoxicillin/clavulanate a nd other antibiotic treatments with 
potential for hepatotoxicity should be avoided. 
Investigational product may be interrupted at the discretion of the Investigator.  Discontinuation 
from the trial is not mandatory in cases of bacterial cholangitis unless signs and symptoms do not 
resolve within a clinically reasonable timeframe (typi[INVESTIGATOR_16195] 1 month or as agreed upon with the Medical Monitor) or the cholangitis becomes life -threatening in the opi[INVESTIGATOR_22011] M edical Monitor.  In any event, investigational product should not be restarted 
until signs and symptoms have resolved and the subjectâ€™s liver biochemistry has returned to pre-cholangitis level s.   
Protocol 747-207 Version 5:   [ADDRESS_21117] with â‰¥[ADDRESS_21118] experiences an IBD flare during the trial (post-Day 0), he/she may remain on investigational product but this should be discussed with the M edical Monitor and IBD flares 
should be treated as follows (but adjusted based upon local guidelines and standards of care, disease severity and personal patient preferences, as appropriate):   aminosalicylates alone (high 
dose if appropriate) or with a topi[INVESTIGATOR_22012]/or topi[INVESTIGATOR_2855], oral, or intravenous 
corticosteroids or immunosuppressant therapy, including anti-TNF therapy.  Surgery may be 
required in severe cases that are refractory to medicinal treatment.  
Subjects who experience [ADDRESS_21119] 
develops a stricture requiring intervention (eg, drainage, ERCP, stent) in order to re- establish bile 
flow.  If the investigational product has been interrupted and the subject  does not show 
improvement within [ADDRESS_21120] administration or to continue in the trial. 
Pruritus 
Pruritus is a common symptom in  PBC but less  common in PSC (Chapman 2011).   Investigator 
guidance for pruritus management strategies are outlined in  Section [IP_ADDRESS] of this protocol.  
Subjects who experience one or more epi[INVESTIGATOR_22013] , despi[INVESTIGATOR_22014]  [IP_ADDRESS], 
should be discontinued from the trial . 
7.4.3. Subject Discontinuation Notification  
The Investigator must notify the Intercept CRA by [CONTACT_22083].  The date when the subject is 
withdrawn and the primary reason(s) for discontinuation must be recorded in the CRF ; additional 
information may be requested by [CONTACT_22084] a discontinuation narrative.  A subject 
will be considered â€œlost to follow-upâ€ (fail to return for a visit) only after reasonable, 
documented attempts to reach the subject prove unsuccessful.  In all cases, a reasonable effort must be made to determine the reason(s) that a subject fails to return for required trial visits or discontinues from the trial.  This information must be documented in the CRF. 
If a subject is withdrawn from either the DB phase or the LTSE phase of the trial early 
(regardless of the cause), all of the End of Treatment  (EOT) evaluations are to be performed at 
the time of withdrawal, and as close as possible to the administration of the last dose of 
investigational product, to the extent possible. 
Protocol 747-207 Version 5:   [ADDRESS_21121] Treatment Regimen 
Subjects enrolled in the trial will be treated with OCA and/or placebo.  On Day 0, subjects will 
be randomized to one of the following treatments:  placebo, 1.5 mg OCA, or 5 mg OCA.  
Because there are 2 different sizes of tablet used in this trial (1.5 mg OCA tablet and matching 
placebo are smaller than the 5 mg OCA and matching placebo), in the DB phase all subjects 
randomized to receive OCA will be administered with both OCA and placebo tablets, whereas subjects randomized to placebo will receive only placebo tablets (ie, a double-dummy approach).  
In order to maintain the blind, the daily treatment regimen for each effective dose is shown in  
Table 6.  At the Week [ADDRESS_21122] whose dose is not titrated, due to safety or tolerability concerns, will remain on their starting treatment (1.5 mg OCA, 5 mg OCA, or placebo) for the final 
[ADDRESS_21123] 12 weeks of the DB phase, subjects will be instructed to administer 2 tablets daily  with water :  one 1.5 mg 
(small) tablet and one 5 mg (big) tablet.   During weeks 12 through 24 of the DB phase, subjects 
will be instructed to administer four tablets daily:  two 1.5 mg (small) tablets and two 5 mg (big) 
tablets. 
During the LTSE subjects will administer open- label OCA as  described in Section  6.4.[ADDRESS_21124] will be administered on the 
day prior to their LTSE Month 24 visit. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 49 
Confidential and Proprietary    Table 6: Daily Tablet Regimen by [CONTACT_22085]  1.5 mg OCA 
Tablet 1.5 mg Placebo 
Tablet 5 mg OCA 
Tablet 5 mg Placebo 
Tablet 
DB Phase After Day 0  
Placebo - 1 - 1 
1.5 mg OCA  1 - - 1 
5 mg OCA  - 1 1 - 
DB Phase After Week 12  
Placebo - 2 - 2 
3 mg OCA  2 - - 2 
10 mg OCA  - 2 2 - 
LTSE 
1.5 mg OCA  1 - - - 
3 mg OCA  2 - - - 
5 mg OCA  - - 1 - 
10 mg OCA  - - 2 - 
8.2. Concomitant Medications  
Relevant information about all concomitant drugs (including prescribed, over- the-counter, or 
herbal preparations) taken prior to (ie, within 30 days of Screening) and during the trial must be 
recorded in the source documents and CRF , as well as any dose or dose regimen changes that 
occur during the trial. 
8.2.1. Ursodeoxycholic A cid 
Subjects taking UDCA  at Day 0 should maintain this dose and the timing of administration of 
UDCA for the duration of the DB phase of the trial (24 weeks).  Subjects who are not taking 
UDCA on e ntry into the trial should not initiate UDCA therapy at any time during their 
participation in the DB phase of the trial.  
During the LTSE phase, UDCA may be used as considered clinically appropriate, provided the dose of UDCA does not exceed 20 mg/kg/day. 
8.2.2. Bile Acid Sequestrants  
While systemic or enteral therapy for pruritus is an exclusion criterion at trial entry, the treatment 
of pruritus during the trial is permitted if required.   
Bile acid sequestrants (BAS), aluminium hydroxide, or smectite- containing  antacids should be 
administered at least [ADDRESS_21125] (ie, they should be used [ADDRESS_21126] administration).  
Protocol 747-207 Version 5:   [ADDRESS_21127] 4 hours apart from UDCA (ie, they should be used 4 hours prior to or 4 hours after 
UDCA administration).  
8.2.3. Prohibited Medications  
Administration of the following medications is prohibited as specified below unless discussed and agreed with the M edical Monitor:  
â€¢ Systemic or enteral therapy for pruritus in the [ADDRESS_21128] adm inistration . 
â€¢ Administration of antibiotics within 1 month of Day 0 (unless subject is on a stable prophylaxis dose for at least 3 months prior to Day 0) , except if administered for 
acute cholangitis whereby [CONTACT_22086] 3 months of Day 0.  
â€¢ NOTE:  Antibiotics are permitted as required during participation in the trial except amoxicillin/clavulanate (Augmentin) which has restrictions as detailed below.  
â€¢ Prohibited from 6 months prior to Day 0 and throughout the LTSE phase of the trial  
unless as noted to discuss with Medical Monitor :  
âˆ’ Fenofibrate or other fibrates  
âˆ’ Potentially hepatotoxic drugs (including Î±-methyl-dopa, sodium valproic acid, 
isoniazide, or nitrofurantoin)  
âˆ’ Amoxicillin/clavulanate (Augmentin) should not be used unless there are no other 
treatment options (this should be discussed with the M edical Monitor in advance 
of their use in this situation, where possible).  Augmentin is also discouraged in the treatment of cholangiti s but is not outright excluded ( Section 7.4.2). 
Subjects being administered the following medications at Day [ADDRESS_21129] been on a stable dose for â‰¥3 months prior to, and including, Day 0 and remain on a stable 
dose throughout the trial:  
â€¢ Anti-TNF and anti-integrin antibodies 
â€¢ Immunosuppressants (eg, azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline) 
â€¢ Corticosteroids  
â€¢ Statins 
8.3. Treatment Compliance 
The Investigator should assess the subjectâ€™s compliance with dosing of investigational product 
on an ongoing basis and at each contact [CONTACT_22087] ; this should be confirm ed by [CONTACT_22088] (ie, count of returned tablets) during subjectsâ€™ on site visits.  
Subjects should be instructed to retain all bottles of investigational product, even if empty, and to 
return them to the Investigator at the subsequent visi t.  The Investigator  or designee should 
Protocol 747-207 Version 5:   [ADDRESS_21130]â€™s dosing compl iance she/he should discuss this 
with the subject, assess the reasons for noncompliance and the likelihood that the subject will 
remain noncompliant, and notify the Sponsor accordingly.  Continued trial eligibility should be 
assessed. 
8.4. Randomization and Blinding 
At Day 0, after review of Inclusion and Exclusion criteria, subjects will be allocated to 1 of 3 treatment groups in a 1:1:1 ratio based on a predefined randomization code (generated by [CONTACT_12066]) using the IWRS, which will serve as the registration system for subjects at Screening, Day 0, and entry into the LTSE phase.  The IWRS will serve as an investigational 
product inventory and management system and may be integrated with the trial database.  
The Investigator or designee will be required to register the subject in the IWRS and may be 
prompted to provide subject data necessary to randomize and allocate the subject to treatment.  
A randomization number will be assigned and investigational product disp ensing information 
(eg. bottle number[s]) will be provided while maintaining the trial blind.  The subjects, 
Investigator, and trial site staff will be blinded to the subjectâ€™s treatment allocation during the 
subjectâ€™s participation in the DB phase of the trial.   The IWRS system will facilitate the 
unblinding of an individual subject at the time the subject completes the DB phase and enters the 
LTSE phase of the trial (ie, subjectsâ€™ treatment allocations are unblinded one-by-one.   
8.4.1. Stratification  
In order to ensure that factors which could potentially affect treatment response are randomized 
in equal proportions to the different treatment groups, subjects will be stratified by  [CONTACT_716]: 
â€¢ The presence or absence of concomitant UDCA use, where no more than 50% of 
subjects recruited will be administering UDCA as part of standard of care at Day 0  
â€¢ Total bilirubin level, where no more than 25% of subjects recruited will have a total 
bilirubin >1.5x ULN and <2.5x ULN at Screening  
8.4.2. Unblinding Procedures â€“ Emergenc y Unblinding  
For the DB phase of the trial, treatment assignment will be made available to the Investigator for 
emergency use only through the IWRS.  When possible, the M edical Monitor should be 
consulted in the event that a medical emergency necessitates unblinding (ie, in situations where 
knowledge of the blinded treatment is necessary for further medical management of the subject).  If it is not reasonable to inform the Medical Monitor in advance of unblinding, the Investigator 
must promptly document in the subjectâ€™s source record and should subsequently contact [CONTACT_22089] (such as 
accidental unblinding or unblinding due to an SAE).  Procedures for unblinding a subjectâ€™s 
treatment will b e provided separately to the I nvestigator.  Similarly, if the Medical Monitor 
breaks the blind for the purpose of evaluating an emergent safety issue, the M edical Monitor will 
document within trial documentation the rationale, circumstances, and the person or persons being informed about the unblinding. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 52 
Confidential and Proprietary    The DSMC (refer to Section 12.6.2) will have access to the IWRS and will be able to unblind 
individual subjects.  Refer to Section  12.6.2 for further details regarding DSMC access to 
blinded and unblinded data.  The DSMC will document, in the closed session DSMC minutes 
(which will be made available to the Sponsor only after the database is locked and the trial is unblinded), details about any unblinded subject data reviews.  Cases of premature unblinding 
(as noted above) will be reviewed by [CONTACT_6802]. 
Access to treatment assignments will also be made available through the IWRS to the 
appropriate, named individual(s) responsible for reporting SAEs and suspected unexpected 
serious adverse reactions (S[LOCATION_003]Rs) to the regulatory a uthorities.  
8.5. Assignment of Site and Subject Numbers  
8.5.1. Site Numbers  
Each trial site selected to participate in this trial will be assigned a Site Number by  [CONTACT_1034].  
The Site Number will be used to identify the site and or Investigator within trial documents.  
This number will also  be recorded in the CRF . 
8.5.2. Subject Numbers  
Subjects will be identified by a [ADDRESS_21131]  will be assigned the next sequentially 
available number  (eg, 001, 002, 003, etc).  
8.6. Visit Procedures  
8.6.1. Visit Windows  
All trial visits during the DB period are relative to Day 0 (eg, if the Week 6 visit occurs 4 days 
late, the Week  12 visit should still be 12 weeks from Day 0).  The Screening visit should occur 
â‰¤30 days (ie, Day - 30 to Day -1) pri or to the Day 0 visit.  All visits during the DB treatment 
period should occur within Â±1 week of the indicated time.  The exception to this is the Week 2 
visit, which should occur within Â± 3 days of the indicated time.  
During the LTSE period, visits are relative to LTSE Day 1 (which is also the DB Week  24 visit) 
and all visits during th is period should occur within Â±[ADDRESS_21132] which should occur within Â± 3 days and the Follow-Up visit, which 
should occur within Â± [ADDRESS_21133] 
and will provide him/her with a copy of the patient information sheet (PIS), containing the 
written information, and the informed consent form (ICF).  The subject will be given sufficient 
time to consider the trial before deciding whether or not to participate, in line with local 
requirements where applicable.  The subject will be informed that participa tion is voluntary and 
that her/his future medical treatment will not be compromised by [CONTACT_22090]/he can withdraw from the trial at any time.  The subject must be willing and able to 
Protocol 747-207 Version 5:   [ADDRESS_21134]â€™s medical notes/source worksheet .  The subject will be 
provided with copi[INVESTIGATOR_22015]. 
At selected trial sites, subjects will have the option to consent to participate in an additional PK 
and bile acid assessment.   
As part of the consenting process, the Investigator or designee will describe the intention for and 
implications of providing blood samples for the analysis of RNA to each subject.  Subjects who 
agree to provide these samples will be required to sign a separate ICF and will be provided with 
a copy of this, in addition to the overall study ICF.  The samples will be stored for up to 1 year after the end of the study. 
8.6.3. Screening Procedures ( Within 30 Days of Day 0) 
The Screening visit assessm ents must be performed within â‰¤30 days (ie, Day -30 to Day -1) prior 
to Day [ADDRESS_21135] meets all the inclusion criteria and none of the 
exclusion criteria.   
Subjects who do not meet all eligibility criteria during Screening may undergo repeat Screening 
assessments (one repeat only) at any time after 30 days from their initial date of consen ting for 
the trial.  Re -screened subjects will be allocated a new screening number.   
The term â€œBaselineâ€ within this protocol, unless otherwise specified, is intended to mean, 
â€œpretrialâ€ or â€œ pretreatmentâ€ (of investigational product ).  It refers to values obtained during the 
Screening, retests, or Day [ADDRESS_21136]â€™s first dose of investigational product.  The 
statistical o r calculated definition(s) of â€œB aselineâ€ to be used in the analyses of the data may be 
different and will be further defined in the statistical analysis plan (SAP) for this trial.  
Screening v isit procedures are as follows:  
â€¢ The subject is to review  the PIS and sign the ICF.  Written informed consent must be 
obtained from the subject before performing any trial related procedures, including 
Screening procedures.   (Note:  Collection of AEs commences from the point the 
subject signs the consent form.) 
â€¢ Assign subject number. 
â€¢ Collect medical  history. 
â€¢ Record prior (within 30 days of Screening ) and current c oncomitant medications . 
â€¢ Verify inclusion and exclusion criteria for eligibility . 
â€¢ Perform a physical examination, including height and weight.  See Section  11.2.2 for 
physical examination requirements. 
â€¢ Record vital signs. 
â€¢ Perform a standard 12- lead electrocardiogram (ECG). 
â€¢ Perform hepatic ultrasound to assess bile duct patency . 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 54 
Confidential and Proprietary    â€¢ For subjects with UC:  provide the diary and request subject completes this the day 
prior to the Day [ADDRESS_21137] their symptoms since the Screening visit .   
â€¢ For subjects with CD:  provide the diary and request subject completes this for each 
of the 7 consecutive days prior to the Day 0 visit.   
â€¢ Obtain blood samples for s erum chemistry , hematology, and coagulation.  
Note:  
If a subject has an ALP value <2x ULN, a further sample may be taken during the 
Screening period (at least 14 days after the initial sample was taken), and provided 
the mean ALP is â‰¥2x ULN, the subject will have met inclusion criterion 4 (ALP at 
Screening â‰¥2x ULN) 
If a subject has a total bilirubin value >1.5x ULN, a further sample may be taken 
during the Screening period (at least 14 days after the initial sample was taken), and 
provided the mean total bilirubin is <2.5x ULN, the subject will have met inclusion 
criterion 5 (t otal bilirubin at Screening <2.5x ULN â€“ in line with the bilirubin 
stratification factor:  no more than 25% of subjects recruited will have a bilirubin >1.5x ULN and <2.5x ULN). 
â€¢ Obtain urine sample for dipstick analysis 
â€¢ Perform a urine-based beta human chorionic gonadotrophin (Î²-hCG) pregnancy test in females of childbearing potential.  If the urine pregnancy test is positive, it should be repeated as a serum pregnancy test.  
â€¢ The subje ct should be:  
âˆ’ Provided with a fecal sampling kit and instructed to collect the sample within 2 days of their Day 0 visit, as described in the laboratory manual.   
âˆ’ Instructed to fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all on site trial visits, but water is permitted.  
8.6.4. Day 0 Procedures 
â€¢ Verify inclusion and exclusion criteria for eligibility . 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ Perform transient elastography (TE) at sites where  the Fibrosc an
Â® TE device  is 
available.  
â€¢ For subjects with UC:  obtain partial Mayo s core (excluding endoscopy)  using the 
data from the diary card provided at the Screening visit . See Appendix B  for details.  
â€¢ For subjects with CD:  complete CDAI assessments using the data from the diary card 
provided at the Screening visit .  See Appendix F  for details.  
â€¢ Administer pruritus visual analogue scale (VAS) subject questionnaire and 5- D Itch 
Questionnaire.  See Appendix C  for details. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 55 
Confidential and Proprietary    â€¢ Assess and record AEs.  
â€¢ Obtain blood samples for the following: 
âˆ’ Serum chemistry , hematology, and coagulation  
âˆ’ FGF-19   
âˆ’ C-reactive protein (CRP) 
âˆ’ Enhanced liver fibrosis (ELF) markers and other analytes 
âˆ’ Plasma bile acids and 7Î±-hydroxy-4- cholesten -3-one (C4)  
âˆ’ Apolipoprotein and nuclear magnetic resonance (NMR) lipoprotein panel 
âˆ’ Genetics study (if subject has consented to provide a sample for RNA analysis)  
â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine based Î²- hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test.  
â€¢ Obtain fecal sample for calprotectin and microbiome assessments (from subjects 
willing to provide a fecal sample). 
â€¢ After verifying eligibility, randomize the subject via the IWRS system .  
â€¢ Dispense the indicated investigational product. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 cons ecutive days prior to their next scheduled visit (for subjects 
with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ All subjects are to administer the first dose of investigation al product  on Day [ADDRESS_21138] should occur at approximately the same time of day throughout the duration of the trial.  Further details are included 
in Section  8.1. 
âˆ’ NOT to take investigational product on the morning of the next trial visit, and  
âˆ’ To bring the investigational product bottle(s) and  
âˆ’ To fast overnight (at least 8 hours) prior to the next trial visit.  Fas ting is required 
prior to all trial visits, but water is permitted , and the subject should dose at the 
visit after all assessments have been performed . 
8.6.5. Week 2 Procedures  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 56 
Confidential and Proprietary    â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch Questionnaire . 
â€¢ Obtain blood samples for s erum chemistry , hematology, and coagulation.  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21139] been performed . 
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns. 
â€¢ Record the visit in IWRS . 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects 
with CD) and the day prior to their next scheduled visit (for UC subjects).   
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next trial visit, and  
âˆ’ To bring the investigational product bottle(s) and  
âˆ’ To fast overnight (at least 8 hours) prior to the next trial visit.  Fasting is required 
prior to all trial visits, but water is permitted , and the subject should dose at the 
visit after all assessments have been performed . 
8.6.6. Week 6 Procedures  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Obtain blood samples for s erum chemistry , hematology, and coagulation. 
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21140] that fasting is required prior to all trial 
Protocol 747-207 Version 5:   [ADDRESS_21141] been performed . 
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns. 
â€¢ Record the visit in IWRS . 
â€¢ Subjects with UC or CD: provide the appropriate diary card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects 
with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s) and  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all trial visits, but water is permitted , and the subject should dose at the visit 
after all assessments have been performed . 
â€¢ The subject should be provided with a fecal sampling kit and instructed to collect the sample within 2 days of her/his Week 12 visit, as described in the laboratory manual.   
8.6.7. Week 12 (Titration Visit) Procedures  
â€¢ Assess and  record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Obtain blood samples for the following: 
âˆ’ Serum chemistry , hematology, and coagulation  
âˆ’ FGF-19  
âˆ’ CRP 
âˆ’ ELF markers and other analytes 
âˆ’ Plasma bile acids and C4  
âˆ’ Apolipoprotein and NMR lipoprotein panel 
â€¢ For sites and subjects participating in PK sampling:  obtain samples for PK analysis 
(see Section 10.5 for sampling schedule) .  Subjects undergoing PK sampling should 
take the currently assigned dose (ie, lower dose); the titrated dose should be taken by 
[CONTACT_22091]. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 58 
Confidential and Proprietary    â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine based Î²-hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Obtain fecal sample for calprotectin and microbiome assessments (from subjects 
willing to provide a fecal sample). 
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21142] been performed . 
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns. 
â€¢ Record the visit in IWRS and indicate if the subject will follow  the titration schedule 
and dispense bottles of investigational product as indicated by [CONTACT_10966].  
Note:  The subjectâ€™s dose will be titrated  as follows , providing there are no limiting 
safety, or tolerability concerns in the opi[INVESTIGATOR_689], whil e maintaining 
the trial blind: the 1.5 mg OCA treatment group will titrate to 3 mg, the 5 mg OCA 
treatment group will titrate to 10 mg OCA, and the placebo group will remain on 
placebo.  DB  treatment will continue for a  further 12 weeks at that dose .   
Any subjects whose dose is not titrated, due to safety or tolerability concerns, will 
remain on their starting treatment (1.5 mg OCA, 5 mg OCA, or placebo) for the remainder of the DB phase to Week 24. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s) and 
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all trial visits, but water is permitted , and the subject should dose at the visit 
after all assessments have been performed . 
8.6.8. Week 14 Procedures  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 59 
Confidential and Proprietary    â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Obtain blood samples for s erum chemistry , hematology, and coagulation. 
â€¢ Verify that the subject has fasted for at least 8 hours . 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21143] been performed . 
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns. 
â€¢ Record the visit in IWRS . 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Reiterate dosing instructions and advise the subject: 
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s) and  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior 
to all trial visits, but water is permitted.  
8.6.9. Week 18 Procedures  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Obtain blood samples for s erum chemistry , hematology, and coagulation.  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21144] that fasting is required prior to all trial 
Protocol 747-207 Version 5:   [ADDRESS_21145] been performed . 
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns. 
â€¢ Record the visit in IWRS . 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects 
with CD) and the day prior to their next scheduled visit (for UC subjects).   
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s) and  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all trial visits, but water is permitted.  
â€¢ The subject should be provided with a fecal sampling kit and instructed to collect the 
sample within 2 days of their Week 24 visit, as described in the laboratory manual.   
8.6.10. Week 24/LTSE Day 1 Procedures  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Perform a physical examination, including weight. 
â€¢ Record vital signs. 
â€¢ Perform a standard 12- lead ECG. 
â€¢ Perform TE at sites where the Fibroscan
Â® TE device  is available. 
â€¢ Perform hepatic ultrasound to assess bile duct patency . 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Subject to complete the Subject Research Questionnaire. 
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry , hematology, and coagulation  
âˆ’ FGF-19  
âˆ’ CRP 
âˆ’ ELF markers and other analytes 
âˆ’ Plasma bile acids and C4  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 61 
Confidential and Proprietary    âˆ’ Apolipoprotein and NMR lipoprotein panel 
âˆ’ Genetics study (if subject has consented to provide a sample for RNA analysis)  
â€¢ For sites participating in PK sampling:  obtain samples for PK analysis (see 
Section 10.5 for sampling schedule). 
â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine based Î²-hCG pregnancy test in females of childbearing potential.  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Obtain fecal sample for calprotectin and microbiome assessments (in subjects willing 
to provide a fecal sample) . 
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21146] that fasting is required prior to all trial 
visits, but water is permitted.  
â€¢ Record the visit in the IWRS and indicate if the subject plans to participate in the LTSE. 
For Subjects Participating in the LTSE:  
â€¢ Re-confirm their consent to participate in the LTSE phase of the trial.  
â€¢ Unblind the subjectâ€™s treatment allocation in IWRS (as detailed in a separate trial 
document) and document the dose of OCA on which the subject will commence the 
LTSE. 
â€¢ Assess investigational product compliance and perform accountability; retrieve us ed 
bottles and document returns. 
â€¢ Dispense indicated bottle(s) of investigational product. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s); and  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior 
to all trial visits, but water is permitted , and the subject should dose at each visit 
after all assessments have been performed . 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 62 
Confidential and Proprietary    For Subjects NOT Participating in the LTSE : 
â€¢ Remind the subject of the date of their Follow-Up visit. 
â€¢ Perform a final investigational product accountability check verifying the amount of 
investigational product dispensed and returned. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects 
with CD) and the day prior to their next scheduled visit (for UC subjects).  
8.6.11. Early Discontinuation and/or Early Termination Procedures:  Double -Blind 
Phase 
Subjects who terminate participation in the trial prior to the Week [ADDRESS_21147] an EOT 
visit as soon as possible following the decision to discontinue therapy.  EOT visit procedures are 
as follows:  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Perform a physical examination, including weight. 
â€¢ Record vital signs. 
â€¢ Perform a standard 12- lead ECG . 
â€¢ Perform TE at sites where the FibroscanÂ® TE device  is available. 
â€¢ Perform hepatic ultrasound to assess bile duct patency . 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Subject to complete the Subject Research Questionnaire. 
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry , hematology, and coagulation 
âˆ’ FGF-19  
âˆ’ CRP 
âˆ’ ELF markers and other analytes 
âˆ’ Plasma bile acids and C4  
âˆ’ Apolipoprotein and NMR lipoprotein panel 
âˆ’ Genetics study (if subject has consented to provide a sample for RNA analysis)  
âˆ’ For sites participating in PK sampling:  obtain samples for PK analysis (see 
Section 10.5 for sampling schedule) 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 63 
Confidential and Proprietary    â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine based Î²-hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Obtain fecal sample for calprotectin and microbiome assessments (in subjects willing 
to provide a fecal sample) . 
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns. 
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF . 
âˆ’ If the subject reports having eaten within 8 hours, document accordingly in the 
source and CRF. 
â€¢ Perform a final investigational product accountability check verifying the amount of 
investigational product dispensed and returned. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Remind the subject of the date of their Follow -Up visit. 
â€¢ Record the visit in IWRS.  
8.6.12. Follow-Up Visit:  Double -Blind Phase  
Subjects who terminate participation in the trial prior to the Week [ADDRESS_21148] : 
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy). 
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Obtain blood samples for s erum chemistry , hematology, and coagulation. 
â€¢ Perform a urine based Î²- hCG pregnancy test in females of child bearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Record the visit in IWRS . 
Protocol 747-207 Version 5:   [ADDRESS_21149] once every 3 months Â±[ADDRESS_21150] needs to 
attend an additional study visit (Pre -Titration visit) as well as have a study contact.  
Pre-Titration Visit  
The Pre-Titration visit occurs approximately 1 week prior to the scheduled LTSE visit to assess 
serum chemistry (ie , ALP and bilirubin) and complete all other laboratory assessments.    
Titration Visit  
Following the Pre- Titration visit, the subject attends for the scheduled 3 monthly visit to 
determine her/his eligibility for titration .  All procedures (except laboratory sample collection) 
for the scheduled trial visit occur as noted in the Schedule of Trial Procedures ( Table 2).  
Subjects experiencing significant AEs (eg , severe pruritus) or other symptoms that are not 
tolerated, may not be eligible for titration.  Under these circumstances, the Investigator should 
contact [CONTACT_22092]/she still plans to up -titrate the subject.  
Contact 
[CONTACT_22093] [ADDRESS_21151] will be recorded in the CRF.  The Investigator may schedule 
an at-clinic Unscheduled/Safety v isit at any time if clinically warranted.  
If the Investigator is not planning on up- titrating a subject during an LTSE visit, the subject 
attends the scheduled [ADDRESS_21152].   
8.6.14. LTSE Day 1 (DB Week 24) Procedures  
See Section 8.6.10 for the LTSE Day 1 (DB Week 24 visit) procedures. 
8.6.15. LTSE Week [ADDRESS_21153] will be contact[CONTACT_22094]  2 weeks after the start of the  LTSE phase to 
assess safety . 
8.6.16. LTSE Month 3, 9, 15, and 21 Procedures 
The following procedures will occur at the Month 3, 9, 15, and 21 LTSE visits: 
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding  endoscopy). 
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5 -D Itch questionnaire . 
â€¢ Obtain blood samples for s erum chemistry , hematology, and coagulation.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 65 
Confidential and Proprietary    â€¢ Perform a urine based bet a Î²-hCG pregnancy test in females of childbearing potential .  
If the urine pregnancy test is positive it should be repeated as a serum pregnancy test.  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21154] that fasting is required prior to all trial 
visits, but water is permitted.  
â€¢ Assess investigational product compliance and perform accounta bility; retrieve used 
bottles and document returns. 
â€¢ Record the visit in IWRS and dispense indicated bottles of investigational product. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects 
with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s) and 
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior 
to all trial visits, but water is permitted.  
â€¢ For the Month 9 and Month 21  visits only: 
âˆ’ The subject should be provided with a fecal sampling kit and instructed to collect the sample within 2 days of their next visit, as described in the laboratory manual.  
â€¢ For the Month 21  visits only: 
âˆ’ The subject should be advised  that their last dose of investigational product is 
administered on the day prior to their Month 24 visit. 
8.6.17. LTSE Month 6 Procedures 
The following procedures will occur at the Month 6 LTSE visit:  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5 -D Itch questionnaire . 
â€¢ Obtain blood samples for : 
âˆ’ Serum chemistry , hematology, and coagulation 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 66 
Confidential and Proprietary    âˆ’ CRP  
âˆ’ Plasma bile acids and C4  
â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine ba sed Î²-hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21155] that fasting is required prior to all trial 
visits, but water is permitted.  
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns. 
â€¢ Record the visit in IWRS and dispense indicated bottle s of investigational product. 
â€¢ Subjects with UC or CD:   provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects 
with CD) and the day prior to their next scheduled visit (f or UC subjects).   
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s) and 
âˆ’ To fast overnight (at least 8 hours) prior to the next vis it.  Fasting is required prior 
to all trial visits, but water is permitted.  
8.6.18. LTSE Month 12 Procedures 
The following procedures will occur at the Month 12 LTSE visit:  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ Perform TE at sites where the FibroscanÂ® TE device is available. 
â€¢ Perform hepatic ultrasound to assess bile duct patency . 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry , hematology, and coagulation 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 67 
Confidential and Proprietary    âˆ’ FGF-19 
âˆ’ CRP  
âˆ’ ELF markers and other analytes 
âˆ’ Plasma bile acids and C4  
âˆ’ Genetics study (if subject has consented to provide a sample for RNA analysis)  
â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine based Î²- hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Obtain fecal sample for calprotectin and microbiome assessments (in subjects willing 
to provide a fecal sample) . 
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21156] that fasting is required prior to all trial 
visits, but water is permitted.  
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns . 
â€¢ Record the visit in IWRS and dispense indicated bottles of investigational product. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subje cts 
with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s) and  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all trial visits, but water is permitted.  
8.6.19. LTSE Month 18 Procedures 
The following procedures will occur at the Month 18 LTSE visit:  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy). 
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire a nd 5-D Itch questionnaire . 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 68 
Confidential and Proprietary    â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry , hematology, and coagulation 
âˆ’ CRP  
â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine based Î²- hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Verify that the subject has fasted for at least 8 hours. âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within [ADDRESS_21157] that fasting is required prior to all trial 
visits, but water is permitted.  
â€¢ Assess investigational product compliance and perform accountability; retrieve used 
bottles and document returns. 
â€¢ Record the visit in IWRS and dispense indicated bottles of investigational product. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Reiterate dosing instructions and advise the subject:  
âˆ’ NOT to take investigational product on the morning of the next visit, and  
âˆ’ To bring the investigational product bottle(s) and  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all trial visits, but water is permitted.  
8.6.20. LTSE Month 24 Procedures 
The following procedures will occur at the Month 24 LTSE visit:  
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Perform a physical examination, including weight. 
â€¢ Record vital signs. 
â€¢ Perform a standard 12- lead ECG. 
â€¢ Perform TE at sites where the Fibroscan
Â® TE device  is available. 
â€¢ Perform hepatic ultrasound to assess bile duct patency . 
â€¢ For subjects with UC:  obtain partial Ma yo score (excluding endoscopy).  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 69 
Confidential and Proprietary    â€¢ Administer pruritus VAS subject questionnaire and 5-D Itch questionnaire . 
â€¢ Subject to complete the Subject Research Questionnaire  
â€¢ Obtain blood samples for : 
âˆ’ Serum chemistry , hematology, and coagulation 
âˆ’ FGF-19 
âˆ’ CRP  
âˆ’ ELF markers and other analytes 
âˆ’ Plasma bile acids and C4  
âˆ’ Genetics study (if subject has consented to provide a sample for RNA analysis)  
â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine based Î²- hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Obtain fecal sample for calprotectin and microbiome assessments (in subjects willing 
to provide a fecal sample) . 
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and CRF. 
âˆ’ If the subject reports having eaten within 8 hours, document accordingly in the 
source and CRF.  
â€¢ Perform a final investigational product accountability check verifying the amount of 
investigational product dispensed and returned. 
â€¢ Subjects with UC or CD:  provide the appropriate diary  card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subj ects 
with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Remind the subject of the date of their Follow-Up visit. 
â€¢ Record the visit in IWRS.  
8.6.21. Early Discontinuation and/or Early Termination Procedures:  LTSE Phase  
Subjects who terminat e participation in the trial during the LTSE s hould have an EOT visit as 
soon as possible following the decision to discontinue therapy.  EOT visit procedures are as 
follows:   
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Perform a physical examination, including weight. 
â€¢ Record vital signs. 
â€¢ Perform a stan dard 12-lead ECG . 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 70 
Confidential and Proprietary    â€¢ Perform TE at sites where the FibroscanÂ® TE device  is available. 
â€¢ Perform hepatic ultrasound to assess bile duct patency . 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy) .  
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Subject to complete the Subject Research Questionnaire  
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry , hematology, and coagulation 
âˆ’ FGF-19 
âˆ’ CRP  
âˆ’ ELF markers and other analytes 
âˆ’ Plasma bile acids and C4  
âˆ’ Genetics study (if subject has consented to provide a sample for RNA analysis)  
â€¢ Obtain urine sample for dipstick urinalysis. 
â€¢ Perform a urine ba sed Î²-hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Where possible, obtain fecal sample for calprotectin  and microbiome assessments 
(in subjects willing to  provide a fecal sample) . 
â€¢ Perform a final investigational product accountability check verifying the amount of 
investigational product dispensed and returned. 
â€¢ Subjects with UC or CD: provide the appropriate diary card and request this is 
completed for the 7 consecutive days prior to their next scheduled visit (for subjects 
with CD) and the day prior to their next scheduled visit (for UC subjects).  
â€¢ Remind the subject of the date of their Follow-Up visit. 
â€¢ Record the visit in IWRS.  
8.6.22. Follow-Up Visit:  LTSE 
All subjects who entered LTSE attend for a Follow -Up visit [ADDRESS_21158] : 
â€¢ Assess and record AEs. 
â€¢ Record current concomitant medications. 
â€¢ Record vital signs. 
â€¢ For subjects with UC:  obtain partial Mayo score (excluding endoscopy). 
â€¢ For subjects with CD:  complete CDAI assessments and assign CDAI score. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 71 
Confidential and Proprietary    â€¢ Administer pruritus VAS subject questionnaire and 5- D Itch questionnaire . 
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry , hematology, and coagulation 
â€¢ Perform a urine based Î²- hCG pregnancy test in females of childbearing potential .  If 
the urine pregnancy test is positive it should be repeated as a serum pregnancy test. 
â€¢ Record the visit in IWRS.  
8.6.23. Unscheduled Safety Visit  
The Investigator may schedule an Unscheduled/Safety visit at any time if clinically  warranted or 
requested by [CONTACT_941] M edical Monitor.  Unscheduled and/or repeat assessments, including additional 
laboratory tests or investigations, may be conducted.  As appropriate, the M edical Monitor 
should be contact[INVESTIGATOR_530].  
9. INVESTIGATIO NAL PRODUCT MATERIALS AND 
MANAGEMENT  
9.1. Investigational Product  
For the purpose of this protocol, the term â€œinvestigational productâ€ describes both OCA and 
placebo tablets.  
The investigational product used for this trial will be 1.5 mg and 5 mg OCA and matching 
placebo tablets.  The 1.5 mg OCA tablet and matching placebo are white, round tablets with no markings.  The 5 mg OCA tablet and matching placebo are white, round tablet s debossed with 
â€œINTâ€ on one side and â€œ3547â€ on the other side.  OCA tablets contain the following inactive 
ingredients:  microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.   
All investigational product will be provided as a tablet for oral administration  and provided in 
high density polyethylene bottles with an induction seal and child resistant c losures.  The 1.5 mg 
OCA tablet and matching placebo are smaller tablets (approximately 6 mm diameter) and will be 
provided in 40 cc bottles.  The 5 mg OCA and matching placebo (approximately 8 mm diameter) 
and will be provided in [ADDRESS_21159] will be manufactured according to Good Manufacturing Practice 
(GMP). 
9.2. Investigational Product Packaging and Labeling 
The packaging and labeling of investigational product supplies will be performed according to 
GMP standards by a designated qualified vendor.  A designated vendor will also be responsible 
for the distribution of the investigational product to the Investigator and, where applicable, for 
providing the Qualified Person release of the investigational product. 
Investigational product will be packaged and labeled as single bottles containing [ADDRESS_21160] bottles will be blinded.  Each bottle will be labeled with a 
Protocol 747-207 Version 5:   [ADDRESS_21161] should be stored in the containers in which it is  received from the 
Sponsorâ€™s supplier, at 15 Â°C to 25Â°C. 
9.4. Investigational Product Administration 
Subjects will be instructed to begin dosing on the day after the Day 0 visit (ie, on Day 1).  Investigational product administration should occur at approximately the same time of day 
throughout the duration of the trial.  Subjects must be i nstructed to swallow the indicated number 
of tablets whole with water ; they must not chew, divide, or crush the tablets.  
9.4.1. Investigational Product  Dispensation  
On Day 0, after confirmation of subject eligibility, the Investigator or designee will dispense investigational product to the subject.  Subjects will receive [ADDRESS_21162] should be instructed to take it later the same 
day, as soon as they remember.  Missed doses should not be taken on a subsequent day (ie, the 
subject should not take more than the prescribed daily dose, as directed).   
9.4.3. Overdose  
The maximum dose of OCA that has been given to humans is [ADDRESS_21163] enrolled in the trial, general medical supportive measures should be provided, including observation and follow-up (eg, serum chemistry) as appropriate.  Due to the extensive enterohepatic recirculation of OCA 
it is likely that it will take several days before blood (and organ) co ncentrations of the drug will 
decrease.  Treatment with cholestyramine ( eg, Questranâ„¢), colesevelam ( eg, Welcolâ„¢) and 
other BAS  is recommended given that they should bind and eliminate the drug in feces.  The 
Sponsor should be notified immediately in the event of a significant overdose. 
Protocol 747-207 Version 5:   [ADDRESS_21164] be stored under the appropriate storage conditions until verification of the contents is 
possible (ideally, within 1 business day from receipt).  The pharmacist or designee should verify 
the investigational product against the shipment documentation.  The pharmacist or designee should contact [CONTACT_22095].  
All investigational product will be provided for use only in this trial and is not to be used for any 
other purpose.  The Investigator or designee will maintain a full record of investigational product 
accountability, including records of individual subject dispensing, missed doses, tablets/bottles 
returned at each visit, and final return or disposition (as directed by [CONTACT_1034]).  
The trial monitor, also known as the Clinical Research Associate (CRA), will review 
accountability records against investigational product dispensed an d that remaining in stock, 
during on site monitoring visits and when the trial is completed, or if it is prematurely terminated.  The CRA will retrieve documentation detailing and confirming the return to depot 
or destruction of the investigational product by [CONTACT_21655] . 
10. ASSESSM ENTS OF EFFICACY  
10.1. Sample Collection  
Blood samples for the assessment of efficacy will be collected at visits indicated in the Schedule 
of Trial Procedu res (Table 1 and Table  2, Section  6.1).  The complete list of planned assessments 
can be found in Appendix A .   
Fasting (8 hours) blood samples are required for efficacy analyses.  For consistency, subjects will be instructed to attend each of their at- site visits in a fasted state and subjects should remain 
fasted until their blood samples have been collected.  At each visit , the Investigator or designee 
will verify that the subject has fasted for at least [ADDRESS_21165] reports having eaten (water is permitted) within [ADDRESS_21166] that fasting 
is required prior to onsite visits.  
Fecal samples will be collected in a subset of subjects for the assessment of GI inflammation, at visits indicated in the Schedule of Trial Procedures.  
Instructions concerning the number and type of samples, including the PK assessments, to be 
collected at each visit, the required sample volumes, sample collection methods, sample 
processing, labeling, and shippi[INVESTIGATOR_22016] a trial-specific laboratory manual.  All 
necessary collection supplies will be provided by [CONTACT_22096].   
10.2. Primary Efficacy Assessments  
The primary efficacy assessment is serum ALP.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 74 
Confidential and Proprietary    10.3. Secondary Assessments 
Hepatic Biochemistry and Indices of Function  
Hepatic biochemistry and indices of function will be assessed by [CONTACT_22097]:  
ALP, ALT, AST, GGT, bilirubin, albumin, and international normalized ratio (INR) 
Hepatic and GI Inflammation, Hepatic Disease and Fibrosis 
Hepatic and GI inflammation, hepatic disease, and fibrosis will be assessed by [CONTACT_22098]:   
Autotaxin and  its metabolites, calprotectin, C -reactive protein (CRP), Cytokeratin -18 (CK-18), 
ELF markers, transient elastography (TE), Immunoglobulin A (IgA), IgG, Immunoglobulin M 
(IgM), Interleukin -6 (IL-6), Interleukin -12 (IL-12), Interleukin-23 (IL-23), transforming growth 
factor-beta (TGF -Î²), tumor necrosis factor- alpha (TNF -Î±). 
The Enhanced Liver Fibrosis (ELFâ„¢) test is a blood test that measures hyaluronic acid (HA), 
procollagen-3 N-terminal peptide (P3NP), and a tissue inhibitor of metalloproteinase 1 (TIMP-1), as a measure of hepatic fibrosis.  
Transient Elastography (TE) is an assessment of hepatic fibrosis using a Fibroscan
Â® TE device 
(Echosens, Paris, [LOCATION_009]) that measures hepatic stiffness.  It is a validated and non- invasive 
measure and will be performed at trial sites that have the equipment.  Trial sites must have staff 
trained in the use and data interpretation of the device.  
GI inflammation will be assessed by [CONTACT_22099]. 
FXR Activity  
FXR activity will be assessed by [CONTACT_22100]- 19 (FGF-19) concentrations. 
Disease-Specific Symptoms  
Disease-specific symptoms of IBD and pruritus will be assessed using the partial Mayo score (only for subjects with UC), CDAI (only for subjects with CD) and as a Pruritus VAS and 5-D 
itch questionnaire, respectively.  
IBD Symptoms  
â€¢ Partial Mayo Score  
The partial Mayo score will be performed by [CONTACT_941] I nvestigator at specified visits to assess 
symptoms associated  with IBD ( Rutgeerts 2005 ).  The full Mayo scoring system includes 
questions related to stool frequency and rectal bleeding, endoscopic findings, and the physicianâ€™s global assessment.  The partial score does not include an endoscopy and will be used in this trial.  
Details of the partial Mayo Ulcerative Colitis Score are shown in Appendix B . 
â€¢ CDAI 
The CDAI will be performed by [CONTACT_941] I nvestigator at specified visits to assess symptoms 
associated with CD (Best 1976) and will be based on the subjectâ€™s recount of their symptoms in 
addition to hematocrit and body weight measurements.  Details of the CDAI are shown in Appendix F . 
Protocol 747-207 Version 5:   [ADDRESS_21167] visit ; and subjects with CD should complete the diary in the [ADDRESS_21168]â€™s medical records 
for SDV and retain th e diary cards.  Pertinent aspects of these data will be recorded in the CRF.  
Data from the Screening period diary card will be recorded at Day 0 . 
Pruritus 
In addition to the assessment of pruritus as an AE with mild, moderate and severe categories, 
pruritus will be specifically assessed by [CONTACT_22101]: 
â€¢ Pruritus VAS  
Subjects will be asked to complete the Pruritus VAS to assess any experiences of pruritus during the trial; they will be asked to initial and date to document confirmation of their responses, and 
the questionnaires should be filed in the subjectâ€™s trial records.  Details of the Pruritus VAS are shown in Appendix C . 
â€¢ 5-D Itch Questionnaire  
This is a questionnaire that has been validated in several different diseases.  It assesses symptoms in terms of 5 domains:  degree, duration, direction, disability and distribution ( Elman 2010).   
10.4. Additional Exploratory Assessments  
Gut Microbiome Genetic Profile 
The gut microbiome will be assessed from fecal samples provided by [CONTACT_22102].  
Genetics Study  
RNA expression resulting from treatment with OCA will be assessed at indicated timepoints during the trial.  Subjects will be permitted to decline to provide a blood sample for the genetics 
study, without affecting their involvement in the trial.  IRB/IEC review and approval will be required and willing subjects must specifically consent to participate in this evaluation.  The 
samples will be stored for up to [ADDRESS_21169] Research Questionnaire will be administered upon completing participation in the DB 
phase â€“ either at the DB Week [ADDRESS_21170]â€™s perception of 
the trial and asks subjects if they felt that their participation in the trial was wo rthwhile and 
whether they would recommend a similar trial to a family member.   The Subject Research 
Questionnaire is included in Appendix E . 
Protocol 747-207 Version 5:   [ADDRESS_21171] of the trial.   
OCA and its conjugates will be assessed at indicated visits and times (see Table 1 and Table 2).  
In addition, total bile acids, UDCA, OCA, CDCA, LCA, cholic acid , deoxycholic acid 
(conjugated and unconjugated forms) and C4 will also be a nalyzed. 
Following collection of the fasted laboratory samples ([ADDRESS_21172]) at Week 12 and 
Week 24 (as noted in Table  1), subjects who are pa rticipating in the PK/bile acid assessment will 
each receive a single dose of their allocated investigational product with approximately 240 mL 
of water.  At Week 12, subjects will receive their dose assigned prior to titration (ie, the lower dose of investigational product).  Serial blood samples will be obtained for measurement of OCA 
and its conjugates prior to dosing and at 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, and [ADDRESS_21173].  After approximately  1 hour postdose, subjects will be fed a meal replacement drink .  
As a secondary efficacy analysis, an exposure response analysis of total plasma OCA (OCA and 
its conjugates) to biomarkers, such as change in ALP and change in bile acids, will be performed 
to help identify optimal doses for this patient population. 
11. ASSESSMENT OF SAFETY  
Safety will be monitored and assessed by [CONTACT_2695]/SAEs, medical history, physical examination, vital signs measurements, ECG results, and clinical laboratory assessments.  
11.1. Adverse Events and Serious Adverse Events 
11.1.1. Definitions  
[IP_ADDRESS]. Adverse Event  
Adverse events (AE) are defined as any untoward medical occurrence associated with the use of the investigational product in humans, whether or not considered related to investigational 
product.  An AE (also referred to as an adverse experience) can be any unfavorable and 
unintended sign (eg, an abnormal laboratory finding), symptom, or disease temporally associated 
with any use of the investigational product, without any judgment about causality and 
irrespective of route of administration, formulation, or dose, including an overdose.   
AEs include, but are not limited to:  (1) a worsening or change in nature, severity, or frequency 
of condition(s) present at the start of the trial; (2) subject deterioration due to primary illness; 
(3) intercurrent illness; and (4) drug interaction.  
Protocol 747-207 Version 5:   [ADDRESS_21174] or asking about the 
occurrence of any specific symptom.  The Investigator should attempt to establish a diagnosis of 
the event based on signs, symptoms, and/or other clinical information.  The diagnosis and not the individual signs/symptoms should be documented as the AE.  For example, if the underlying disease process is a str oke, it would not be appropriate to record the AE by [CONTACT_22103] â€œsudden numbness, dizziness, and difficulty speaking.â€  The AE medical term of â€œstroke or cerebrovascular accidentâ€ should be recorded as it more accurately describes the AE.  
[IP_ADDRESS]. Serious Adverse Event  
An AE is considered â€˜seriousâ€™ if, in the view of either the I nvestigator  or Sponsor , it results in 
any of the following outcomes: 
â€¢ Death; 
â€¢ Is immediately life threatening ; 
â€¢ Requires in -patient hospi[INVESTIGATOR_1081] ; 
â€¢ Results in persistent or significant disability or incapacity ; 
â€¢ Results in a congenital abnormality or birth defect; 
â€¢ Is an important medical event that may jeopardize the subject or may require medical intervention to prevent one of the outcomes listed above.  
Events not considered to be SAEs are hospi[INVESTIGATOR_5315]: 
â€¢ Routine monitoring of the studied indication and not associated with any deterioration in condition or AE; 
â€¢ Elective treatment for a pre -existing condition that did not worsen; 
â€¢ Respi[INVESTIGATOR_22017].  
[IP_ADDRESS]. Treatment Emergent Adverse Event  
A treatment emergent adverse event (TEAE) is any event not present prior to the initiation of the investigational product or any event already present that worsens in either intensity or frequency 
following exposure to the investigational product. 
11.1.2. Relationship to Investigational Product 
The Investigator will document her/his opi[INVESTIGATOR_22018]  7.  An AE for which there is a 
â€˜reasonable possibilityâ€™ that the investigational product caused the AE is otherwise referred to as 
suspected adverse reaction (SAR).   â€˜Reasonable possibilityâ€™ means there is evidence to suggest a 
causal relationship between the investigational product and the AE.   
If the relationship between the AE/SAE and the investigat ional product is determined to be 
â€œpossibleâ€, â€œprobableâ€ or â€œdefiniteâ€ the event will be considered to be related to the 
investigational product for the purposes of expedited regulatory reporting. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 78 
Confidential and Proprietary    Table 7: Relationship of AEs to Investigational Product 
Relationship Description  
Definite A reaction that follows a reasonable temporal sequence from administration of the 
investigational product  or in which the investigational product  level has been 
established in body fluids or tissue; that follows a known or expected response pattern to the suspected drug; and that is confirmed by [CONTACT_3895][INVESTIGATOR_22019] , and reappearance of the reaction 
on repeated exposure.  
Probable  A reaction that follows a reasonable temporal sequence from administration of the investigational product; that follows a known or expected response pattern to the 
suspected investigational product; that is confirmed by [CONTACT_13635][INVESTIGATOR_22020]; and that could not be reasonably explained by [CONTACT_20612]â€™s clinical state. 
Possible A reaction that follows a reasonable temporal sequence from administration of the investigational product; that follows a known or expected response pattern to the suspected investigational product; but that could readily be produced by a number of 
other factors.  
Unlikely A reaction that does not follow a reasonable temporal sequence from administration of the investigational product; that does not follow a known or suspected response pattern to the suspected investigational product; and that could reasonably be 
explained by [CONTACT_11176]â€™s clinical state.  
Not Related  Any event that does not meet the above criteria.  
11.1.3. Recording Adverse Event Severity  
AEs must be graded for severity (ie, intensity).  A severity category of mild, moderate, or severe, 
as defined in  Table [ADDRESS_21175] be entered on the AE CRF.  It should be noted that the term â€œsevereâ€ 
used to grade intensity is not synonymous with the term â€œserious.â€  T he assessment of severity is 
made regardless of investigational product relationship or of the seriousness of the AE. 
Table 8: Severity of AEs  
Grade Clinical Description of Severity  
1 = Mild Causing no limitation of usual activities; the subject may experience slight 
discomfort.  
2 = Moderate Causing some limitation of usual activities; the subject may experience annoying 
discomfort.  
3 = Severe  Causing inability to carry out usual activities; the subject may experien ce 
intolerable discomfort or pain.  
[IP_ADDRESS]. Severity of Pruritus (as an AE)  
Pruritus was the most common AE seen in the Phase [ADDRESS_21176] experienced within â‰¤3 months of 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 79 
Confidential and Proprietary    Screening , pruritus requiring systemic or enteral treatment are excluded from participating  in this 
trial.  
To ensure consistency in reporting, the following guidelines for assessing severity of pruritus 
should be used both for AE reporting and during pretreatment as sessment.  As pruritus is a 
subjective symptom, clinical judgment should be used to determine its severity and management.  
Subjects who experience a treatment emergent AE of severe pruritus should not be titrated to a 
higher dose. 
Table 9: Severity of Pruritus  
Pruritus Grade  Clinical Description of Severity for Pruritus  Titration Eligibility 
Guideline  
1 = Mild Generally localized; causing no limitation of usual activities 
or minimal sleep disturbance; the subject may  experience 
slight discomfort.  Medicinal intervention is not indicated. Yes 
2 = Moderate Intense or widespread; causing some limitation of usual activities or sleep disturbance; the subject may experience 
annoying discomfort.  Medicinal intervention may be 
indicated.  Yes; use clinical 
judgment  
3 = Severe  Intense or widespread and interfering with activities of daily 
living (ADL), ie, causing inability to carry out usual activities, or severe sleep disturbance; the subject may experience intolerable disco mfort. Medicinal intervention is typi[INVESTIGATOR_22021].  No 
In the phase 2 PBC trials, Investigators tried a number of different approaches to help relieve 
pruritus symptoms.  Severe pruritus typi[INVESTIGATOR_22022] (ie, within the first 2 weeks a fter starting therapy ).  In the 747-202 trial, about 80% of the patients who were started 
on BAS or other drugs or interventions during the trial completed the trial as planned.  In the Phase 3 trial, similar approaches were employed in addition to evaluation of lower doses:  27% of subjects in the 10 mg group added a BAS compared to 20% of subjects in the titration arm and 
11% of placebo subjects.  Consistent with the use of lower doses and pruritus mitigation 
strategies withdrawals due to pruritus were minimized ([ADDRESS_21177] in the titration arm and 7 in the 
10 mg OCA arm withdrew due to pruritus compared to none in the placebo arm ). 
Since pruritus is such a subjective symptom (and the most common symptom in PBC patients), clinical judgment needs to be applied to the management of each subject.  However, the following recommendations are made for the management of subjects experiencing significant 
pruritus in this PSC trial: 
â€¢ Prescribe BAS, eg, cholestyramine, colestipol, colestimide, or colesevelam.  The 
greatest experience to date has been with cholestyramine.  Theoretically, colesevelam 
may be more palatable (tablet) and more effective.  Patients taking BAS should be instructed to stagger their dosing of investigational product and UDCA ensuring at least [ADDRESS_21178] (and UDCA).   
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 80 
Confidential and Proprietary    â€¢ Dose frequency modification:  Less frequent dosing of investigational product (eg, on 
alternate days) may be tried, after which subjects may return to their original daily 
dose, if and as tolerated.   
â€¢ Drug holiday:  A drug holiday is defined as an I nvestigator â€˜prescribedâ€™ complete 
interruption of dosing for 1 or more consecutive days (ie, non-daily dosing does not constitute a drug holiday).  For subjects with severe pruritus, instruct the subject to 
stop taking investigational product until the pruritus subsides to an acceptable level at 
which time it should be restarted (likely, on a modified, alternate day dosing schedule).  Details of drug holidays and/or nondaily dosing regimens should be 
recorded in the CRF.  Such cases should be discussed with the Medical Monitor. 
â€¢ Other therapi[INVESTIGATOR_22023].  
11.1.4. Reporting of Adverse Events and Serious Adverse Events  
[IP_ADDRESS]. Reporting of Adverse Events  
AE data will be collected from the time that signed informed consent is obtained until the subject 
fully completes her/his trial participation of the trial.  
All AEs, whether believed by [CONTACT_941] I nvestigator  to be related or unrelated to the investigational 
product, must be documented in the subjectâ€™s medical records, in accordance with the 
Investigator â€™s normal clinical practice and on the AE CRF.   Each AE is to be evaluated for 
duration, intensity, frequency, seriousness, outcome, other actions taken, and r elationship to the 
investigational product. 
[IP_ADDRESS]. Reporting of Serious Adverse Events 
In agreeing to the provisions of this protocol, the Investigator accepts all legal responsibilities for 
immediate reporting of SAEs to the Sponsor.  Immediate reporting implies  within [ADDRESS_21179] be reported to the Sponsor.  SAEs are reported by [CONTACT_22104].  Entering the SAE data into the EDC system will automatically 
notify the Sponsor of the event.  In the event that the EDC system is inaccessible, an SAE may 
reported by: 
â€¢ E-mail to the SAE email address:  [EMAIL_380]  
â€¢ Fax using a paper SAE report form:  +[PHONE_352] 
â€¢ Telephone:  + [PHONE_351] 
If an SAE is repo rted by [CONTACT_12221], an SAE Report form must also be completed in the 
EDC system as soon as the EDC system is accessible.  At a minimum, the following information 
should be provided at the time of the initial report:   
â€¢ Subject number  
â€¢ Event term  
â€¢ At least 1 criterion classifying the event as serious  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 81 
Confidential and Proprietary    â€¢ Name [CONTACT_22168]   
â€¢ Causal relationship to the investigational product 
The Investigator will assess whether the event is causally related to the investigational product.  
The Sponsor, will also assess whether the event is causally related to the investigational product 
in addition to assessing the overall safety profile of the investigational product.  The Sponsor will 
notify the appropriate regulatory agencies as well as all partic ipating Investigator s of 
investigational new drug (IND)  Safety Reports/Expedited S afety Reports that occur during the 
trial within the time frames required by [CONTACT_22105].  An SAE assessed with possible, 
probable, or definite causal relationship  to the investigational product and unexpected according 
to the IB Reference Safety Information (RSI), is known as a suspected unexpected serious 
adverse reaction (S[LOCATION_003]R).  The Investigator must report S[LOCATION_003]Rs using the SAE reporting 
method described above. 
Following the initial report, any additional information obtained by [CONTACT_941] I nvestigator about the 
SAE must be reported promptly to the Sponsor in the same manner as described above for the 
initial SAE report.  Any supporting source documentation should be faxed to +[PHONE_352] or 
emailed to [EMAIL_380] as soon as possible.   
The Investigator is responsible for submitting Safety Reports/Expedited S afety Reports received 
from the Sponsor to her/his local IRB/IEC , in compliance with  the local country requirements.  
For the European Union, the Sponsor will notify the regulatory agencies and report S[LOCATION_003]Rs via the Eudra Vigilance database within 7 calendar days of a S[LOCATION_003]R involving death or a life-
threatening S[LOCATION_003]R, and all other S[LOCATION_003]Rs within 15 calendar days.   Documentation of the 
submissions to IRBs/IEC s and health authorities (as applicable)  must be retained in the 
appropriate trial file(s).  As instructed by [CONTACT_1034], S afety Reports/Expedited S afety Reports 
should be retained in the appropr iate Investigat or site trial files, or with the IB.  
11.1.5. Anticipated Serious Adverse Events Associated with PSC  
There are a number of events which are commonly associated with PSC and for the Sponsorâ€™s 
regulatory reporting purposes, these events are considered to be â€˜Expectedâ€™ in this patient 
population and are listed in the IB.   
The Investigator remains responsible for reporting to the Sponsor all SAEs including the events 
identified here: 
â€¢ GI and hepatic malignancie s including CCA, pancreatic cancer, colorectal cancer  
â€¢ Ascites 
â€¢ Cholecystitis 
â€¢ Cholangitis (including bacterial cholangitis) 
â€¢ Pancreatitis  
â€¢ IBD and IBD flare  (including UC and CD)  
â€¢ Bile duct strictures (dominant or otherwise)  
â€¢ Steatorrhea  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 82 
Confidential and Proprietary    â€¢ Vitamin deficiency  
â€¢ Osteoporosis/osteopenia  
â€¢ Fractures 
â€¢ Variceal bleeding  
â€¢ Cirrhosis 
â€¢ Worsening PSC 
â€¢ Any of the above that result in Death 
11.1.6. Additional Investigator Responsibilities for SAEs  
The safety data recorded in the CRF represent the official record of all AEs and SAEs reported in 
the trial.  The Investigator should comply with requests by [CONTACT_941] M edical Monitor or other Sponsor 
personnel to record the SAE on the subjectâ€™s AE CRF.  Other supporting documents such as 
radiology reports, hospi[INVESTIGATOR_8838], and autopsy reports should also be provided, 
when appropriate.  Additionally, upon request by [CONTACT_1034], the Investigator should provide 
input into the SAE narrative and provide timely information to ensure prompt follow-up and 
closure of the SAE report.  
The Investigator and supporting personnel responsible for subject care should discuss with the 
Medical Monitor any need for supplemental investigations of SAEs.  The results of these 
additional assessments must be reported to the Medical Monitor.   
11.1.7. Notification of Post- Trial SAEs  
If an Investigator beco mes aware of an SAE that may be attributable to the investigational 
product at any time after the end of the trial, the Sponsor shou ld be notified immediately 
(ie, within 24 hours). 
All SAEs that occur within [ADDRESS_21180] be reported to the Sponsor within 24 hours by [CONTACT_22106]  [IP_ADDRESS]. 
11.1.8. Follow-U p of AEs and SAEs  
All AEs must be followed during the course of the trial until the AE resolves, is no longer of clinical concern, has stabilized or is otherwise explained, or the subject is lost to follow up.  
AEs ongoing at the final visit that are deemed to be â€˜possibly, probably, or definitelyâ€™ related or 
of other clinical significance must be followed for as long as necessary to adequately evaluate the safety of the subject or until the event stabilizes, resolves, or is no longer of clinical concern.  If resolved, a resolution date for the AE should be documented on the CRF .  The Investigator 
must ensure that follow- up includes any supplemental investigations indicated to elucidate the 
nature and/or causality of the AE.  This m ay include additional laboratory tests or investigations, 
or consultation with other healthcare professionals, as considered clinically appropriate by [CONTACT_3786]. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 83 
Confidential and Proprietary    All subjects showing possible drug-induced liver injury should be followed until all 
abnormalities return to normal or to the baseline state.  Drug -induced liver injury may develop or 
progress even after the causative drug has been stopped.  Results should be recorded in the CRF.  Note that longer follow -up can sometimes reveal an off -drug repetition of what had appeared to 
be drug-induced liver injury, indicating that liver injury was related to underlying liver disease.  
11.1.9. Pregnancy and Follow -Up  
Pregnancies are not considered SAEs in and of themselves; however if a female trial participant 
becomes pregnant while she is enrolled in the clinical trial  investigational product must be 
stopped immediately.  The Sponsor must be notified within 24 hours of the Investigator â€™s 
awareness of the pregnancy by [CONTACT_22107] + [PHONE_352] or [EMAIL_380] .  
The subject must be followed by [CONTACT_22108].  The Investigator 
should notify the Sponsor of the outcome of the pregnancy by [CONTACT_22109].  The mother (and infant) will be followed as considered appropriate by [CONTACT_941] I nvestigator  and the M edical Monitor. 
The Investigator must contact [CONTACT_22110], in advance, any subject 
whose pregnancy is early terminated and would like to continue to participate in the trial.  A minimum requirement for allowing the subject to restart dosing is documentation of a negative 
serum Î²-hCG test.  However, this is not in and of itself a guarantee for being allowed to continue 
in the study. 
11.2. Other Safety Parameters  
11.2.1. Medical History/Demographics  
A complete medical history will be obtained from the subject at s creening.  Demographic 
characteristics (age, gender, race, ethnicity, etc) will be recorded , as will any historical or on 
study data on colonoscopi[INVESTIGATOR_014] (mucosal and histological) within the last [ADDRESS_21181] for clinical findings, the Investigator  or designee will perform a physical 
examination at the time  points specified in the Schedule of Trial Procedures ( Table 1 and 
Table 2).  If clinically significant abnormalities are observed before administration of the first 
dose of investigational product on Day 1, they should be reported as adverse events.  If clinically 
significant abnormalities are observed after the first administration of investigational product on 
Day 1, the Investigator should assess and decide if they are new adverse events and report them accordingly.  The physical examination should include the following  at a minimum:   
â€¢ General appearance  
â€¢ Height (Screening visit only) 
â€¢ Weight 
â€¢ Skin 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 84 
Confidential and Proprietary    â€¢ Head, eyes, ear s, nose and throat (HEENT) 
â€¢ Neck 
â€¢ Lymph nodes 
â€¢ Chest/Respi[INVESTIGATOR_2133]  
â€¢ Cardiovascular system  
â€¢ Abdominal region 
â€¢ Extremities  
â€¢ Musculoskeletal system  
â€¢ Mental status  
â€¢ Neurological system. 
11.2.3. Vital Signs  
Vital signs will be assessed at indicated visits: oral temperature, sitting heart rate, respi[INVESTIGATOR_22024] (BP).  When taking heart rate, respi[INVESTIGATOR_22025], 
subjects should be seated quietly for a minimum of [ADDRESS_21182] ID number, date and time.  
11.2.5. Laboratory Assessments  
All laboratory tests will be analyzed by a Central Laboratory (except urine or serum pregnancy 
tests).  Blood and urine samples will be collected and analyzed or tested, according to the SOP of 
the testing facility  and all samples will be collect ed while the subject is fasting.  Full instructions 
concerning the number, volume, and type of samples to be collected at each visit will be detailed in the trial- specific laboratory manual.  The manual will also include details of sample collection 
methods, labelling, and shippi[INVESTIGATOR_22026]. 
Fasting (8 hours) blood samples are required for lipid, glucose (serum chemistry), and bile acid 
analyses.  For consistency, subjects will be instructed to attend each of their onsite visits (except Screening) in a fasted state and subjects should remain fasted until their blood samples have been 
collected.  At each visit the Investigator or designee will verify w hether the subject has fasted for 
at least [ADDRESS_21183] reports having 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 85 
Confidential and Proprietary    eaten (water is permitted) within [ADDRESS_21184] that fasting is required prior to all trial visits.  
â€¢ Hematology and Coagulation  (hemoglobin, hematocrit, white blood cell [WBC] 
count with differential, platelets, red blood cell [RBC] count , INR, prothrombin time,  
partial thromboplastin time ) 
â€¢ Serum chemistry including albumin, blood urea nitrogen (BUN), creatinine, direct (conjugated) bilirubin, indirect (unconjugated) bilirubin,  total bilirubin, AST ), ALT, 
ALP, GGT, electrolytes [calcium, chloride, potassium, sodium , magnesium ], glucose, 
total protein, and blood lipi[INVESTIGATOR_805] (total cholesterol, low density lipoprotein [ LDL], HDL 
and very low density lipoprotein (VLDL) fractions and triglycerides [TG])  
â€¢ Apolipoprotein and NMR lipoprotein panel: ApoA1, ApoB, ApoE, HDL, LDL, 
triglycerides, VLDL.  HDL, LDL, and VLD L cholesterol concentrations, particle 
numbers and sizes will be assessed.  
â€¢ IgG4 (Screening visit only)  
â€¢ Urine dipstick (pH, specific gravity, protein, glucose, ketones, bilirubin, blood) 
All subjects with laboratory tests containing clinically significant abnormal values are to be 
followed regularly until the values return to normal ranges; until a valid reason, other than test-article related AE, is identified; or until further follow -up is deemed medically unnecessary.  
Urine based Î²-hCG pregnancy tests will be performed in female subjects of childbearing 
potential per protocol specified visits.  Additionally, in accordance with local country or site 
requirements, additional urine pregnancy tests may be performed.  If a urine pregnancy test is 
positive, a serum pregnancy test must be performed to confirm the result.  If positive, the 
Sponsor must be notified and the subject will be followed as outlined in Section 11.1.9 until 
pregnancy outcome.  
12. STATISTICS  
12.1. Analysis Populations 
The following analysis populations will be used: 
Intent-to-Treat (ITT) Population  
All randomized subjects who receive any amount of investigational product will be included in 
the ITT population.  Treatment assignment will be based on the randomized treatment.  The ITT 
population will be used for the analysis of all efficacy data.  
Week 12 Completer Population 
Completer population will include all ITT subjects who complete the DB Week 12 ALP 
assessment.  Treatment assignment will be based on the randomized treatment.     
Week 24 Completer Population Completer population will include all ITT subjects who complete the DB Week 24 ALP 
assessment.  Treatment assignment will be based on the randomized treatment.     
Protocol 747-207 Version 5:   [ADDRESS_21185] 9 0% 
power to detect a treatment difference for change in ALP assuming 20% dropout and the mean 
absolute changes in ALP for OCA and placebo treatment groups are approximately - 20% 
and -5%, respectively, with a pooled standard deviation of 16, based on a 2- sided independent 
2-group t-test at an alpha level of 0.05.  
12.3. Efficacy Analysis 
One of the primary objective s of this proof of concept trial is to evaluate the efficacy of OCA in 
subjects with PSC.  The primary population for efficacy analys es is the ITT population.  
Sensitivity analyses will be conducted using the Completer population. 
12.3.1. Primary Efficacy Analysis 
The primary efficacy endpoint i s the Week 24 change from Baseline in ALP.  Th e primary 
efficacy analysis will compare the Week 24 ch ange from Baseline in ALP between OCA 10 mg  
treatment group and placebo using an analysis of covariance (ANCOVA) model with fixed 
effects for treatment group and randomization strata, and Baseline as a covariate.   
12.3.2. Secondary Efficacy Analysis 
Secondary efficacy analyses of hepatic biochemistry and function parameters (eg, ALT, AST, 
and GGT)  will be summarized by [CONTACT_22111] -Baseline visit.  The change from Baseline will also  be summarized.  
Baseline is defined as the mean of all available evaluations prior to treatment.  Hepatic 
biochemistry and function parameters will be analyzed  using the same ANCOVA model as 
specified for the primary efficacy analysis. 
A hierarchical appr oach will be used for multiplicity adjustments.  If the primary efficacy 
analysis is statistically significant (p <0.05), the following order will be used in the testing 
procedure to compare the change from Baseline in ALP between OCA and placebo:  
â€¢ Week 12:  OCA 5 mg treatment group (randomized to 5 mg for the initial 12 weeks 
followed by 10 mg for the latter 12 weeks) vs. placebo 
â€¢ Week 24:  OCA 3 mg treatment group (randomized to 1.5 mg for the initial 12 weeks followed by 3 mg for the latter 12 weeks) vs. placebo  
â€¢ Week 12:  OCA 1.5 mg treatment group (randomized to 1.5 mg for the initial 
12 weeks followed by 3 mg for the latter 12 weeks) vs. placebo 
If at any step a comparison above is not statistically significant, then all subsequent comparisons 
will be ex ploratory rather than confirmatory.   
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 87 
Confidential and Proprietary    In addition, secondary efficacy analyses of ALP response rates, defined as ALP to <1.5x ULN, 
will compare OCA treatment groups and placebo at Week [ADDRESS_21186] stratified by [CONTACT_22055].   
Hepatic stiffness measurements (based on TE) will be summarized by [CONTACT_22112] -Baseline visit.  The ELF score and its 
components (HA, P3NP, T1MP-1) and the other markers of fibrosis and/or inflammation will be 
summarized based on available data by [CONTACT_22113] -Baseline visit.  The change from Baseline will be analyzed using the 
same ANCOVA model as specified for the primary efficacy analysis. 
Subgroup analyses will be evaluated as deemed appropriate, including but not limited to, those subjects who start antibiotics after first dose of investigational product.  
Full details regardin g the planned analyses, methods, and outputs for the trial will be included in 
the SAP. 
12.4. Pharmacokinetics 
PK parameters will be determined for OCA, glyco -OCA, tauro -OCA, and total OCA (OCA plus 
conjugates).  PK parameters, including the following, will be calculated using non-compartmental methods where appropriate:  
â€¢ C
max:  maximum concentration (observed) 
â€¢ tmax:  time to C max  
â€¢ AUCt:  area under the concentration -time curve from time [ADDRESS_21187] sampling time 
with measurable analyte concentration, calculated  by [CONTACT_22114]- response assessment will be made comparing endpoints such as ALP and bile acids 
(eg, change in ALP relative to baseline) to the average exposure of total OCA (eg, AUC or C ss 
[steady-state concentration]) to help define an appropriate dose of OCA in this patient 
population.   
Full details regarding the planned analyses, methods, and outputs for the trial will be detailed in 
the SAP. 
12.5. Safety Analysis  
12.5.1. Adverse Events  
A treatment emergent AE ( TEAE) is any AE that newly appeared, increased in frequency, or 
worsened in severity following initiation of investigational product.  AEs occurring between the 
signing of informed consent but prior to first dose of investigational product are considered  
pretreatment AEs.  Treatment -emergent AEs will be summarized by [CONTACT_3148], system organ 
class, and preferred  term defined using the Medical Dictionary of Regulatory Activities  
(MedDRA).  The number of events, the number of subjects, and the percent of subjects w ho 
experienced at least one TEAE will be presented for each system organ class and for each 
preferred term by [CONTACT_1570].  TEAEs that lead to early  withdrawals , serious TEAEs , and 
TEAEs by [CONTACT_22115].   Additional det ails 
will be provided in the SAP.  
Protocol 747-207 Version 5:   [ADDRESS_21188], and visit, including 
scheduled and unscheduled/repeat measurements.  Laborat ory assessments that are outside of 
normal ranges will be flagged.  Baseline values, the values at each visit, and changes from 
Baseline values will be summarized for each of the quantitative laboratory assessments by 
[CONTACT_1570].  Baseline is defined as the mean of all available evaluations prior to treatment 
(except for lipoprotein assessments where Baseline will be the fasted Day 0 assessment).    
12.5.3. Additional Safety Analysis  
Additional safety assessments include vital signs and ECGs.  V ital signs will be summarized by 
[CONTACT_22113] -Baseline visit.  
The change from Baseline will also be summarized.  ECGs will be summarized by [CONTACT_22116].  The shift fr om baseline will also be summarized.   Baseline 
is defined as the mean of all available evaluations prior to treatment.    
12.6. Interim Analyses and Data Monitoring  
12.6.1. Interim Analysis  
An unblinded interim analysis will be conducted after approximately 50% of subjec ts have 
completed the initial 12 -weeks of blinded treatment.  The trial will not be terminated early for 
futility.  The interim analysis will compare at Week 12, the same variable as will be analyzed for the primary endpoint, the change from Baseline in ALP, between OCA treatment groups (1.5 mg 
and 5 mg) and placebo using an analysis of covariance (ANCOVA) model with fixed effects for 
treatment group and randomization strata and Baseline as a covariate.  No adjustments to the alpha level will be made.  
In addition, once all subjects have completed the DB phase of the study, the DB database will be locked, unblinded, and full analyses will be performed.  The specific details of both the interim and end of double-blind analyses will be documented in the SAP. 
12.6.2. Data and Safety Monitoring Committee 
An independent DSMC will review safety data from this trial, as well as other ongoing OCA 
trials at approximately quarterly intervals, but at least every 6 months.  The DSMC includes internationally recognized hepatologis ts, pharmaceutical physicians and statistician(s).  All have 
considerable experience with clinical trial conduct and DSMCs, prior to joining the OCA DSMC.  Candidates are screened for conflicts of interest and any candidate found to have such a conflict is not offered membership.  Conflicts of interest are assessed regularly, and if members 
are found to have a new conflict of interest they w ill be replaced.  The DSMC meets 
approximately quarterly at scheduled meetings and ad hoc meetings are convened, as 
appropriate.  The DSMC reviews all Intercept -sponsored Phase 2 and 3 studies.  Members of the 
DSMC will no t be allowed to participate as Investigator s in this trial and will not otherwise 
consult for the Sponsor.   
SAE information will be provided to the DSMC on an ongoing basis as SAEs occur.  Adhoc 
(closed) DSMC meetings for review of unblinded data from subjects who experience SAEs, as 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 89 
Confidential and Proprietary    requested by [CONTACT_22117], will be arranged.  The DSMC will review data on a periodic basis to 
ensure the safe and proper treatment of subjects.  Based on review of these data, the DSMC will 
advise the Sponsor on the validity and scientific merit of continuing the trial.   
The DSMC  operates under an appropriate charter (in compliance with relevant regulatory 
guidance) that defines its organization and operation and includes specific procedures for each 
trial.  The DSMC will prepare written minutes of both its open and closed sessions for each trial.  
The closed minutes will be made available to the Sponsor only after the database is locked.  
Data listings provided to the DSMC do not contain individual patient treatment information; 
however, the DSMC will have access to the database an d may unblind individual subject  data as 
appropriate.  Summary tables reviewed by [CONTACT_22118] â€œdummyâ€ labels, ie, the actual treatment groups are used, but are not identified. Data 
reviewed during the meetings will include, at a minimum, disposition, demographics, exposure, 
clinical laboratory results, MedDRA coded AE s, and AEs leading to early withdrawal of study 
drug.  At ea ch meeting, detailed narratives of interval SAEs (including events resulting in death) 
are reviewed by [CONTACT_22119] a cumulative list of all SAEs. 
The DSMC may request additional analyses if deemed necessary to fulfill the mission of the 
DSMC.  The DSMC will determine if an unscheduled meeting is necessary based on the 
additional data.  At a minimum , the occurrence of 2 life threatening SAEs or an SAE resulting in 
death will trigger an unscheduled and unblinded review of the data by [CONTACT_6802]. 
All Investigator s and responsible IRB s/IECs will be informed of any decisions made by [CONTACT_22120], which alter the 
conduct of this trial.  The Investigator s will inform the subjects of such actions and the protocol, 
PIS and consent will be revised, as appropriate.  
13. DIRECT ACCESS TO S OURCE DATA/DOCUMENTS  
13.1. Trial Monitoring  
Trial records at each site will be monitored at regular intervals by a representative of the Sponsor, the CRA.  The role of the CRA is to aid the Investigator in the maintenance and documentation of complete, accurate, legible, well organized, and easily retrievable data.  In 
addition, the CRA will ensure the Investigator 's understanding of all applicable regulations 
concerning the clinical evaluation of the investigational product and will ensure an understanding 
of the protocol, reporting responsibilities and the validity of the data.  This will include ensuring 
that full and appropriate essential documentation is available.  
In order to perform this role, the CRA must perform source data verification and as such must be 
given access to the subjectâ€™s primary source documentation (eg, paper or electronic medical records such as consent to participate in the trial, visit dates, scr eening and randomization 
numbers, demographic information, medical history, disease history, physical examination, vital 
signs, laboratory assessments [copy of laboratory reports], AEs, concomitant medications, dates 
of dispensing investigational product, ECGs, etc) that support data entries in the CRF.  The CRF  
Protocol 747-207 Version 5:   [ADDRESS_21189] be completed promptly after each visit to allow the progress and results of the trial to be 
closely followed by [CONTACT_941] M edical Monitor. 
13.2. Investigator Audits and Inspections  
The Investigator should understand that it may be necessary for the Sponsor, the IRB/IEC,  and/or 
a regulatory agency to conduct one or more site audits during or after the trial and agrees to 
allow access to all trial related documentation and information and be available for discussion 
about the trial.   
14. QUALITY C ONTROL AND QUALITY ASSURANCE 
Logic and consistency checks will be performed on all data entered into the CRF  or ultimately 
transferred into the database to ensure accuracy and completeness.   
Training sessions, r egular monitoring of the trial at the trial site by [CONTACT_22121] (eg, CRA), instruction manuals, data verification, cross checking, and data audits will be performed to ensure quality of all trial data.  Investigatorsâ€™ meetings and/or onsite trial initiations will be performed to prepare I nvestigator s and other trial site personnel for appropriate 
collection of trial data.  
To ensure compliance with Good Clinical Practices (GCP) and all applicable regulatory requirements, the Sponsor may conduct a quality assurance audit.  Please see Section 13.[ADDRESS_21190] be approved or given a favorable opi[INVESTIGATOR_22027] I RB/ IEC as 
appropriate.  The Investigator must submit written IRB/IEC approval to Intercept before he or 
she can enroll an y subject into the trial.  The Investigator is responsible for providing the IB and 
any other available safety information and information about payments and compensation 
available to trial subjects to the ethics committee for review.  
The Investigator is responsible for informing the IRB /IEC of any amendment to the protocol in 
accordance with local requirements.  A favorable opi[INVESTIGATOR_22028], unless the amendment is necessary to reduce immediate risk to 
trial participants.  In addition, the IRB / IEC must approve all advertising used to recruit subjects 
for the trial.  The protocol must be reapproved by [CONTACT_1201]/ IEC upon receipt of amendments and 
annually, as local regulations require.  
The Investigator is also responsible for providing the IRB with reports of any SARs  any other 
trial conducted with the investigational product .  The Sponsor will provide this information to 
the Investigator. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 91 
Confidential and Proprietary    Progress reports and notifications of SARs will be provided to the IRB/IEC according to local 
regulations and guidelines.  Investigators or the Sponsor or its designee will provide reports to 
the IRB/IEC as requested, as a minimum annually, and after the trial is complete.  
15.2. Ethical Conduct of the Trial  
The trial will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and are 
consistent with ICH/GCP, applicable regulatory requirements. 
15.3. Written Informed Consent 
The Investigator (s) at each center will ensure that the subject is given full and adequate oral and 
written information about the nature, purpose, possible risk, and benefit of the trial.  Subjects 
must also be notified that they are free to discontinue from the trial at any time.  The subject 
should be given the opportunity to ask questions and allowed time to consider the information 
provided. 
The subjectâ€™s signed and dated  ICF must be obtained before conducting any trial procedures. 
The Investigator(s) must maintain the original, signed ICF.  A copy of the signed ICF must be 
given to the subject.  
15.4. Subject Confidentiality and Data Protection  
All information obtained during the conduct of the trial with respect to the subject will be 
regarded as confidential and confidentiality of all subjects will be maintained.  Monitors 
(eg, CRA, Medical Monitor), auditors, and inspectors will require access to a subjectâ€™s medical 
notes for the purpose of source document verification, but the subjectâ€™s confidentiality will be maintained at all times.  An agreement for disclosure of any such information will be obtained in writing and is included in the statement of informed consent.  The trial data shall not be disclosed 
to a third party (with the exception of auditors and/or regulatory authorities) without the written 
consent of the Sponsor .  All data shall be secured against unauthorized access.  
The Investigator will maintain a list of subjects â€™ names and identifying information (eg, subjectâ€™s 
hospi[INVESTIGATOR_7965], unique subject number).  This list will not be collected by [CONTACT_1034]. 
The written information sheet will explain that trial data will be stored in a computer database, 
maintaining confidentiality in accordance with national da ta protection legislation.  All data 
computer processed by [CONTACT_22122]/randomization code/subject initials/site number, only.   
When personal data on subjects are stored or processed by [CONTACT_22123], the data must be protected 
to prevent their disclosure to unauthorized third parties.  The pertinent sections of the data 
protection laws in which the country is being conducted will be complied with in full. 
The written PIS will explain that, for data verific ation purposes, authorized representatives of the 
Sponsor, a regulatory authority, or an IRB/IEC  may require direct access to parts of the hospi[INVESTIGATOR_22029], including subjectâ€™s medical history.  
Protocol 747-207 Version 5:   [ADDRESS_21191] instructions for the trial 
site staff and a telephone number where he or she can be reached.  
Named physician(s) will be responsible for the medical follow -up of subjects, as applicable.  
16.1. AE Reporting  
The Investigator is responsible for recording AEs reported by [CONTACT_22124].  In agreeing to the provisions of this protocol, the I nvestigator 
accepts all legal responsibilities for immediate reporting of SAEs to the Sponsor. 
16.2. Protocol Deviations 
The Investigator is not permitted to deviate from the protocol in any significant way without 
proper notification to the Sponsor (or designee).  Only the Sponsor may amend the protocol.  
Any change in trial conduct consider ed necessary by [CONTACT_22125], who will then issue a formal protocol amendment to implement the change and obtain regulatory approval.  The only exception is when the Investigator considers a subject â€™s safety to be compromised if immediate action is not taken. 
16.3. Regulatory Documentation  
The following regulatory documentation must be completed or provided and maintained: 
â€¢ Approved PIS and ICF (all versions)  
â€¢ IRB/IEC approvals (of protocol/amendments, subje ct questionnaires, etc)  
â€¢ Form FDA 1572  
â€¢ Current medical license  (US) 
â€¢ Curriculum vitae  
â€¢ Laboratory certification and reference ranges  
â€¢ Financial disclosure forms 
16.4. Ethics Review  
Please see Section 15.1 for th e Investigator â€™s responsibilities regarding ethics review.  
16.5. Archiving and Record Retention  
The Investigator should retain all correspondence relating to this trial in the Investigator Site File 
(ISF).  Any trial documents stored elsewhere should have their location referenced in the ISF. 
All Sponsor-specific essential documents relating to the trial, including the ISF itself, source 
documents and subject medical files (retained per country specific regulations), completed trial subject log, and confidential subject identificatio n list will be retained by [CONTACT_22126] 747-207 Version 5:   [ADDRESS_21192].  These 
documents should be retained for a longer period, however, if required by [CONTACT_8146](s) or if needed by [CONTACT_1034].  In the event that storage of records becomes a problem at any time during this period, the Sponsor should be consulted for 
assistance.   At the end of the minimum period, the Investigator should obtain written 
authorization from the Sponsor prior to the destruction of any records.  The Investigator will 
notify the Sponsor if ownership of documents or responsibility for the trial site is transferred.   The Sponsor will inform Investigators should it become aware of any changes in 
storage requirements.  
17. PUBLICATION POLICY 
The Sponsor intends to p ublish the results of all of the clinical trials that it sponsors consistent 
with the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, 
October 2013). Consistent with the recommendations of the editors of several leading medical journals, the International Committee of Medical Journal Editors (ICMJE), authorship of 
publications resulting from Intercept sponsored studies should fairly recognize the activities of 
those that have made a significant contribution to the trial 
(http://www.icm je.org/ethical_1author.html, accessed May 22, 2013).  Thus, it is anticipated that 
authorship will reflect the contribution made  by [CONTACT_22127], the Investigators, and 
others involved, such as statisticians.   
In recent years, issues about confli cts of interest and accuracy of the trial data have been raised in 
the medical press.  Accordingly, the Sponsor has developed publication guidelines for clinical 
trials that are appropriate for this trial.  Key issues include the following:  
â€¢ Clinical Trial Registries (eg, clinicaltrials.gov):  A description of the trial and relevant design elements (eg, basic design, objectives and endpoints, sample size, trial population, and key inclusion/exclusion criteria) and results (when available) will be 
published o nline in a manner consistent with applicable regulatory guidelines.  
â€¢ Overview:  Investigator s, reviewers, and editors will have the right to audit the data to 
verify its accuracy.  
â€¢ Responsibility:  Each I nvestigator  is responsible for the accuracy and completeness of 
all data from her/his site.  The Sponsor (or its representatives) is responsible for the 
accuracy of the data entered into the trial databases and the analyses conducted.  
â€¢ Data Management:  The Sponsor will establ ish data management and the SAP.  The 
Investigators will have the opportunity to provide input into the plans.  The 
Investigators will have the right to review the audit reports and data resolution 
decisions prior to the establishment of a clean file.  The Investigator s will have the 
right to appoint appropriately qualified auditors, with GCP experience, to audit the 
Sponsorâ€™s data prior to the establishment of a clean file.  The Investigator s must 
provide adequate notice (at least 2 months) to the Sponsor of their intention to audit a trial.  The audit should be conducted in a timely manner to allow the resolution of discrepancies before a clean file is established.  The Investigator s will bear all the 
Protocol 747-207 Version 5:   [ADDRESS_21193] be conducted in such a 
manner as to minimize the time to create the clean file.  
â€¢ Authorship:  Interc ept, in collaboration with the Investigator s, will establish the 
appropriate authorship and responsibility for drafting trial documents in accordance with the principles of the ICMJE.  All manuscripts will be reviewed and agreed upon 
before submission for publication by [CONTACT_15064].   
â€¢ Single Center Publication and Additional Publications:  This is a multicenter trial and 
is designed to be published with complete data from all the trial sites.  Single center 
publications are therefore not considered appropriate.  Any such publications should clearly state that the data are â€˜extractedâ€™ from a multicenter trial and that the trial was 
not intended, or statistically powered, for data presentation by a single trial site.   
â€¢ Intercept Review of External Manuscripts:  Consistent with this, Investigator s must 
submit any draf ts of any publications or presentations that may arise from this trial to 
the Sponsor for review and approval and to ensure consistency with the policy in this protocol at least [ADDRESS_21194] facts and to 
represent its, or the Publication Committeeâ€™s, opi[INVESTIGATOR_22030].  
â€¢ Confidentiality:  Investigator s will conduct all interactions with the compan y and 
with third parties consistent with the executed confidentiality agreements.  While publication, by [CONTACT_7586], presents the critical scientific data in a public forum, some information (such as future plans, results of nonclinical studies or chemical formulae) 
may still need to remain confidential.  
â€¢ Medical Journal Review:  Upon request, all pertinent trial data and information will be made available as supplemental information for journal editors and reviewers to 
evaluate and audit, eg, protocol and amendments, data tabulations, etc.  Arrangements 
will be made to maintain the confidentiality of such supplemental information.  Arrangements will also be made to maintain the confidentiality of the identity of 
journal reviewers.  Records will be maintained of which documents and datasets were 
reviewed.  
18. LIST OF REFERENCES  
Al Mamari S, Djordjevic J, Halliday JS, et al. Improvement of serum alkaline phosphatase to 
<1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in 
primary sclerosing cholangitis. J Hepatol. 2013 Feb;58(2):329-34. 
Albanis E, Alvarez CE, Pruzanski M, et al. INT-747, a novel FXR activator, reverses hepatic 
fibrosis and cirrhosis in thiocetamideinduced liver injury in rats. Hepatology. 2005;42(Supplement 1):Abstract 1040. 
Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary 
sclerosing cholangitis. J Hepatol. 2002 Mar;36(3):321-7. 
Protocol 747-207 Version 5:   [ADDRESS_21195] WR, Becktel JM, Singleton JW, et al.  Development of a Crohn's disease activity index. 
National Cooperative Crohn's Disease Study. Gastroen terology. 1976 Mar; 70 (3): 439-444. 
Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006 Jun;3(6):318-28. 
CEREP. In Vi tro pharmacology:High-throughput profile - Study of INT-747. 2008 June 7, 
2008;Study #[ZIP_CODE]. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing 
cholangitis. Hepatology. 2010 Feb;51(2):660-78. 
Chapman R. Primary sclerosing cholangitis. Autoimmune Liver Disease. 2011; 39(10):558-591. 
Cipriani S, Mencarelli A, Chini MG, et al. The bile acid receptor GPBAR -1 (TGR5) modulates 
integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 
2011;6(10):e25637. 
EASL. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of 
Hepatology. 2009;51:237-67. 
Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and 
advances in diagnosis and management . Gastroenterology. 2013 Sep;145(3):521-36. 
Elman S, Hynan L, Gabriel V, et al. The 5- D itch scale: a new measure of pruritus. British 
Journal of Dermatology. 2010 Dec; 162: 587-593 
Fevery J, Verslype C, Lai G, et al. Incidence, diagnosis, and therapy of cholangiocarcinoma in 
patients with primary sclerosing cholangitis. Dig Dis Sci. 2007 Nov;52(11):3123-35. 
Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits 
inflammation and preserves the intestinal barrier in inflamma tory bowel disease. 
Gut. 2011 Apr;60(4):463-72. 
Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet. 2013 Nov 9;382(9904):1587-99. 
Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver 
Dis. 2006 Feb;26(1):42-51. 
Lee YM, Kim DJ. Primary Sclerosing Cholangitis. New England Journal of Medicine. 
1995;332:924-33. 
Lee YM, Kaplan M, and the Practice Guideline Committee of the ACG.  Management of 
Primary Sclerosing Cholangitis. AJG 2002 Mar; 97(3):528-534. 
Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic 
regulation. Physiol Rev. 2009 Jan;89(1):147-91. 
Levy C, Lindor KD. Primary sclerosing cholangitis: epi[INVESTIGATOR_623], natural history, and 
prognosis. Semin Liver Dis. 2006 Feb;26(1):22-30. 
Li YT, Swales KE, Thomas GJ, et al. Farnesoid x receptor ligands inhibit vascular smooth 
muscle cell inflammation and migration. Arterioscler Thromb V asc Biol. 
2007 Dec;27(12):2606-11. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 96 
Confidential and Proprietary    Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing 
Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997 Mar 6;336(10):691-5. 
Lindor KD, Kowdley KV, Luketic VA, et al. High -dose ursodeoxycholic acid for the treatment 
of primary sclerosing cholangitis. He patology. 2009 Sep;50(3):808-14. 
Lindstrom L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline 
phosphatase and survival times of patients with primary sclerosing cholangitis. Clin 
Gastroenterol Hepatol. 2013 Jul;11(7):841-6. 
Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. 
Science. 1999 May 21;284(5418):1362-5. 
Mookerjee RP, Mehta G, Balasubramaniyan V, et al, Hepatic dimethylarginine-
dimethylaminohydrolase1 is reduced in cirrhosis a nd is a target for therapy in portal 
hypertension. J Hepatol. 2015 Feb; 62(2):325-331. 
Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary 
sclerosing cholangitis: a 5 -year multicenter, randomized, controlled study. Gastroenterology. 
2005 Nov;129(5):1464-72. 
Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha -ethyl-chenodeoxycholic acid (6- ECDCA), 
a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 
2002 Aug  15;45(17):3569-72. 
Pols TW, Nori ega LG, Nomura M,:  The bile acid membrane receptor TGR5 as an emerging 
target in metabolism and inflammation. J Hepatol. 2011;54:1263-1272. 
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy 
for ulcerative colitis . N Engl J Med. 2005 Dec 8;353(23):2462-76. 
Talwalkar JA, Chapman RW. The resurgence of serum alkaline phosphatase as a surrogate 
biomarker for prognosis in primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 
2013 Jul;11(7):847-9. 
Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor 
FXR/BAR. Mol Cell. 1999 May;3(5):543-53. 
Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in 
hepatic inflammatory response. Hepatology. 2008 Nov;48(5):1632-43. 
Worthington J, Chapman R. Primary sclerosing cholangitis. Orphanet J Rare Dis. 2006;1:41. 
Protocol 747-207 Version 5:   [ADDRESS_21196] OF PLANNED LABO RATORY ANALYTES  
Serum Chemistry  
alanine transaminase (ALT; SGPT)  
albumin  
alkaline phosphatase (ALP)  
aspartate aminotran sferase (AST; SGOT)  
bicarbonate  
bilirubin: total, unconjugated (indirect) & conjugated (direct)  
blood urea nitrogen ( BUN) 
calcium 
chloride  
creatinine  
free fatty acids  
gamma-glutamyl transpeptidase (GGT)  
glucose 
HDL 
LDL 
magnesium  
phosphorus potassium 
sodium 
thyroid hormones (T3, T4, TSH)  total cholesterol  
total protein  
triglycerides  
vitamin D  
VLDL  
Apolipoprotein and NMR Lipoprotein  Analysis  
ApoA1 
ApoB 
ApoE HDL 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 98 
Confidential and Proprietary    LDL 
triglycerides  
VLDL 
HDL, LDL, and VLDL cholesterol concentrations, particle numbers and sizes will be 
assessed. 
Hematology  
hematocrit  
hemoglobin  
platelets  
RBC count (incl. MCV, HBE [MCH], MCHC)  
WBC with differential  
neutrophils* 
lymphocytes* monocytes* 
eosinophils* 
basophils* 
Coagulation Parameters 
prothrombin time (PT and INR) partial thromboblastin time (PTT)  
Biomarkers of Inflammation  
autotaxin & its metabolites  
CRP 
IgA 
IgG 
IgG4 
IgM 
IL-6 
IL-12 
IL-23 
TGF-Î² 
TNF-Î± 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 99 
Confidential and Proprietary    Biomarkers of Fibrosis  
Enhanced Liver Fibrosis (ELF) markers: Hyaluronic acid, P3NP, TIMP -1 
CK-18 
FXR Activity  
FGF-19 
Bile Acids (conjugated & unconjugated forms)  
C4 
CDCA 
Cholic acid  
Deoxycholic acid 
Lithocholic acid  
OCA Total bile acids  
UDCA 
Genetics Test  
 RNA 
Urine Dipstick  
bilirubin 
blood glucose 
ketones 
pH protein 
specific gr avity 
Urine Pregnancy  
Urine Î²-hCG pregnancy test in females of childbearing potential.  If the urinary test is 
positive it should be repeated as a serum pregnancy test.  
Fecal Samples  
calprotectin  
gut microbiome (fecal bacterial genome) 
* Further evaluation if appropriate Note:  The above list is not all inclusive and some tests may not be performed if not required. 
 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 100 
Confidential and Proprietary    APPENDIX B. PARTIAL MAYO SCORING SYSTEM FOR 
ASSESSMENT OF ULCERA TIVE COLITIS ACTIVIT Y 
Partial Mayo Scoring System for Assessment of Ulcerative Colitis Activity  
(The Partial Mayo Score  ranges from 0 -9, with higher scores indicating more severe disease)  
Stool Frequency  (Each patient serves as his or her own control to establish the degree of abnormality of 
the stool frequency)  
0 = Normal no. of stools for this patient  
1 = 1 to 2 stools more than normal  
2 = 3 to 4 stools more than normal  
3 = 5 or more stools more than normal  
Subscore, 0 to 3  
Rectal Bleeding  (The daily bleeding score represents the most severe bleeding of the day)  
0 = No blood seen  
1 = Streaks of blood with stool less than half the time  
2 = Obvious blood with stool most of the time 
3 = Blood alone passes  
Subscore, 0 to 3  
Physicianâ€™s Global Assessment  (This assessment acknowledges the two other criteria, the patientâ€™s daily 
recollection of abdominal discomfort and general se nse of wellbeing, and other observations, such as 
physical findings and the patientâ€™s performance status)  
0 = Normal  
1 = Mild disease  
2 = Moderate disease  
3 = Severe disease  
Subscore, 0 to 3  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 101 
Confidential and Proprietary     APPENDIX C. PRURITUS VISUAL ANAL OGUE SCALE   
Visual Analog Scale 
Severity : Draw a line anywhere on the scale that best represents the severity of your itching   
 
 
                        No itching                                             Worst possible itching                
                
 (See example below ) 
                                            
         0                 2                 4                 6                8               10 
 
  
 
                                                        Example:  
                 
 
Note :  Size of actual  VAS is 10cm.  
 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 102 
Confidential and Proprietary    APPENDIX D. 5-D ITCH SCALE 
 
 
 

Protocol 747-207 Version 5:   [ADDRESS_21197].  
 Your identity will remain entirely confidential. Thank you!  
 
Did you feel that participatin g in this clinical study was 
worthwhile?  
(1 â€“ Disagree strongly - 5 â€“ Agree strongly)  1   2   3   4   5  
Comment:   
Would you recommend participation in a clinical study 
to a relative or a close friend, with the same condition? (1 â€“ Disagree strongly - 5 â€“ Agree strongly)  1   2   3   4   5  
Comment:  
What were some of the features of the study that you 
liked (tick all that apply)?   Better medical care / attention  
 Helpi[INVESTIGATOR_22031], please specify:   
 
Comment:  
What were some of the features of the study that you 
disliked (tick all that apply)?   Study was overly invasive  
 Expectations of study were not met  
 Study was overly disruptive to usual routine  
 Medical care was less than I expected  
 Interaction with medical staff was less than I expected  
 Other, please specify:   
 
Comment:  
Thank you very much for your participation.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 104 
Confidential and Proprietary    APPENDIX F. CROHNâ€™S  DISEASE ACTIVITY  INDEX 
 
(CDAI: adapted from Best 1976)  
 
Clinical or laboratory variable Weighting 
factor 
Number of liquid or soft  stools each day for seven days  x 2 
Abdominal pain  (graded from 0 -3 on severity) each day for seven days  x 5 
General wellbeing, subjectively assessed from 0 (well) to 4 (terrible) each day 
for seven days  x 7 
Presence of complications* x 20 
Taking Lomotil or opi[INVESTIGATOR_22032]  x 30 
Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite)  x 10 
Hematocrit  of <0.47 in men and <0.[ADDRESS_21198] weight  x 1 
 
*One point each is added for each set of complications: 
 
â€¢ the presence of joint pains (arthralgia) or frank arthritis  
â€¢ inflammation of the iris or uveitis  
â€¢ presence of erythema nodosum, pyoderma gangrenosum, or aphthous ulcers 
â€¢ anal fissures, fistulae or abscesses  
â€¢ other fistulae  
â€¢ fever during the previous week 
 
   
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 105 
Confidential and Proprietary    APPENDIX G. PROTOCOL VERSION 2 â€“ SUMMARY OF CHANGES  
 
1. Background 
Protocol 747- [ADDRESS_21199] 2012.  The original protocol was not submitted to IRBs/IECs.  
 
2. Rationale 
The changes detailed below address comments raised by [CONTACT_22128].    
3. Summary of Changes  
The following revisions were made to the protocol in Protocol Version 2.   
 (Note:  Differences have been indicated in bold font.)   
 
 
3URWRFRO 9HUVLRQ0DU
 3DJH
&RQILGHQWLDODQG3URSULHWDU\6HFWLRQ 2ULJLQDO7H[W 5HYLVHG7H[W
3DJH 2ULJLQDO9HUVLRQ-XQ 9HUVLRQ 6HSWHPEHU 
6\QRSVLV
3ODQQHG1XPEHURI7ULDO6LWHV$SSUR[LPDWHO\ (XURSHDQG8QLWHG6WDW HV>86@ $SSUR[LPDWHO\ (XURSHDQG8QLWHG6WDWHV>86@
6\QRSVLV
0HWKRGRORJ\/76(
QG
SDUDJUDSK8SRQDVXEMHFWÂ¶VFRPSOHWLRQ RIWKH:HHNYLVLWDWWKH
HQGRIWKH'%SKDVHWKHWULDOEO LQGZLOOEHEURNHQLQRUGHU
WRDVVLJQWKHVWDUWLQJ2&$GRVHIRUWKH/76(SKDVH8SRQDVXEMHFWÂ¶VFRPSOHWLRQ RIWKH'%SKDVH WKHWULDO
EOLQGZLOOEHEURNHQLQRUGHU WRDVVLJQWKHVWDUWLQJ2&$
GRVHIRUWKH/76(SKDVH
6\QRSVLV0HWKRGRORJ\/76(WKSDUDJUDSK'XULQJWKH/76(SKDVHVXEMHFWV PD\WLWUDWHWRKLJKHU
GRVHVRI2&$DWDIUHTXHQF\QRWJUHDWHUWKDQ PRQWKO\XS
WRDPD[LPXP GDLO\GRVHRIPJGDLO\'XULQJWKH/76(SKDVHVXEMHFWV PD\WLWUDWHWRKLJKHU
GRVHVRI2&$DWDIUHTXHQF\QRWJUHDWHUWKDQ PRQWKO\
LHDWHDFKRIWKHVFKHGXOHGYLVLWV XSWRDPD[LPXP
GRVHRIPJGDLO\
6\QRSVLV7ULDO'HVLJQ6FKHPDWLF


6\QRSVLV
,QFOXVLRQ&ULWHULRQ&KRODQJLRJUDSK\RURWKHUDSSURSULDWHLPDJLQJPRGDOLW\
ZLWKLQPRQWKVRI'D\FRQVLV WHQWZLWKDGLDJQRVLVRI
36&0XVWKDYHDGLDJQRVLVRI36&EDVHGRQ
FKRODQJLRJUDSK\DWDQ\SRLQWLQWLPHDQGPXVWKDYH
KDGDFKRODQJLRJUDSK\ZLWKLQWKHSDVWPRQWKV

Protocol 747-207 Version 5:   18 Mar 2016 
 Page 107 
Confidential and Proprietary    Section Original Text Revised Text  
Synopsis, 
Inclusion Criterion #5  Note 2: Subjects with documented Gilbertâ€™s syndrome 
may be allowed to participate in the study after discussion with the medical monitor.  Note 2 has been deleted from this section and moved to 
Synopsis, Exclusion Criterion #10 (see below). 
Synopsis, 
Inclusion Criterion #6  For subjects with concomitant IBD:  colonoscopy within 
12 months of Day 0 confirming no dysplasia or colorectal 
cancer For subjects with concomitant IBD:   
a. Colonoscopy within 12 months of Day 0 confirming no dysplasia or colorectal cancer  
b. Subjects with Crohnâ€™s Disease (CD) must be in 
remission as defined by a Crohnâ€™s Disease Activity 
Index (CDAI) <150. 
c. Subjects with ulcerative colitis (UC) must either be 
in remission or have mild disease.   Remission is 
defined as a partial Mayo score of â‰¤ 2 with no 
individual sub- score exceeding 1.  Mild disease is 
defined as a partial Mayo score â‰¤ 3 with no 
individual sub -score exceeding 1 point.  
Synopsis, Inclusion Criterion # 7 Note 3: Note 2: 
Synopsis, Inclusion Criterion #9  Contraception:  female subjects of ch ildbearing potential 
must use â‰¥ 1 effective (â‰¤1% failure rate) method of 
contraception during the trial and until [ADDRESS_21200] dose of IP (including LTSE doses).  Contraception:  female subjects of childbeari ng potential 
must use â‰¥[ADDRESS_21201] dose of IP (including LTSE doses).  
Synopsis, 
Exclusion Criterion #3  Exclusion criterion has been added/inserted; all other 
criteria numbering has subsequently shifted.  Small duct cholangitis in the absence of large duct disease 
Synopsis, 
Exclusion Criterion #4  Presence of clinical complications of chronic liver disease 
or clinically significant hepatic decompensation, 
including:  Presence of clinical complications of chronic liver disease 
or clinically significant hepatic decompensation, 
including:  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 108 
Confidential and Proprietary    Section Original Text Revised Text  
(Change to 7th bullet, only.)  
â€¢ Current splenomegaly as evidenced by [CONTACT_22129] < 50 x109/L (Change to 7th bullet, only.)  
â€¢ Platelet coun t <50 x 109/L 
Synopsis, 
Exclusion Criterion #8  History of any  bowel resection unless permitted with 
prior discussion and written approval from Sponsor 
medical monitor  History of small bowel resection  
Synopsis, 
Exclusion Criterion #9  History of other chronic liver diseases, â€¦ non-alcoholic 
fatty liver disease (NAFLD), hepatitis B virus (u nless 
seroconverted and no positive Hepatitis B Virus DNA) and 
hepatitis C virus  History of other chronic liver diseases  â€¦ non-alcoholic 
fatty liver disease (NAFLD), autoimmune hepatitis , 
hepatitis B virus (unless seroconverted and no positive Hepatitis B  Virus DNA) and hepatitis C virus  
Synopsis, 
Exclusion Criterion #10  Moved from Synopsis, Inclusion Criterion # 5, which 
previously read:   
Note 2:  Subjects with documented Gilbertâ€™s syndrome 
may be allowed to participate in the study after discussion with the medical monitor.  Known Gilbertâ€™s syndrome or elevations in unconjugated (indirect) bilirubin >ULN  
Synopsis, 
Exclusion Criterion #14  Exclusion criterion inserted. Administration of antibiotics is prohibited â‰¤1 month 
of Day 0. 
Synopsis, 
Exclusion Criterion #15  Administration of the follow ing medications is prohibited 
â‰¤6 months of Day 0 and throughout the DB phase of the 
trial: ... or nitrofurantoin).  Administration of the follow ing medications is prohibited 
â‰¤6 months of Day 0 and throughout the tri al: â€¦ or 
nitrofurantoin).  
Synopsis, Exclusion Criterion #16  IBD flare during Screening (up to and including Day 0). IBD flare during Screening (up to and including Day 0), 
where â€œflareâ€ is defined as follows: 
â€¢ UC flare:  partial Mayo Score â‰¥5, and  
â€¢ CD flare:  CDAI â‰¥250 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 109 
Confidential and Proprietary    Section Original Text Revised Text  
Synopsis, 
Criteria for Evaluation: Disease Specific Symptoms  Two additional items added Pruritus 5 -D questionnaire  
 
Crohnâ€™s disease activity index (CDAI)  
Synopsis, 
Statistical Methods: Efficacy Analyses The co-primary efficacy endpoints are the absolute 
changes from Baseline in ALP at Week 12 and 
Week 24.  The primary efficacy analysis at Week 12 will 
compare the absolute change from Baseline in ALP 
between OCA treatment groups ( 1.5 mg and 5 mg) and 
placebo using an analysis of covariance (ANCOVA) model with fixed effects for treatment group and randomization strata and Baseline as a covariate.  The primary efficacy analysis at Week 24 will compare the absolute change from Baseline in ALP between OCA treatment groups (3 mg and 10 mg) and placebo using the same ANCOVA model as the Week 12 analysis.   
 
The co-primary endpoints will be tested using a 
hierarchical approach to control the overall 
significance level for multiple visit and dose comparisons.  
  
Secondary efficacy analyses of hepatic biochemistry 
and function parameters will use the same ANCOVA 
models as the primary endpoints.  
  
In addition, secondary efficacy analysis  of ALP response 
rates, defined as ALP to < 1.5x ULN, will compare OCA The primary efficacy endpoint is the Week 24 change 
from Baseline in ALP .  The primar y efficacy analysis 
will compare the Week 24 change from Baseline in 
ALP between the OCA 10 mg treatment group  and 
placebo using an analysis of covariance (ANCOVA) 
model with fixed effects for treatment group and 
randomization strata and Baseline as a covariate.  
Secondary efficacy analyses of hepatic biochemistry 
and function parameters will use the same ANCOVA 
models as the primary endpoints.  A hierarchical 
approach will be used for multiplicity adjustments.  If 
the primary efficacy analysis is statistica lly significant 
(p <0.05), the following order will be used in the testing 
procedure to compare the change from Baseline in ALP between OCA and placebo:  
â€¢ Week 12:  OCA 5 mg treatment group 
(randomized to 5 mg for the initial 12 weeks followed by 10 mg for the latter 12 weeks) vs. 
placebo 
â€¢ Week 24:  OCA 3 mg treatment group 
(randomized to 1.5 mg for the initial 12 weeks followed by 3 mg for the latter 12 weeks) vs. placebo  
Protocol 747-207 Version 5:   [ADDRESS_21202] stratified by [CONTACT_22130].  Missing values are 
considered a non- response. â€¢ Week 12:   OCA 1.5 mg treatment group 
(randomized to 1.5 mg for the initial 12 weeks 
followed b y 3 mg for the latter 12 weeks) vs. 
placebo 
If at any step the  comparison is not statistically 
significant, then all subsequent comparisons will be 
exploratory rather than confirmatory.   
In addition, secondary efficacy analyses of ALP resp onse 
rates, defined as ALP to <1.5x ULN, will compare OCA 
treatment groups vs. placebo at Week [ADDRESS_21203] stratified by [CONTACT_22130].  Missing values will 
be considered a non- response.  
An unblinded interim analysis for planning purposes will be conducted after approximately 50% of patients 
have completed the initial 12 -weeks of blinded 
treatment.  The trial will not be terminated early for 
futility.  The interim analysis will compare at Week 12, 
the same variable as will be analyzed for the primary 
endpoint, the change from Baseline in ALP, between OCA treatment groups (1.5 mg and 5 mg) and placebo 
using an analysis of covariance (ANCOVA) model with 
fixed effects for treatment group and randomization strata and Baseline as a covariate.  No adjustments to 
the alpha level will be made.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 111 
Confidential and Proprietary    Section Original Text Revised Text  
Synopsis, 
Statistical Methods: Safety Analyses, 2
nd 
paragraph â€¦ The absolute change from Baseline will also be 
summarized.   ... The change  from Baseline will also be summarized.  
Synopsis, 
Statistical Methods: PK and PD Analyses The pharmacokinetics (PK) of OCA and other bile acids 
will be evaluated, including AUC
t, Cmax, tmax, etc.   The pharmacokinetics (PK) of OCA and other bile acids 
will be evaluated, including AUC t, Cmax, and t max, 
Synopsis, Statistical Methods: Sample Size Justification  A sample size of [ADDRESS_21204] 95% power to detect a 
treatment difference for change in ALP assuming the mean percentage change in ALP for OCA andâ€¦ A sample size of [ADDRESS_21205] 90% power to detect a 
treatment difference for change in ALP assuming the 
mean absolute change  in ALP for OCA and â€¦. 
List of Abbreviations New text inserted  
 
  Text correction:  IgG4:  immunoglobulin G4 CD:  Crohnâ€™s disease CDAI:  Crohnâ€™s disease activity index  
UC:  ulcerative colitis  
 IgG4:  Immunoglobulin G4 
5.5, 2nd 
paragraph An increase in liver function tests â€¦ that are several fold 
higher (20 to 50 mg daily)  than those studied in this 
protocol (1.5 mg, 3 mg, 5 mg, and 10 mg) doses.   An increase in liver function tests â€¦. that are several fold 
higher (primarily  20 to 50 mg daily) than those studied 
in this protocol (1.5 mg, 3 mg, 5 mg, and 10 mg) doses.   
7.1, LTSE, 
2nd paragraph Upon a subjectâ€™s completion of the Week [ADDRESS_21206]â€™s completion of the DB phase , the trial 
blind will be broken in order to assign the starting OCA dose for the LTSE phase.   
3URWRFRO 9HUVLRQ0DU
 3DJH
&RQILGHQWLDODQG3URSULHWDU\6HFWLRQ 2ULJLQDO7H[W 5HYLVHG7H[W

)LJXUH


7DEOH9LVLW
7\SH	9LVLW:LQGRZV6FUHHQLQJÂ”G
'
&RQWDFW:Â“G
9LVLW:Â“ZN9LVLW:Â“ZN
9LVLW:Â“ZN
&RQWDFW:Â“ZN
9LVLW:Â“ZN9LVLW:Â“ZN
9LVLW:/76('(27Â“ZN
)86FUHHQLQJÂ”G
'
9LVLW:Â“G
9LVLW:Â“ZN
9LVLW:Â“ZN
9LVLW:Â“ZN
9LVLW:Â“ZN
9LVLW:/76('(27Â“ZN
)8Â“ZN
7DEOH 1HZSURFHGXUHVDGGHG 3DUWLDO0D\R6FRUH6FUHHQLQJYLVLW	IROORZXSYLVLW
&'$,DOOYLVLWV
7DEOH 3UXULWXV9$6 3UXULWXV9$6 DQG'
7DEOH
/DERUDWRU\(YDOXDWLRQV6HUXP%LOH$FLGV 3ODVPD%LOH$FLGV

Protocol 747-207 Version 5:   18 Mar 2016 
 Page 113 
Confidential and Proprietary    Section Original Text Revised Text  
Table 1, 
footnote b Week 2 and 14 visits are contacts to assess AEs and 
treatment compliance; these are not clinic visits.  Week 12 is the Dose Titration Visit.  
Table 1, footnote j TE: at trial sites where the FibroscanÂ® TE device is 
available.  Partial Mayo score completed only for subjects with UC. 
Table 1, footnote l Questionnaire completed with input from the subject.  CDAI completed only for subjects with CD. 
Table 1, footnote q IP accountability/compliance will include review of tablets 
and bottles dispensed and returned at each clinic visit.  For 
subject contacts (ie, non -clinic visits), compliance with 
dosing and evaluation of missed doses should be discussed with the subject.  IP accountability/compliance will include review of tablets and bottles dispensed and returned at each clinic 
visit.   
Table 1, 
footnote t For female subjects of child bearing potential, a urine Î²-hCG test is used.  If the urine test is positive, it is to be repeated as a serum pregnancy  test.  See Section 8.[ADDRESS_21207] whose pregnancy is early terminated and wishes to continue in the trial.  
 Other analytes includes an additional bloo d sample for 
exploratory analysi s. 
Table 1, footnote u Fecal sample:  for measurement of calprotectin and gut fecal microbiome; provision of a fecal sample by [CONTACT_22075].  The subject should be instructed to collect a fecal sample within [ADDRESS_21208] consented for PK sampling procedures. 
Table 1, footnote k New footnote Subjects wit h UC and CD will be asked to complete a 
diary recording details of their symptoms in the 7 days prior to their next scheduled visit.  
Table 2 New procedures added  Partial Mayo Score (M3, M9, M15, M21 & Follow-U p 
Visit) 
CDAI (all visits)  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 114 
Confidential and Proprietary    Section Original Text Revised Text  
Table 2 Pruritus VAS Pruritus VAS and 5-D 
Table 2, 
Laboratory Evaluations Serum Bile Acids & C4  Plasma Bile Acids & C4  
Table 2, 
footnote i Questionnaire completed with input from the subject. Partial Mayo score completed only for subjects with UC. 
Table 2, 
footnote k IP accountability / compliance will include review of 
tablets and bottles dispensed and returned at each clinic 
visit. CDAI completed  only for subjects with CD. 
Table 2, 
footnote o Fecal sample:  for measurement of calprotectin and gut fecal microbiome; pro vision of a fecal sample by [CONTACT_22131].  The subject should be instructed to collect a fecal sample within [ADDRESS_21209] 
paragraph During the LTSE phase subjects ma y titrate to higher 
doses of OCA, at a frequency not greater than monthly , up 
to a maximum dose of 10 mg daily. During the LTSE phase subjects may titrate to higher doses of OCA, at a frequency not greater than 3 monthly  
(ie, at each of the scheduled visits),  up to a maximum 
dose of 10 mg daily. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 115 
Confidential and Proprietary    Section Original Text Revised Text  
7.4.3 Adjustments to or stoppi[INVESTIGATOR_22006]- defined doses 
may be considered based on DSMC evaluation of OCA 
safety and tolerability.  Adjustments to or stoppi[INVESTIGATOR_22006]- defined doses 
may be considered based on DSMC evaluation of OCA safety and tolerability.  At a minimum, the occurrence 
of two life threatening  serious adverse events ( SAEs) 
or an SAE resulting in death will trigger an unscheduled and unblinded review of the data by [CONTACT_22079].  
8.2, Inclusion Criterion #[ADDRESS_21210] a diagnosis of PSC (based on 
cholangiography at any point in time) and must have had a cholangiography within the past 12 months.  
8.2, Inclusion 
Criterion #5  Note 2: Subjects with documented Gilbertâ€™s syndrome 
may be allowed to participate in the study after discussion 
with the medical monitor.  Note 2 has been deleted from this section and moved to 
Synopsis, Exclusion Criterion #10 (see below). 
8.2, Inclusion 
Criterion #6  For subjects with concomitant IBD:  colonoscopy within 
12 months of Day 0 confirming no dyspla sia or colorectal 
cancer 
 For subjects with concomitant IBD:   
a. Colonoscopy within 12 months of Day 0 
confirming no dysplasia or colorectal cancer 
b. Subjects with Crohnâ€™s Disease (CD) must be in remission as defined by a Crohnâ€™s Disease Activity Index (CDAI) <150. 
c. Subjects with ulcerative colitis (UC) must either be in remission or have mild disease.   
Remission is defin ed as a partial Mayo score 
of â‰¤2 with no individual sub- score exceeding 
1.  Mild disease is de fined as a partial Mayo 
score â‰¤3 with no individual sub- score 
exceeding 1 point.  
8.2, Inclusion Criterion # 7 Note 3: Note 2: 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 116 
Confidential and Proprietary    Section Original Text Revised Text  
8.2, Inclusion 
Criterion #9  Contraception:  female subjects of childbeari ng potential 
must use â‰¥ 1 effective (â‰¤1% failure rate) method of 
contraception during the trial and until [ADDRESS_21211] dose of IP (including LTSE doses).  Contraception:  female subjects of childbearing potential 
must use â‰¥[ADDRESS_21212] dose of IP 
(including LTSE doses).  
8.2, 
Exclusion Criterion #3  Exclusion criterion has been added/inserted; all other 
criteria numbering has subsequently shifted.  Small duct cholangitis in the absence of large duct disease 
8.2, 
Exclusion Criterion #4  Presence of clinical complications of chronic liver disease 
or clinically significant hepatic decompensation, including:  
(Change to 7
th bullet, only.) 
â€¢ Current splenomegaly as evidenced  by [CONTACT_22129] < 50 x109/L Presence of clinical complications of chronic liver disease 
or clinically significant hepatic decompensation, 
including:  
(Change to 7th bullet, only.) 
â€¢ Platelet count <50 x 109/L 
8.2, 
Exclusion Criterion #8  History of any  bowel resection unless permitted with 
prior discussion and written approval from Sponsor 
medical monitor  History of small bowel resection  
8.2, 
Exclusion Criterion #9  History of other chronic liver diseases, â€¦ non-alcoholic 
fatty liver disease (NAFLD), hepatitis B virus (unless 
seroconverted and no positive Hepatitis B Virus DNA) and hepatitis C virus  History of other chronic liver diseases , â€¦ non-alcoholic 
fatty liver disease (NAFLD), autoimmune hepatitis , 
hepatitis B virus (unless seroconverted and no positive Hepatitis B Virus DNA) and hep atitis C virus  
8.2, 
Exclusion Criterion #10  Moved from Synopsis, Inclusion Criterion # 5, which 
previously read:   
Note 2: Subjects with documented Gilbertâ€™s syndrome 
may be allowed to participate in the study after discussion with the medical monitor.  Known Gilbertâ€™s syndrome or elevations in unconjugated (indirect) bilirubin >ULN  
8.2, 
Exclusion Criterion #14  Exclusion criterion inserted. Administration of antibiotics is prohibited â‰¤1 month 
of Day 0. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 117 
Confidential and Proprietary    Section Original Text Revised Text  
8.2, 
Exclusion Criterion #15  Administration of the following medications is prohibited 
â‰¤6 months of Day 0 and throughout the DB phase of the 
trial: ... or nitrofurantoin).  Administration of the follow ing medications is prohibited 
â‰¤6 months of Day 0 and throughout the trial : â€¦ or 
nitrofurantoin).  
8.2, Exclusion Criterion #16  IBD flare during Screening (up to and including Day 0). IBD flare during Screening (up to and including Day 0), 
where â€˜flareâ€™ is defined as follows:  
â€¢ UC flare:  partial Mayo Score â‰¥ 5, and  
â€¢ CD flare:   CDAI â‰¥250 
8.4.1, Clinical 
Laboratory 
Values, 2nd 
bullet Two consecutive measurements of conjugated (direct) 
bilirubin > 2x ULN AND >2x the Baseline value in the 
absence of evidence of new biliary obstruction. Two consecutive measurements of total bilirubin > ULN 
AND >2x the Baseline value in the absence of evidence 
of new biliary obstruction.  
8.4.1, IBD Flares (new section) New text inserted into protocol.  Subjects who experience 3 or more IBD flare- ups in 
one year during the study will be discontinued, where â€˜flareâ€™ is defined as follows:  
â€¢ for UC flare: as a partial Mayo Score â‰¥5, 
and  
â€¢ for CD flare:  as a CDAI â‰¥[ADDRESS_21213] to discontinue from the trial:  The following events are considered appropriate 
(potential) reasons for a subject to discontinue from the trial: 
8.4.2, 
Bactierial Cholangitis â€¦ in conjunction with clinical signs and symptoms and 
positive diagnostic imaging tests.  Subjects should 
temporarily interrupt treatment with IP and receive 
standard of care treatment.  Use of amoxicillin/clavulanate is discouraged, but these may 
be used if  there are no other treatment options; this ... in conjunction with clinical signs and symptoms and 
positive diagnostic imaging tests.  Local guidelines 
should be followed for the management of patients with acute bacterial cholangitis.  In the absence of 
such loca l guidelines, the following guidelines should 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 118 
Confidential and Proprietary    Section Original Text Revised Text  
should be discussed with the medical monitor in 
advance of a decision to treat with these medications.  
Discontinuation from the trial is not mandatory in 
cases of bacterial cholangitis unless signs and 
symptoms do not resolve within a clinically reasonable 
timeframe (within 1 month or as agreed upon with the 
medical monitor) or the cholangitis becomes life 
threatening in the opi[INVESTIGATOR_22033].  In any event, IP should not be 
restarted  until signs and symptoms have resolved and 
the subjectâ€™s liver biochemistry has returned to pre-
cholangitis levels.  
A subject with frequent (frequency as judged by [CONTACT_22132]) 
bacterial cholangitis events shou ld be discontinued from 
the trial. be followed if acute cholangitis is suspected :  
â€¢ Diagnosis of acute cholangitis should be 
established based on a combination of 
typi[INVESTIGATOR_22034], laboratory data, and imaging findings.  Subsequent to an 
intervention to relieve biliary obstruction acute cholangitis may occur with typi[INVESTIGATOR_22035], right upper quadrant pain, and jaundice (also known as the Charcot triad).  Further confirmation of the 
diagnosis should then be made via 
laboratory data (eg, elevated C- reactive 
protein levels and/or leukocytosis) and abdominal imaging tests (magnetic resonance cholangiopancreatography; MRCP).   
â€¢ Treatment of acute cholangitis should be 
directed towards treatment of the biliary 
infection and relieving obstruction.  
Therefore, treatment is comprised of systemic antibiotic therapy and biliary drainage procedures, with appropriate supportive care.  
â€¢ Antibiotic agents should be administered 
empi[INVESTIGATOR_22009].   Blood and 
bile cultures should also be performed at the earliest opportunity and prior to initiating antibiotic treatment, if possible.  
â€¢ The selection of an antibiotic agent should 
be based on likely infecting bacteria, the 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 119 
Confidential and Proprietary    Section Original Text Revised Text  
severity of the disease, and the presence of 
comorbidities.  Empi[INVESTIGATOR_22036].  The use of 
amoxicillin/clavulanate and other antibiotic treatments with potential for hepatotoxicity should be avoided.  
Subjects should temporarily interrupt treatment with IP and receive standard of care treatment.  Discontinuation from the trial is not mandatory in  
cases of bacterial cholangitis unless signs and symptoms do not resolve within a clinically reasonable timeframe (typi[INVESTIGATOR_16195] 1 month or as agreed upon with the medical monitor) or the cholangitis becomes life threatening in the opi[INVESTIGATOR_22033].  In any event, IP should not be restarted until signs and symptoms have resolved and the subjectâ€™s liver biochemistry has returned to pre -cholangitis levels.  
 
A subject with [ADDRESS_21214] experiences an IBD flare during the trial (post-Day 0), he/she may remain on IP but this should be 
discussed with the medical monitor. If a subject experiences an IBD flare during the trial 
(post-Day 0), he/she may remain on IP but this should be discussed with the medical monitor and IBD flares 
should be treated as follows (but adjusted based upon 
local guidelines and standards of care, disease severity and personal patient preferences, as appropriate): aminosalicylates alone (high dose if appropriate) or 
with a topi[INVESTIGATOR_22012]/or topi[INVESTIGATOR_2855], oral , or 
Protocol 747-207 Version 5:   [ADDRESS_21215] bullet poin t Administration of antibiotics within 1 month of Day 0, except if administered for acute cholangitis whereby [CONTACT_22086] 3 months of Day 0.  
NOTE:  Antibiotics are permitted as required during 
participation in the trial except amoxicillin /clavulanate 
(Augmentin) which has restrictions as detailed below.  
9.2.3, 3rd 
bullet â€¢ Prohibited from 6 months prior to Day 0 and 
throughout the DB phase of the trial (these are 
not prohibited during the LTSE): â€¦  
 
 -Amoxicillin/clavulanate should not be used unless there 
are no other treatment options (this should be discussed with the medical monitor in advance of their use in this situation, where possible) â€¢ Prohibited from 6 months prior to Day 0 and 
throughout the LTSE phase of the trial unless 
as noted to discuss with Medical Monitor : 
â€¦ 
  
-Amoxicillin/clavulanate (Augmentin) should not be 
used unless there are no other treatment options (this should be discussed with the medical monitor in advance of their use in this situation, where possible).  Augmentin 
is also discouraged in the treatment of cholangitis  but 
is not outrig ht excluded (Section 8.4.2).  
9.4, 1st 
paragraph At Day 0, after review â€¦ treatment groups in a 1:1:1 ratio 
across sites based  on â€¦ LTSE phase. At Day 0, after review â€¦ treatment groups in a 1:1:1 ratio based  on â€¦ LTSE phase.  
Protocol 747-207 Version 5:   [ADDRESS_21216] 
paragraph All trial visits during the DB period are relative to Day 0 
(eg, if the Week 4  visit occurs 4 days late, the Week 8 
visit should still be 8 weeks from Day 0).  The Screening 
visit should occur â‰¤30 days prior to the Day 0 visit.  All visits and contacts  during the DB treatment period should 
occur within Â± [ADDRESS_21217]  at Week 2, which should 
occur within Â± 3 days of the indicated time. All trial visits during the DB period are relative to Day 0 (eg, if the Week 6  visit occurs 4 days late, the Week 12 
visit should still be 12 weeks from Day 0).  The 
Screening visit should occur â‰¤30 days prior to the Day 0 visit.  All visits during the DB treatme nt period should 
occur within Â± 1 week of the indicated time.  The 
exception to this is the Week 2 visit, which should occur within Â±3 days of the indicated time. 
9.6.3, 9th bullet New bullet 9 . For subjects with UC):  provide the diary and request subject completes this for each of the 7 consecutive days prior to the next scheduled visit.  
9.6.3, 10th bullet New bullet 10. For subjects with CD:  provide the diary and request 
subject completes this for each of the 7 consecutive days prior to the next scheduled visit .  
9.6.3, 11th bullet ... no more than 25% of subjects recruited will have a bilirubin >1.5x ULN and <2.5x ULN).  In addition, 
subjects with documented Gilbertâ€™s syndrome may be 
allowed to participate in the study after discussion with the medical monitor.  â€¦ no more than 25% of subjects recruited will have a bilirubin >1.5x ULN and <2.5x ULN).   
9.6.4, 5th bullet Obtain Partial Mayo Scoring System for Assessment of Ulcerative Colitis Activity (partial Mayo score, excluding endoscopy).  See Appendix B for details. For subjects with UC:  obtain partial Mayo score 
(excluding endoscopy).  See Appendix B for details.  
9.6.4, 6th bullet New bullet 6  For subjects with CD:  complete CDAI assessments 
and assign CDAI score.  See Appendix F for details.  
9.6.4, 7th 
bullet Administer pruritus v isual analogue scale (VAS) subject 
questionnaire.  See Appendix C for details. Administer pruritus visual analogue scale (VAS) subject questionnaire and 5 -D Itch Questionnaire.  See 
Appendix C for details. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 122 
Confidential and Proprietary    Section Original Text Revised Text  
9.6.4, 9th 
bullet, 5th 
sub-bullet Serum bile acids and 7Î±-hydroxy-4- cholesten -3-one (C4)  Plasma bile acids and 7Î±-hydroxy-4- cholesten -3-one 
(C4) 
9.6.3, 15th 
bullet New bullet 15. Subjects with UC or CD: provide the diary and request this is completed for [ADDRESS_21218]:  
- All subjects are to â€¦ Further details are included in 
Section 9.1. 
Book the date and time for the Week [ADDRESS_21219]: 
-All subjects are to â€¦ Further details are included in 
Section 9.1. 
-NOT to take IP on the morning of the next trial 
visit, and  
-To bring the IP bottle(s) and  
-To fast overnight (at least 8 hours) prior to the 
next trial visit.  Fasting is required prior to all trial visits, but water is permitted, and the subject should dose at the visit after all assessments have been performed.  
9.6.[ADDRESS_21220] to assess the following:  
â€¢ Assess and record AEs 
â€¢ Record current concomitant medications 
â€¢ Assess IP compliance  
â€¢ Reiterate dosing instructions and advise the 
subject: 
-NOT to take IP on the morning of the next trial visit, Week 2 Procedures  
â€¢ Assess and record AEs 
â€¢ Record current concomitant medications 
â€¢ Record vital signs  
â€¢ For subjects with UC:  obtain partial Mayo 
score (excluding endoscopy)  
â€¢ For subjects with CD:  complete CDAI 
assessments and assign CDAI score 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 123 
Confidential and Proprietary    and  
-To bring the IP bottle(s) and 
-To fast overnight (at least 8 hours) prior to the next 
trial visit.  Fasting is required prior to all trial visits, 
but water is permitted.  â€¢ Administer pruritus VAS subject 
questionnaire and 5 -D Itch Questionnaire  
â€¢ Obtain blood samples for serum chemistry 
and hematology  
â€¢ Verify that the subject has fasted for at least [ADDRESS_21221] been performed.  
â€¢ Assess IP compliance and perform 
accountability; retrieve used bottles and 
document returns  
â€¢ Record the visit in IWRS an d dispense 
indicated bottles of IP  
â€¢ Provide the diary and request this is completed for 7 consecutive days prior to 
the next scheduled visit.  
â€¢ Reiterate dosing instructions and advise the 
subject: 
-NOT to take IP on the morning of the next trial visit, 
and  
-To bring the IP bottle(s); and  
-To fast overnight (at least 8 hours) prior to the next 
trial visit.  Fasting is required prior to all trial visits, 
but water is permitted , and the subject should dose 
Protocol 747-207 Version 5:   [ADDRESS_21222] been 
performed.  
9.6.6, title Week 8 Procedures Week 6 Procedures 
9.6.6, 4th 
bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC:  obtain partial Mayo score 
(excluding endoscopy)  
9.6.6, 5th bullet New bullet 5  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.6, 6th bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
9.6.6, 8th bullet, 2nd sub-bullet â€¦ fasting is required prior to all trial visits, but water is permitted.  â€¦ fasting is required prior to all trial visits, but water is permitted, and the subject should dose at the visit after 
all assessments have been performed.  
9.6.6, 11th bullet New bullet 1 1 Subjects with UC or CD: provide the diary and request this is completed for [ADDRESS_21223] sub-bullet â€¦ Fasting is required prior to all trial visits, but water is 
permitted.  â€¦ Fasting is required prior to all trial visits, but water is permitted, and the subject should dose at the visit after 
all assessments have been performed.  
9.6.7, 4th bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC:   obtain partial Mayo score 
(excluding endoscopy)  
9.6.7, 5th bullet New bullet 5  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.7, 6th bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 125 
Confidential and Proprietary    Section Original Text Revised Text  
9.6.7, 7th 
bullet, 5th 
sub-bullet Serum bile acids and C4  Plasma bile acids and C4  
9.6.7, 12th bullet, 2nd sub-bullet â€¦ fasting is required prior to all trial visits, but water is permitted.  â€¦ fasting is required prior to all trial visits, but water is permitted, and the subject should dose at the visit after 
all assessments have been performed.  
9.6.7, 15th bullet New bullet 1 5 Subjects with UC or CD: provide the diary and request this is completed for [ADDRESS_21224]:  
-NOT to take IP on the morning of the next visit, 
and  
-To bring the IP bottle(s) and  
-To fast overni ght (at least 8 hours) prior to the 
next visit.  Fasting is required prior to all trial visits, but water is permitted, and the subject should dose at the visit after all assessments have been performed.  
9.6.8, title Week 16 Procedures Week 14 Procedures 
9.6.8, 4th bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC :  obtain partial Mayo score 
(excluding endoscopy)  
9.6.8, 5th bullet New bullet 5  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.8, 6th bullet  Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 126 
Confidential and Proprietary    Section Original Text Revised Text  
9.6.8, 8th 
bullet, 2nd 
sub-bullet â€¦ fasting is required prior to all trial visits, but water is permitted.  â€¦ fasting is required prior to all trial visits, but water is permitted, and the subject should dose at the visit after 
all assessments have been performed.  
9.6.8, 11th bullet New bullet 1 1 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.9, title Week 20 Procedures Week 18 Procedures 
9.6.9, 4th 
bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC :  obtain partial Mayo score 
(excluding endoscopy)  
9.6.9, 5th 
bullet New bullet 5  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.9, 6th bullet  Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
9.6.9, 8th bullet, 2nd sub-bullet â€¦ fasting is required prior to all trial visits, but water is permitted.  â€¦ fasting is required prior to all trial visits, but water is permitted, and the subject should dose at the visit after 
all assessments have been performed.  
9.6.9, 11th bullet New bullet 11 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.10, 8th bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC:  obtain partial Mayo score 
(excluding endoscopy)  
9.6.10, 9th bullet New bullet 9  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.10, 10th bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS sub ject questionnaire and 5-D 
Itch questionnaire  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 127 
Confidential and Proprietary    Section Original Text Revised Text  
9.6.10, 12th 
bullet, 5th 
sub-bullet Serum bile acids and C4  Plasma bile acids and C4  
9.6.10, For Subjects Participating in the LTSE, 5th bullet New bullet 5 Subjects with UC or CD: provide the diary and request this is completed for [ADDRESS_21225] 
sub-bullet â€¦ Fasting is required prior to all trial visits, but water is permitted.  â€¦ Fasting is required  prior to all trial visits, but water is 
permitted and the subject should dose at each visit after 
all assessments have been performed.  
9.6.10, For Subjects NOT Participating in the LTSE, 3
rd bullet New bullet 3 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.11, 8th bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC :  obtain partial Mayo score 
(excluding endoscopy)  
9.6.11, 9th bullet New bullet 9 For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.11, 10th bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 128 
Confidential and Proprietary    Section Original Text Revised Text  
9.6.11, 12th 
bullet, 5th 
sub-bullet Serum bile acids and C4  Plasma bile acids and C4  
9.6.11, 13th bullet New bullet 13 For sites participating in PK sampling: obtain samples for PK analysis (see section 11.5 for sampling schedule)  
9.6.11, 19th bullet New bullet 19 Subjects with UC or CD: provide the diary and 
request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.12, 4th bullet New bullet 4  For subjects with UC:  obtain partial Mayo score 
(excluding endoscopy)  
9.6.12, 5th bullet New bullet [ADDRESS_21226] s with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.12, 5th bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
9.6.14 See Section 9.6.12 for the LTSE Day 1 (DB Week 24 
visit) procedures.  See Section 9.6.10 for the LTSE Day 1 (DB Week 24 
visit) procedures.  
9.6.15, 4th bullet New bullet 4  For subjects with UC:  obtain partial Mayo score 
(excluding endoscopy)  
9.6.15, 5th bullet New bullet 5 For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.15, 6th 
bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
9.6.15, 12th bullet New bullet 1 2 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior 
to their next scheduled visit.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 129 
Confidential and Proprietary    Section Original Text Revised Text  
9.6.16, 4th 
bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC :  obtain partial Mayo score 
(excluding endoscopy)  
9.6.16, 5th bullet New bullet 5  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.16, 6th 
bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
9.6.16, 7th bullet, 3
rd 
sub-bullet Serum bile acids and C4  Plasma bile acids and C4  
9.6.16, 13th bullet New bullet 1 3 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.17, 6th bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC :  obtain partial Mayo score 
(excluding endoscopy)  
9.6.17, 7th bullet New bullet 7  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.17, 8th 
bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
9.6.17, 9th bullet, 5
th 
sub-bullet Serum bile acids and C4  Plasma bile acids and C4  
9.6.17, 16th bullet New bullet 1 6 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.18, 4th 
bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC :  obtain partial Mayo score 
(excluding endoscopy)  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 130 
Confidential and Proprietary    Section Original Text Revised Text  
9.6.18, 5th 
bullet New bullet 5  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.18, 6th 
bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
9.6.18, 13th bullet New bullet 1 3 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.19, 8th 
bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC :  obtain partial Mayo score 
(excluding endoscopy)  
9.6.19, 9th 
bullet New bullet 9  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.19, 10th 
bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
9.6.19, 12th bullet, 5
th 
sub-bullet Serum bile acids and C4  Plasma bile acids and C4  
9.6.19, 19th bullet New bullet 1 9 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.20, 8th bullet Obtain partial Mayo score (excluding endoscopy) For subjects with UC :  obtain partial Mayo score 
(excluding endoscopy)  
9.6.20, 9th bullet New bullet 9  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.20, 10th bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 131 
Confidential and Proprietary    Section Original Text Revised Text  
9.6.20, 12th 
bullet, 5th 
sub-bullet Serum bile acids and C4  Plasma bile acids and C4  
9.6.20, 13th bullet New bullet 1 7 Subjects with UC or CD: provide the diary and request this is completed for 7 consecutive days prior to their next scheduled visit.  
9.6.21, 4th bullet New bullet 4  For subjects with UC:   obtain partial Mayo score 
(excluding endoscopy)  
9.6.21, 5th bullet New bullet 5  For subjects with CD:  complete CDAI assessments 
and assign CDAI score 
9.6.21, 6th 
bullet Administer pruritus VAS subject questionnaire  Administer pruritus VAS subject questionnaire and 5-D 
Itch questionnaire  
11.3, Disease Specific Symptoms, 1
st paragraph  Disease-specific symptoms of IBD and pruritus will be assessed using the partial Mayo score and as a Pruritus VAS respectively.  
 Disease-specific symptoms of IBD and pruritus will be assessed using the partial Mayo score (only for subjects with UC), CDAI (only for subjects with CD) and as a 
Pruritus VAS and 5-D itch questionnaire  respectively.  
11.3 Disease Specific Symptoms, IBD Symptoms, 
CDAI New paragraph inserted  The CDAI will be performed by [CONTACT_22133] 
(Best 1976) and will be based on the subjectâ€™s recount of their symptoms in addition to hematocrit and body weight measurements.  Details of the CDAI are shown 
in Appendix F.  
To assist sites with recording and calculating the partial Mayo score and the CDAI subjects with UC & CD, respectively, will be asked to complete a diary in the [ADDRESS_21227]â€™s 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 132 
Confidential and Proprietary    Section Original Text Revised Text  
medical records for SDV and retain the diary cards.  
Pertinent aspects of these data will be recorded in the 
CRF. 
11.3, Disease Specific Symptoms, Pruritus Subjects will be asked to complete the Pruritus VA â€¦  
Details of the Pruritus VAS are shown in Appendix C. In addition to the assessment of pruritus as an AE with mild, moderate and severe categories, pruritus will be specifically assessed by [CONTACT_22101]:  
â€¢ Pruritus VAS  
Subjects will be asked to complete the Pruritus â€¦ Details 
of the Pruritus VAS are shown in Appendix C. 
â€¢ 5-D Itch Questionnaire  
This is a questionnaire that has been validated in several different diseases.  It assesses symptoms in terms of 5 domains:  degree, duration, direction, 
disability and distribution (Elman 2010).   
11.4, paragraph 3 New paragraph inserted  Exploratory Analytes 
Blood samples for future analysis related to the effects 
of OCA or FXR activation w ill be collected at specified 
timepoints during the study and may be assayed on an exploratory research basis.  The samples will be stored for up to 2 years after the end of the study.  
11.5, 4th 
paragraph Subjects should not drink additional water for 1 hour after taking the dose of IP and will remain fasted until the 
4 hour sample is collected.  Lunch will be provided 
following collection of the 4 hour PK sample; the lunch will be a meal replacement drink with nutrition information that has been and submitted to and approved by [CONTACT_22134].  Subjects should not drink additional water for 1 hour after taking the dose of IP. After approximately 1 hour 
postdose, subjects will be fed a standardiz ed meal 
consisting of a Nutridrinkâ„¢ (Nutricia).    
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 133 
Confidential and Proprietary    Section Original Text Revised Text  
[IP_ADDRESS], 2nd 
paragraph 2nd paragraph added to this section Events not considered to be SAEs are hospi[INVESTIGATOR_22037]: 
â€¢ Routine monitoring of the studied indication 
and not associated with any deterioration in condition or AE;  
â€¢ Elective treatment for a pre -existing 
condition that did not worsen;  
â€¢ Respi[INVESTIGATOR_22038].  
12.1.5 Expected Serious Adverse Events  
There are a number of events which are commonly 
associated with PSC and for reporting purposes, these 
events are considered to be â€˜Expectedâ€™ in this patient population: Anticipated Serious Adverse Events Associated with PSC 
There are a number of events which are commonly associated with PSC and  for the Sponsorâ€™s Regulatory  
reporting purposes, these events are considered to be â€˜Expectedâ€™ in this patient population and are listed 
below.  The investigator remains responsible for 
reporting to the Sponsor all SAEs including the events identified here:  
12.2.1 â€¦ Demographic characteristics (age, gender, race, ethnicity, etc) will be recorded.  â€¦ Demographic characteristics (age, gender, race, ethnicity, etc) will be recorded, as will any historical or 
on study data on colonoscopi[INVESTIGATOR_014] (mucosal and 
histological) within the last 3 years and prior and on study liver biopsies, hepatic imaging, etc.  Reports should be available in the source data.  
12.2.2 â€¦ If clinically significant abnormalities are observed before administration of the first dose of IP on Day 1, they 
should be reported in the subjectâ€™s medical history.    â€¦ If clinically significant abnormalities are observed 
before administration of the first dose of IP on Day 1, 
they should be reported as adverse events.    
Protocol 747-207 Version 5:   [ADDRESS_21228] 
bullet point Hematology (hemoglobin, hematocrit, white blood cell [WBC] count with differential, platelets, red blood cell [RBC] count) Hematology and Coagulation  (hemoglobin, hematocrit, 
white blood cell [WBC] count with differential, platelets, red blood cell [RBC] count, INR, prothrombin time , 
partial thromboplastin time ) 
13.[ADDRESS_21229] 95% power to detect a 
treatment difference for a change in ALP assuming a 20% dropout and the mean  percentage changes â€¦ alpha level 
of 0.05. A sample size of [ADDRESS_21230] 90%  power to detect a 
treatment difference for a change in ALP assuming a 20% dropout and the mean absolute  changes â€¦ alpha level of 
0.05. 
13.3 One of the primary objectives of this proof of concept trial is to evaluate the efficacy of OCA in subjects with PSC.  
Accordingly, the primary efficacy analysis will evaluate 
the absolute change from Baseline in ALP with each 
dose of OCA versus placebo.   The primary population for 
efficacy analyses will use the ITT population.  Sensitivity 
analyses will be conducted using the Completer 
populations. One of the primary objectives of this proof of concept trial is to evaluate the efficacy  of OCA in subjects with PSC.  
The primary population f or efficacy analyses is the ITT 
population.  Sensitivity analyses will be conducted using the Completer populations. 
13.3.1 The co-primary efficacy endpoints are  the absolute 
changes from Baseline in ALP at Week 12 and Week 24.  
The primary efficacy analysis at Week 12 will compare 
the change from Baseline in ALP between OCA treatment groups (1.5 mg and 5 mg) and placebo using 
an analysis of covariance (ANCOVA) model with fixed 
effects for treatment group and randomization strata and Baseline as a covariate.  The primary efficacy analysis at Week 24 will compare the change from 
Baseline in ALP between OCA treatment groups (3 mg The primary efficacy endpoint is  the Week 24 change 
from Baseline in ALP.  The primary efficacy analysis will 
compare the Week 24 change from Baseline in ALP 
between OCA 10 mg treatment group and placebo 
using an analysis of covariance (ANCOVA) model with 
fixed effects for treatment group and randomization strata 
and Baseline as a covariate.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 135 
Confidential and Proprietary    Section Original Text Revised Text  
and 10 mg) and placebo using the same ANCOVA 
model as the Week [ADDRESS_21231] & 
2nd 
paragraphs Secondary efficacy analyses of hepatic biochemistry and 
function parameters (eg, ALT, AST, and GGT) will use 
the same ANCOVA models as the primary endpoints.  
Hepatic biochemistry and function parameters  will be 
summarized by [CONTACT_22135] â€¦ of all available 
evaluations prior to treatment.   Secondary efficacy analyses of hepatic biochemistry and 
function parameters (eg, ALT, AST, and GGT) will be 
summarized by [CONTACT_22136] â€¦ of all available evaluations prior to treatment.  Hepatic biochemistry 
and function parameters will be analyzed using the 
same ANCOVA model as specified for the primary efficacy analysis.  
A hierarchical approach will be used for multiplicity adjustments.  If the primary efficacy analysis is statistically sig nificant (p  <0.05), the following order 
will be used in the testing procedure to compare the change from Baseline in ALP between OCA and placebo: 
â€¢ Week 12:  OCA 5 mg treatment group 
(randomized to 5 mg for the initial 12 weeks 
followed by 10 mg for the latt er 12 weeks) 
vs. placebo 
â€¢ Week 24:  OCA 3 mg treatment group 
(randomiz ed to 1.5 mg for the initial 
12 weeks fol lowed by 3 mg for the latter 
12 weeks) vs. placebo  
â€¢ Week 12:  OCA 1.5 mg treatment group 
(randomized to 1.5 mg for the initial 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 136 
Confidential and Proprietary    Section Original Text Revised Text  
12 weeks fol lowed by 3 mg for the latter 
12 weeks) vs. placebo  
If at any step a comparison above is not statistically 
significant, then all subsequent comparisons will be exploratory rather than confirmatory.    
13.3.2, 3rd paragraph In addition, secondary efficacy analysis  of ALP 
â€¦ stratification factor.  In addition, secondary efficacy analyses  of ALP 
â€¦ stratification factor.  
13.3.2, 4th paragraph â€¦ The change from Baseline will be analyzed using an ANCOVA model with a fixed effect for treatment group and the Baseline values as a covariate.   â€¦ The change from Baseline will be analyzed using the same ANCOVA model as specified for the primary 
efficacy analysis.   
13.3.2, 5th paragraph 5th paragraph added to this section Subgroup analyses will be evaluated as deemed appropriate, including but not limited to, those subjects who start antibiotics after first dose of investigational product.  
13.4, 1st 
paragraph PK parameters will be determined for OCA, glyco -OCA, 
tauro-OCA, and total OCA (OCA plus conjugates).  The 
following  PK parameters will be calculated using non -
compartmental methods where appropriate:  PK parameters will be determined for OCA, glyco -OCA, 
tauro-OCA, and total OCA (OCA plus conjugates). PK 
parameters, including the following , will be calculated 
using non- compartmental methods where appropriate:  
13.4, 2nd paragraph An exploratory exposure- response assessment will be 
made comparing â€¦ in this patient population.   An exposure- response assessment will be made 
comparing ... in this patient population.   
13.5.2 Baseline values, the values at each visit  â€¦ assessments by 
[CONTACT_3148] .  Baseline is defined as â€¦ treatment (except for 
lipoprotein assessments where Baseline will be Day 0 ).   Baseline values, the values at each visit  â€¦ assessments by 
[CONTACT_1570].   Baseline is defined as â€¦  treatment 
(except for lipoprotein assessments where Baseline will be the fasted  Day 0 assessment ).   
13.5.3 The change from Baseline will also be summarized.  The absolute change from Baseline will also be 
summarized.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 137 
Confidential and Proprietary    Section Original Text Revised Text  
13.6 & 13.6.1 13.6 Interim Analysis  
A formal interim efficacy analysis (eg, at Week 12) is 
not planned.  However,  once all subjects have completed 
the DB phase of the study, the DB database will be locked 
and unblinded and analyses will performed .  The 
specific details of the analyses will be documented in the SAP.   13.6 Interim Analyses and Data Monitoring 
13.6.1 Interim Analysis (new section)  
An unblinded interim analysis will be conducted after 
approximately 50% of subjects have completed the initial [ADDRESS_21232] completed the DB 
phase of the study, the DB database will be locked, 
unblinded, and full analyses will be performed.  The 
specific details of  both the interim and end of double -
blind analyses will be documented in the SAP.    
Protocol 747-207 Version 5:   [ADDRESS_21233] the 
previous S ection 13.7 (Data Safety Monitoring 
Committee) that include s some of the original text of 
Section 13.7. 
 
13.7 Data Safety Monitoring Committee 
An independent DSMC will review safety data at periodic 
intervals from this and other OCA trials .  Members of 
the DSMC will not be allowed to participate as investigators in this trial and will not otherwise consult for the Sponsor.   13.6.2 Data and Safety Monitoring Committee 
An independent DSMC will review safety data at periodic 
intervals from this trial.  The DSMC includes 
internationally recognized hepatologists, pharmaceutical physicians and statistician (s).  All have 
considerable experience with clinical trial conduct and DSMCs, prior to joining the OCA DSMC. Candidates are screened for conflicts of interest and any candidate 
found to have such a conflict is not offered 
membership. Conflicts of interest are assessed regularly, and if members are found to have a new conflict of interest they would be replaced. The DSMC meets approximately quarterly at scheduled meetings and ad hoc meetings are convened, as appropriate.  The DSMC reviews all Intercept sponsored Phase 2 
and 3 studies.  Members of the DSMC will not be allowed 
to participate as investigators in this trial and will not 
otherwise consult for the Sponsor.   
13.6.2, 2nd 
paragraph The DSMC will review safety data â€¦ treatment of 
subjects. The DSMC will review data â€¦ treatment of subjects.  
13.6.2, 3rd 
paragraph The DSMC operates under an appropriate charter â€¦ that 
will define  its organization â€¦ each trial.  The DSMC operates under an appropriate charter â€¦ that 
defines its organization â€¦ each trial.   
13.6.2, 4th & 
5th paragraphs Two new paragraphs inserted into this section.  Data listings provided to the DSMC do not contain individual patient treatment information; however, the DSMC will have access to the database and may unblind individual subject data as appropriate. Summary tables reviewed by [CONTACT_22137] 747-207 Version 5:   18 Mar 2016 
 Page 139 
Confidential and Proprietary    Section Original Text Revised Text  
treatment columns with â€˜dummyâ€™ labels, ie, the actual 
treatment gro ups are used, but are not identified. Data 
reviewed during the meetings will include, at a 
minimum, disposition, demographics, exposure, clinical laboratory results, MedDRA coded AE s, and 
AEs leading to early withdrawal of study drug. At each meeting, deta iled narratives of interval SAEs 
(including events resulting in death) are reviewed by 
[CONTACT_22119] a cumulative list of all SAEs.  
 
The DSMC may request additional analyses if deemed 
necessary to fulfill the mission of the DSMC.  The DSMC will d etermine if an unscheduled meeting is 
necessary based on the additional data.  At a minimum the occurrence of two life threatening SAEs or an SAE resulting in death will trigger an unscheduled and unblinded review of the data by [CONTACT_6802].  
[ADDRESS_21234] WR, Becktel JM, Singleton JW, et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976 Mar; 70 (3): 439â€“444. 
 Elman S, Hynan L, Gabriel V, et al. The 5- D itch scale: 
a new measure of pruritus. British Journal of 
Dermatology. 2010 Dec; 162: 587- 593 
Appendix D New appendix added 5-D Itch Questionnaire included.  
Appendix F New appendix added  CDAI included  
 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 140 
Confidential and Proprietary    APPENDIX H. PROTOCOL VERSION 3 â€“ S UMMARY OF CHANGES  
Background:  Protocol 747-207 has been prepared as a Phase 2 trial to evaluate the potential 
clinical benefit of OCA in PSC.  
Rationale:  Version 3 of the protocol includes changes to clarify eligibility criteria, procedures, 
and minor editorial changes.  
Summary of Changes:   The following revisions were made to the P rotocol Version 2 in 
Protocol Version  3.  (Note:  Deletions are stricken and additions are indicated in bold font.)   
Minor grammatical changes are not detailed unless i ncluded with other changes 
(eg, capi[INVESTIGATOR_602], punctuation).  
 
 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 141 
Confidential and Proprietary     
Section Original Text Revised Text  
Cover Page  
 Original Version:  06 Jun 2014 
Version 2:  24 September 2014 Original Version:  06 Jun 2014 
Version 2:  24 September 2014 
Version 3:  [ADDRESS_21235]  2015 
Investigatorâ€™s 
Agreement  By [CONTACT_12006], I hereby [CONTACT_22052] I have read, understood and agreed to abide by [CONTACT_22138], instructions and restrictions contained in Protocol 747-207 and in accordance with Good Clinical Practice (CPMP/ICH/135/95), 21CFR Part 
[ADDRESS_21236] read, understood and agreed to abide by [CONTACT_22138], instructions and restrictions contained in Protocol 747-207 and in accordance with Good Clinical Practice (CPMP/ICH/135/95), the 
Declaration of Helsinki, and all regulatory requirements for protection of human subjects in clinical studies and privacy requirements for the protection of individual and company data. 
Contact 
[CONTACT_22139] â€“ [ADDRESS_21237]: Roya Hoosmand-Rad, MD, PhD 
Executive Director, Clinical Research  
Mobile:  +[PHONE_353] ( Pacific Time Zone) 
Telephone:  +[PHONE_354] (Pacific Time Zone) 
Email:  rhooshmand- [EMAIL_382]  
 Clinical Operations and Project Management  
Contact:  [CONTACT_22053] -Jones BSc (Hons)  
Head EU Clinical Operations  
Telephone:  [PHONE_355] (GMT) Mobile:  [PHONE_356] (GMT) 
Email:  [EMAIL_381] Medical Monitor â€“ [ADDRESS_21238]:  Bar bara Scholz, MD, MPH  
Mobile:  + [PHONE_351] ( Pacific Time Zone) 
Email:  barbara.scholz @interceptpharma.com  
 Clinical Operations and Project Management  
Contact:  [CONTACT_22053] -Jones BSc (Hons)  
VP, Head of Clinical Operations, EU  
Telephone:  [PHONE_355] (GMT) Mobile:  [PHONE_356] (GMT) 
Email:  [EMAIL_381] 
  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 142 
Confidential and Proprietary    Section Original Text Revised Text  
Synopsis, Long-
Term Safety Extension Phase (LTSE) Following completion of participation in the DB  
phase, subjects will continue in the study in the  open-
label long- term safety extension ( LTSE) phase for a 
further [ADDRESS_21239]â€™s completion of the DB phase, the 
trial blind will be  broken in order to assign the 
starting OCA dose for the LTSE phase.  It is intended 
that subjects will commence treatment at [ADDRESS_21240] to be titrated in line with the below 
schedule, this should be discussed with the medical 
monitor  
â€¢ Placebo at end of DB ïƒ   5 mg OCA in 
LTSE 
â€¢ 3 mg OCA at end of DB ïƒ  5 mg OCA in 
LTSE 
â€¢ 10 mg OCA at end of DB ïƒ   10 mg OCA 
in LTSE 
Those subjects who did not up- titrate their dose at 
Week 12 in the DB phase can remain on their DB 
dose, or commence at 5 mg at the decision of the 
investigator based on safety and tolerab ility of the 
DB dose at Week 24 . Following completion of participation in the DB  
phase, subjects will be asked to reconfirm their 
consent for participation  in the open-label long-
term safety extension ( LTSE) phase ( a further 
24 months ).   
Upon a subjectâ€™s completion of the DB phase, the 
trial blind will be broken in order to assign the 
starting OCA dose for the LTSE phase.  It is intended that subjects will commence treatment at 5  mg OCA, 
except those subjects who completed treatment in the DB phase with 10 mg OCA who will continue at 10 mg OCA unless safety and tolerability warrant a 
dose reduction to 5 mg. 
â€¢ Placebo at end of DB ïƒ   5 mg OCA in 
LTSE 
â€¢ 3 mg OCA at end of DB ïƒ  5 mg OCA in 
LTSE 
â€¢ 10 mg OCA at end of DB ïƒ   [ADDRESS_21241] to be titrated in line with the above schedules, this may be discussed with the Medical Monitor.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 143 
Confidential and Proprietary    Section Original Text Revised Text  
During the LTSE phase, subjects may titrate to higher  
doses of OCA, at  a frequency not greater than 
3 monthly (ie, at each of the scheduled LTSE visits), 
up to a maximum dose of 10 mg daily.  The guideline 
for an increase i n the dose of OCA is based on 
tolerability and the goal of achieving an ALP level 
<1.5x the ULN.  Doses of OCA should be titrated as 
follows, unless clinically indicated:  1.[ADDRESS_21242] to a prior dose or 
dosing frequency and this should be discussed with 
the Intercept medical monitor in advance. 
A few Sponsor representatives may be unblinded 
during the trial.  If there are any findings regarding 
safety, tolerability, or efficacy that indicate an 
alternative  optimal LTSE starting dose, the starting 
dose in the LTSE may be reduced.  During the LTSE phase, subjects may titrate to higher  
doses of OCA, at  a frequency not greater than 
3 monthly (ie, at each of the scheduled LTSE visits) , 
up to a maximum dose of 10 mg daily.  The guideline 
for an increase in the dose of OCA is based on tolerability and the goal of achieving an ALP level 
<1.5x ULN.  Doses of OCA should be titrated as 
follows, unless clinically indicated:  1.[ADDRESS_21243] 
Inclusion Criteria  6. For subjects with concomitant IBD:   
a. Colonoscopy within 12 months of Day 0 confirming no dysplasia or colorectal cancer 6. For subjects with concomitant IBD:   
a. Colonoscopy (if the subject has a colon) 
or other appropriate endoscopic 
procedure within 12 months of Day 0 
confirming no dysplasia or colorectal 
cancer 
Protocol 747-207 Version 5:   [ADDRESS_21244] been stable for â‰¥[ADDRESS_21245] exceeded 20 mg/kg/day 
during this time.  
Note 2:  Subjects will be stratified according to UDCA use and no more than 50% of subjects 
administering UDCA at Day [ADDRESS_21246] been stable for â‰¥[ADDRESS_21247] exceeded 20 mg/kg/day 
during this time.  
Note 2:  Subjects not taking UDCA at Day [ADDRESS_21248] taken UDCA for â‰¥[ADDRESS_21249] not 
take UDCA during the DB period.  Subjects 
will be stratified according to UDCA use , and no 
more than 50% of subjects administering UDCA 
at Day [ADDRESS_21250] 
Inclusion Criteria  8. For subjects being administered biologic 
treatments (eg, Anti-TNF or anti -integrin 
monoclonal antibodies), immunosuppressants  or 
systemic corticosteroids they must have been on a 
stable dose for â‰¥3 months prior to, and including, 
Day 0 and should plan to remain on a stable dose 
throughout the trial.  8. Subjects being administered biologic treatments 
(eg, anti-TNF or anti -integrin monoclonal 
antibodies), immunosuppressants , systemic 
corticosteroids , or statins , must have been on a 
stable dose for â‰¥[ADDRESS_21251] 
Inclusion Criteria  9. Contraception:  f emale subjects of childbearing 
potential must use â‰¥[ADDRESS_21252] dose of IP (including LTSE 
doses). 9. Contraception:  f emale subjects of childbearing 
potential must use â‰¥1 effective method (â‰¤1% failure rate) of contraception during the trial and 
until [ADDRESS_21253] (including LTSE doses).  
Effective methods of contraception are 
considered to be those listed below : 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 145 
Confidential and Proprietary    Section Original Text Revised Text  
â€¢ Double barrier method, ie, (a) co ndom 
(male or female) or (b) diaphragm, with 
spermicide; or 
â€¢ Intrauterine device; or  
â€¢ Vasectomy (partner), or 
â€¢ Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, 
intramuscular implant or injection); or  
â€¢ Abstinence, if in line with the preferred 
and usual lifestyle of th e subject [where 
abstinence is defined as refraining from heterosexual intercourse during the trial duration (from first administration 
of investigational product until [ADDRESS_21254])]  
Synopsis 
Methodology Exclusion Criteria  
and  
Section 8.[ADDRESS_21255] 
Exclusion Criteria  4. Presence of clinical complications of chronic liver 
disease or clinically significant hepatic 
decompensation, including:  
â€¢ Current Child Pugh classification B or C 
â€¢ History of, or current diagnos is or 
suspi[INVESTIGATOR_1884], cholangiocarcinoma or other 
hepatobiliary malignancy, or biliary tract dysplasia.  
â€¢ History of liver transplantation, current 
placement on a liver transplant list, or 
current model of end stage liver disease 
(MELD) score â‰¥12 5. Presence of clinical complications of chronic liver disease or clinically significant hepatic 
decompensation, including:  
â€¢ Current Child-Pugh classification B or C 
â€¢ History of, or current diagnosis or suspi[INVESTIGATOR_1884], cholangiocarcinoma or other 
hepatobiliary malignancy, or biliary tract dysplasia.  
â€¢ History of liver transplantation, or current model of end stage liver disease ( MELD) 
score â‰¥12 
Protocol 747-207 Version 5:   [ADDRESS_21256] 
Exclusion Criteria  5. Clinical evidence of dominant stricture (as evidenced by [CONTACT_22140] 
12 months prior to Day 0) 5. Clinical evidence of dominant stricture (as evidenced by [CONTACT_22140] 
12 months prior to Day 0) or current biliary 
stent 
Synopsis 
Methodology Exclusion Criteria  
and  
Section 8.[ADDRESS_21257] 
Exclusion Criteria  9. History of other chronic liver diseases , including, 
but not limited to, primary biliary cirrhosis (PBC), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, hepatitis B virus (unless seroconverted and no positive Hepatitis B Virus DNA) and 
hepatitis C virus  9. History of other chronic li ver diseases , including, 
but not limited to, primary biliary cirrhosis (PBC), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, hepatitis B virus (unless seroconverted and no positive Hepatitis B Virus DNA) , hepatitis 
C virus, and overlap syndrome  
Synopsis Methodology Exclusion Criteria  
and  
Section 8.[ADDRESS_21258] 
Exclusion Criteria  12. Currently experie ncing, or experienced within 
â‰¤1 month of Screening, moderate to severe 
pruritus requiring systemic or enteral treatment , 
or any history of severe pruritus 12. Currently experiencing, or experienced within 
â‰¤[ADDRESS_21259] 
Exclusion Criteria  14. Administration of antibiotics is prohibited â‰¤1 month of Day 0. 
14. Administration of antibiotics is prohibited 
â‰¤1 month of Day 0 (unless subject is on a stable 
prophylaxis dose for at least 3 months prior to 
Day 0). 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 147 
Confidential and Proprietary    Section Original Text Revised Text  
Synopsis Efficacy 
Analyses An unblinded interim analysis for planning purposes 
will be conducted after approximately 50% of 
patients have completed the initial 12 -weeks of 
blinded treatment.  The trial will not be terminated 
early for futility.  The interim analysis will compare 
at Week 12, the same variable as will be analyzed for 
the primary endpoint: the change from Baseline in 
ALP, between OCA treatment groups (1.5 mg and 5 
mg) and placebo using an analysis of covariance 
(ANCOVA) model with fixed effects for treatment 
group and randomization strata and Baseline as a 
covariate.  No adjustments to the alpha level will be 
made. Text Moved to Synopsis Interim Analysis  
Interim Analysis  
An unblinded interim analysis for planning 
purposes will be conducted after approximately 
50% of subject s have completed the initial 
12-weeks of blinded treatment.  The trial will not 
be terminated early for futility.  The interim analysis will compare at Week 12, the same 
variable as will be analyzed for the primary endpoint: the change from Baseline in ALP, 
between OCA treatment groups (1.5 mg and 5 mg) 
and placebo using an analysis of covariance (ANCOVA) model with fixed effects for treatment 
group and randomization strata and Baseline as a 
covariate.  No adjustments to the alpha level will be made.  
List of 
Abbreviations and 
Definitions of Terms IP   investigational product RSI:  Reference Safety Information  
S[LOCATION_003]R:  suspected unexpected serious adverse reaction 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 148 
Confidential and Proprietary    Section Original Text Revised Text  
Section 5.3.2 
Nonclinical Effects on Cholestasis The results of trials performed in rodent models of 
cholestasis involving the administration of chemical 
agents that severely injure bile ducts (such as carbon 
tetrachloride [CCl
4] or lithocholic acid [LCA]) 
provide evidence that OCA is effective in preventing 
or reducing chol estasis in vivo.  In the LCA model, 
co-infusion of OCA fully reversed the impairment of 
bile flow and protected against liver cell injury (Pellicciari  2002, Vairappan 2009
). 
Results of other trials  have demonstrated that OCA 
significantly reduces fibrotic collagen synthesis in 
vitro and in various rodent models of chronic liver 
injury that involve fibrosis and eventual cirrhosis, 
consistent with the progression of PSC (Albanis 2005, Vairappan 2009
).   The results of trials performed in rodent models of 
cholestasis involving the administration of chemical 
agents that severely injure bile ducts (such as carbon 
tetrachloride [CCl 4] or lithocholic acid [LCA]) 
provide evidence that OCA is effective in preventing 
or reducing cholestasis in vivo .  In the LCA model, 
co-infusion of OCA fully reversed the impairment of 
bile flow and protected against liver cell injury (Pellicciari  2002). 
Results of other trials  have demonstrated that OCA 
significantly reduces fibrotic collagen synthesis in 
vitro and in various rodent models of chronic liver 
injury that involve fibrosis and eventual cirrhosis, 
consistent with the progression of PSC (Albanis 2005, Mookerjee 2015).   
Section 5.4 Clinical Experience with Obeticholic Acid  To date, OCA has been evaluated in the clinic in a 
total of 17 completed and ongoing trials , including 
patients with PBC and  other chronic liver diseases 
(eg, portal hypertension and nonalcoholic steatohepatitis [ NASH]) and healthy volunteers.  
Additional trials are also planned to further 
characterize the pharmacokinetic (PK) and pharmacodynamics (PD)  properties of OCA as well 
as the safety and efficacy of OCA in subjects with PBC and other chronic liver diseases. 
As of [ADDRESS_21260] one dose of OCA in completed or ongoing trials.  
Of these, 4 14 (40%) were PBC s ubjects with 
exposure up to approximately 4.5 years .  Overall, the 
PK profile of OCA is consistent with that expected of To date, OCA has been evaluated in the clinic in a total of 25 completed and 8 ongoing trials , including 
patients with PBC and  other chronic liver diseases 
(eg, portal hypertension and nonalcoholic steatohepatitis [ NASH]) and healthy volunteers.  
Additional trials are also planned to further 
characterize the pharmacokinetic (PK) and pharmacodynamic (PD)  properties of OCA as well as 
the safety and efficacy of OCA in subjects with PBC and other chronic liver diseases . 
As of [ADDRESS_21261] one dose of OCA in completed 
or ongoing trials.  Overall, the PK profile of OCA is 
consistent with that expected of a bile acid.  Phase 1 
PK trials demonstrated that OCA was rapi[INVESTIGATOR_22039] 747-207 Version 5:   [ADDRESS_21262] Pruritus is a common symptom of chronic cholestatic 
diseases such as PBC and PSC.  In subjects with PBC, treatment with OCA has been shown to cause a 
dose-dependent exacerbation of this common 
symptom and similar results can be expected in subjects with PS C.  Pruritus has also been observed 
in clinical trials with OCA in other indications  and in 
healthy volunteers, but at  a lower frequency and at 
higher doses than that observed in subjects with 
chronic cholestasis.  Investigator guidance for 
pruritus manage ment strategies are outlined in 
Section [IP_ADDRESS] of the protocol.  
Other potential risks include liver toxicity , especially 
at higher doses of OCA, which is consistent with nonclinical findings and the chemical characteristics 
of OCA as a bile acid and detergent.  An increase in 
liver function tests and hepat ic AEs, including 
jaundice, were observed in subjects with PBC and 
NASH who were treated at doses that are several fold Investigators are referred to the current IB for a 
thorough presentation of the safety data associated with OCA.  An overview is as follows: 
Pruritus is a common symptom of chronic cholestatic diseases such as PBC and PSC.  In subjects with PBC, treatment with OCA has been shown to cause a 
dose-dependent exacerbation of this common 
symptom and similar results can be expected in subjects with PS C.  Pruritus has also been observed 
in clinical trials with OCA in other indications  and in 
healthy volunteers, but at  a lower frequency and at 
higher doses than that observed in subjects with 
chronic cholestasis.  Investigator guidance for 
pruritus manage ment strategies are outlined in 
Section [IP_ADDRESS] of the protocol.  
Other potential risks include liver toxicity , especially 
at higher doses of OCA, which is consistent with nonclinical findings and the chemical characteristics 
of OCA as a bile acid and dete rgent.  An  increase in 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 150 
Confidential and Proprietary    Section Original Text Revised Text  
higher (primarily 20 to 50  mg daily) than those 
studied in this protocol (1.5 m g, 3 mg, 5 mg, and 
10 mg) doses.  This is an important potential risk in 
subjects with PSC, where there is the possibility of 
dominant strictures of intra - and extra -hepatic bile 
ducts that could restrict bile flow.  In order to monitor 
bile duct patency, the trial protocol requires that sites 
perform an ultrasound at the end of the DB phase and thereafter annually in the LTSE.  Consistent with this 
potential risk, the present trial excludes subjects who have had, or who are suspected of having, a recent dominant stricture (Section  8.3).  In addition, the trial 
calls for mandatory discontinuation of investigational 
product (IP) in those subjects whose liver chemistry 
(AST, ALT  and or bilirubin) di splay clinically 
significant increases following the initiatio n of 
therapy (Section 8.4.1).  The doses used in the 
present trial (1.5 mg to 10 mg) are amongst the 
lowest doses of OCA tested to date in a clinical 
setting. 
Lipoprotein changes have also been observed with 
OCA dosing in s ubjects with PBC (including a 
decrease in high density lipoprotein [HDL]).  The 
clinical significance of these lipid findings remains 
unclear and is being studied further.  Notably, despi[INVESTIGATOR_22040], they generally remained within normal limits.   The relevance of  
these findings to subjects with PSC is unclear  and 
will be investigated further in this trial.  Investigators 
are referred to the current IB for a thorough 
presentation of the safety data associated with OCA.  liver function tests and hepat obiliary AEs, including 
jaundice, ascites and acute cholecystitis were 
observed in subjects  with PBC and NASH who were 
treated at doses that are several fold higher (primarily 20 mg to 50 mg daily) than those studied in this protocol (1.5 mg, 3 mg, 5 mg, and 10 mg) doses.  
This is an important potential risk in subjects with 
PSC, where there is the possibility of dominant strictures of intra - and extra- hepatic bile ducts that 
could restrict bile flow.  In  order to monitor bile duct 
patency, the trial protocol requires that sites perform an ultrasound at Screening, at the end of the DB 
phase, and annually in the LTSE.  Consistent with 
this potential risk, the present trial excludes subjects who have had, or who are suspected of having, a 
recent dominant stricture (Section  8.3).  In addition, 
the trial calls for mandatory discontinuation of 
investigational product in those subjects whose liver chemistry (AST , ALT and or bilirubin) di splay 
clinically significant increases following the initiation 
of therapy ( Section 8.4.1).  The doses used in the 
present trial (1.5 mg to 10 mg) are amongst the lowest doses of OCA tested to date in a clinical setting. 
Lipoprotein changes have also been observed with OCA dosing in s ubjects with PBC (including a 
decrease in high -density lipoprotein [HDL]).  The 
clinical significance of these lipid findings remains unclear and is being studied further.  Notably, despi[INVESTIGATOR_22041], they generally 
remained within normal limits.   The relevance of 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 151 
Confidential and Proprietary    Section Original Text Revised Text  
In addition, the Data Safety Monitoring Commit tee 
(DSMC) will review safety data from the present trial 
as well as other ongoing OCA trials on a periodic 
basis.  Adjustments to or stoppi[INVESTIGATOR_22042]-defined doses may be considered based on DSMC evaluation of OCA safety and tolerability as 
noted in Section  7.4.3.  A few Sponsor 
representatives may be unblinded during the trial, as 
it is anticipated that this may speed a decision to 
make a dosing change in the study, if necessary.  If 
there are any findings regarding safety, tolerability, 
or efficacy that indicate an alternative optimal LTSE 
starting dose, the starting dose in the LTSE may be 
reduced. these findings to subjects with PSC is unclear  and 
will be investigated further in this trial. 
In addition, the Data Safety Monitoring Committee (DSMC) will review safety data from the present trial 
as well as other ongoing OCA trials at 
approximately quarterly intervals but at least 
every 6 months .  Adjustments to or stoppi[INVESTIGATOR_22042]-defined doses may be considered based on 
DSMC evaluation of OCA safety and tolerability as 
noted in Section  7.4.3. 
Section 7.1 Overall 
Trial Design  Long-Term Safety Extension  Phase (LTSE)  
Following completion of participation in the DB 
phase at Week 24 , subjects will continue in the study 
in the open-label long- term safety extension (LTSE) 
phase for a further [ADDRESS_21263]â€™s completion of the DB phase, the 
trial blind will be broken in order to assign the 
starting OCA dose for the LTSE phase.  It is intended that subjects will commence treatment at 5  mg OCA, 
except those subjects who completed treatment in the DB phase with 10 mg OCA who will continue at 10 mg OCA unless safety and tolerability warrant a 
dose reduction to 5 mg.  The titration schedule and Long-Term Safety Extension Phase (LTSE)  
Following completion of participation in the DB phase, subjects will be asked to reconfirm their 
consent for participation in the LTSE phase (a further 24 months) .  The schedule of trial 
procedures for the LTSE is shown in Table 2. 
Upon a subjectâ€™s completion of the DB phase, the trial blind will be broken in order to assign the starting OCA dose for the LTSE phase.  It is intended 
that subjects will commence treatment at 5  mg OCA, 
except those subjects who completed treatment in the 
DB phase with 10 mg OCA who will continue at 
10 mg OCA unless safety and tolerability warrant a 
dose reduction to 5 mg.  The titration schedule and options for the LTSE phase are detailed in 
Section 7.4.2.  If an Investigator does not wish for a 
Protocol 747-207 Version 5:   [ADDRESS_21264] to be titrated in line with the below schedule 
this should be discussed with the medical monitor:   
A limited number of Sponsor representatives will 
remain unblinded during the DB phase of the study.  
If there are any findings regarding safety, to lerability, 
or efficacy that indicate an alternative optimal LTSE 
starting dose, the starting dose in the LTSE may be 
reduced.  subject to be titrated in line with Table 4, this may be 
discussed with the Medical Monitor.  
Schedule of Trial 
Procedures, Table 1 
Double-Blind 
Phase Screening  
D0 
Hepatic Ultrasound at W24 
Dispense IP at D0, W2, W6, W12, W14, W18, W24 
Serum Chemistry & Hematology  
 
No Text  
 Footnote d:  The Week 24 visit is the final visit 
during the DB treatment period.  For subjects who 
continue into the LTSE, the Week 24 visit is also 
Day 1 of the LTSE.  
 
 Screening (Day -30 to Day -1)  
Day [ADDRESS_21265]  at Day 0,W12, 
W24 
Serum Chemistry, Hematology, & Coagulation 
Parameters  
Footnote b:   Day [ADDRESS_21266] to be eligible to continue in the trial.  
Footnote d:  The Week 24 visit is the final visit 
during the DB treatment period.  For subjects who 
continue into the LTSE, the Week 24 visit is also Day 1 of the LTSE, and unblinding occurs after the  
Week 24/LTSE Day [ADDRESS_21267] been completed (except dispensing of open -label 
investigational product).  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 153 
Confidential and Proprietary    Section Original Text Revised Text  
Footnote g:  Height is measured only at the Screening 
Visit. 
 
Footnote i :  TE:  at trial sites where the FibroscanÂ® 
TE device is available.  
 
 
  
 
No Text 
   
 
Footnote k: Subjects with UC and CD will be asked 
to complete a diary recording details  of their 
symptoms in the 7 days prior to their next scheduled 
visit. 
 
   
Footnote m :  Questionnaire completed with input 
from the subject.  Footnote h:  Height is measured at the Screening visit 
only. 
 
Footnote j:  TE: at trial sites where the FibroscanÂ® 
TE device is available.  TE has a 5 -day visit 
window.  For the Day 0 assessment, TE should 
occur either on Day 0 or within 5 days prior to 
Day 0.  For the Week 24 assessment , the TE 
should occur within Â±5  days of the onsite visit if it 
is not possible to sched ule the TE on the same day 
as that visit, but the visit(s) should remain within the overall visit window.  
Footnote k:  Hepatic ultrasound has a Â±5 -day visit 
window (ie, if it is not possible to schedule the ultrasound on the same day as the onsite visit, it 
may occur within 5 days on either side of the visit, 
but the visit(s) should remain within the overall 
visit window).  
Footnote m :  Subjects with UC will be asked to 
complete a diary  the day prior to their next trial 
visit, recording details since their last scheduled 
visit.  Subjects with CD should complete the diary 
in the [ADDRESS_21268] data from the Screening period are collected 
at the Day 0 visit. 
Footnote o:  Questionnaire completed by  [CONTACT_423].  
 
Footnote r:  Investigational product is dispensed only 
for subjects who continue into the LTSE.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 154 
Confidential and Proprietary    Section Original Text Revised Text  
Footnote r:  Investigational product is dispensed only 
for subjects who continue into the LTSE.  (Dispensing of open -label investigational produc t 
occurs after  completion of the Week 24/LTSE 
Day [ADDRESS_21269]â€™s treatment allocation .) 
Schedule of Trial 
Procedures, Table 2 
LTSE Phase  No Text 
Serum Chemistry & Hematology 
 
Footnote c:  The LTSE D1 is also the final visit 
(Week 24) of the DB treatment period.  
 
 
 
No Text  
 
 
Footnote h:  TE:  at trial sites where the FibroscanÂ® 
TE device is available.  
 
 
No Text 
 
 
 Contact [CONTACT_22141]2 Â± 3d â€“ Safety Contact 
[CONTACT_22142], Hematology, & Coagulation 
Parameters  
Footnote c:  The LTSE D1 is also the final visit 
(Week 24) of the DB treatment period.  For subjects 
continuing into the LTSE, unblinding occurs after 
the Week 24/LTSE Day [ADDRESS_21270] been 
completed (except dispensing of open -label 
investigational product).  
Footnote g:  The Safety Contact [CONTACT_22143], and does not require an onsite visit. 
Footnote i :  TE:  at trial sites where the FibroscanÂ® 
TE device is available.  The TE should occur within 
Â±5 days of the onsite visit if it is not possib le to 
schedule the TE on the same day as that visit, but 
the visit(s) should remain within the overall visit 
window. 
Footnote j:  Hepatic ultrasound has a Â±5 -day visit 
window (ie, if it is not possible to schedule the ultrasound on the same day as the onsi te visit, it 
may occur within 5 days on either side of the visit, 
but the visit(s) should remain within the overall visit window).  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 155 
Confidential and Proprietary    Section Original Text Revised Text  
Footnote j :  Subjects with UC and CD will be asked 
to complete a diary recording details of their 
symptoms  in the 7 days prior to their next scheduled 
visit. 
  
Footnote l :  Questionnaire completed with input from  
the subject.  
No Text Footnote l:  Subjects with UC will be asked to 
complete a diary the day prior to their next trial visit, recording details since their last scheduled 
visit.  Subjects with CD should complete the diary 
in the 7 days prior to their next clinic visit.  
Footnote n :  Questionnaire completed by  [CONTACT_423].  
 
Footnote o:  Investigational product is dispensed 
only for subjects who continue into the LTSE.  
(Dispensing of open- label investigational product 
occurs after completion of the Week 24/LTSE Day 
[ADDRESS_21271]â€™s treatment allo cation.)  
Section 7.4.[ADDRESS_21272]â€™s completion of the Week 24 visit, at 
the end of the DB phase, the trial blind will be broken 
in order to assign the starting OCA dose for the LTSE phase.  It is intended that subjects will commence 
treatment at 5 mg OCA, except those subjects who 
completed treatment in DB with 10 mg OCA who 
will continue at 10 mg OCA (Table 4) unless safety 
and tolerability warrant a dose reduction to [ADDRESS_21273] to be 
titrated in line with the below schedule this should be 
discussed with the medical monitor:   
During the LTSE , phase subjects may titrate to higher 
doses of OCA, at a frequency not greater than 
3 monthly (ie, at each of the scheduled visits), up to a 
maximum dose of 10 mg daily.  The guideline for an increase in the dose of open- label OCA is based on 
the goal of achieving ALP <1.5x ULN and Upon a subjectâ€™s completion of the Week 24 visit, at 
the end of the DB phase, the trial blind will be broken 
in order to assign the starting OCA dose for the LTSE phase.  It is intended that subjects will commence 
treatment at 5 mg OCA, except those subjects who 
completed treatment in the DB phase with 10 mg 
OCA who will continue at 10 mg OCA ( Table 4) 
unless safety and tolerability warrant a dose reducti on 
to [ADDRESS_21274] to be 
titrated in line with the above schedules, this may 
be discussed with the Medical Monitor.  
During the LTSE phase subjects may titrate to higher 
doses of OCA, at a frequency not greater than 
3 monthly (ie, at each of the scheduled visits), up to a maximum dose of 10 mg daily.  The guideline for an 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 156 
Confidential and Proprietary    Section Original Text Revised Text  
tolerability.  Subjects may be titrated in the order 
1.5 mg to 3 mg, 3 mg to 5 mg, and 5 mg to 10 mg 
unless otherwise clinically indicated .  An increase in 
the dose of OCA may occur at intervals no more 
frequent than once per month. increase in the dose of open -label OCA is based on 
the goal of achieving ALP <1.5x ULN and tolerability.   Doses of OCA should be titrated as 
follows, unless clinically indicated:   1.5 mg to 3 mg, 
3 mg to 5 mg, and 5 mg to10 mg. 
Section 7.4.3 
Safety Criteria for Adjustment or Stoppi[INVESTIGATOR_22043] (DSMC) will 
review safety data from the present trial as well as 
other ongoing OCA trials on a periodic basis.  
Adjustments to or stoppi[INVESTIGATOR_22006]-defined 
doses may be considered based on DSMC evaluation of OCA safety and tolerability.  At a minimum, the 
occurrence of two life threatening serious adverse 
events (SAEs) or an SAE resulting in death will 
trigger an unscheduled and unblinded review of the 
data by [CONTACT_22144].  Section  7.5 details the criteria for trial 
termination.  Reasons for discontinuation of individual subjects are noted in Section  8.4.1 and 
Section 8.4.2.  An independant Data Safety Monitoring Committee 
(DSMC) will review safety data from this trial as 
well as other ongoing OCA trials at approximately 
quarterly intervals but at least every 6  months.  
Adjustments to or stoppi[INVESTIGATOR_22006]-defined 
doses may be considered based on DSMC evaluation 
of OCA safety and tolerability.  At a minimum, the 
occurrence of 2 life threatening serious adverse 
events (SAEs) or an SAE resulting in de ath will 
trigger an unscheduled and unblinded review of the data by [CONTACT_22144].  Section  7.5 details the criteria for trial 
termination.  Reasons for discontinuation of individual subjects are noted in Section  8.4.1 and 
Section 8.4.2. 
Section 7.5 Criteria 
for Trial Termination  The Sponsor reserves the right to terminate the trial at 
any time.  The Sponsor reserves the right to terminate the trial at any time.  Additionally, it is agreed that, for 
reasonable cause, the Investigator may terminate 
the trial at his/her site at any time.  
Section 8.4.[ADDRESS_21275] be made to determine the 
reason(s) why a subject fails to return for final visit or Other Reasons for Study Discontinuation  
A subject should be discontinued from the study 
if:  
Protocol 747-207 Version 5:   [ADDRESS_21276] be recorded on the appropriate case report 
form (CRF).  The following events are considered 
appropriate (potential) reasons for a subject to 
discontinue from the trial:  
â€¢ The subject decides that it is in his/her 
best interest.  It is fully understood that all 
subjects volunteer for the trial and that they may w ithdraw their consent to 
continue in the trial at any time.  
â€¢ The investigator considers that it is 
advisable or in the best interest of the 
subject  
â€¢ There is a major violation of the clinical 
trial protocol for the subject  
â€¢ Noncompliance of the subject  
â€¢ The development of any exclusion criteria 
(see Section 8.3)  
â€¢ An inability to provide blood or urine 
samples 
â€¢ The occurrence of clinical or laboratory 
AEs considered by [CONTACT_941] i nvestigator to be 
clinically important  â€¢ The subject decides that it is in his/her 
best interest.  It is fully understood that all 
subjects volunteer for the trial and that 
they may withdraw their consent to 
continue in the trial at any time.  
â€¢ The Investigator considers that it is 
advisable or in the best interest of the subject.  
â€¢ There is a major violation of the clinical 
trial protocol for the subject that would 
jeopardize the subjectâ€™s safety and/or 
data quality . 
â€¢ There is significant n oncompli ance of the 
subject that would jeopardize the 
subjectâ€™s safety and/or data quality . 
â€¢ The development of any exclusion criteria 
(see Section 8.3) that would jeopardize 
the subjectâ€™s safety and/or data quality . 
â€¢ The subject is consistently unable to 
provide blood or urine samples . 
â€¢ There is an occurrence of clinical or 
laboratory AEs considered by [CONTACT_22145], 
such that they would jeopardize the 
subjectâ€™s safety . 
A reasonable effort must be made to determine 
the reason(s) why a subject fails to return for 
his/her final visit or is discontinued from the trial.  
Protocol 747-207 Version 5:   [ADDRESS_21277] be recorded on 
the appropriate case report form (CRF).  
Section 8.4.[ADDRESS_21278] of care treatment .  
Discontinuation from the trial is not mandatory in 
cases of bacterial cholangitis unless signs and 
symptoms do not resolve within a clinically reasonable timef rame (typi[INVESTIGATOR_16195] 1 month or as 
agreed upon with the m edical monitor) or the 
cholangitis becomes life threatening in the opi[INVESTIGATOR_22033].  In any event, IP  
should not be restarted until signs and symptoms have resolved and the subjectâ€™s liver biochemistry has returned to pre -cholangitis levels.   Investigational product may be interrupted at the 
discretion of the Investigator.  Discontinuation from 
the trial is not mandatory in cases of bacterial 
cholangitis unless signs and symptoms do not resolve 
within a clinically reasonable timeframe (typi[INVESTIGATOR_16195] 1 month or as agreed upon with the M edical 
Monitor) or the cholangitis becomes life- threatening 
in the opi[INVESTIGATOR_2511] I nvestigator or Medical 
Monitor.  In any event, investigational product  
should not be restarted until signs and symptoms have resolved and the subjectâ€™s liver biochemistry has returned to pre -cholangitis levels.   
Section 8.4.[ADDRESS_21279] develops a 
stricture requiring intervention (eg , drainage, ERCP, 
stent) in order to re -establish bile flow.   The medical 
monitor should be contact[CONTACT_22146]â€™s 
eligibility to continue in the trial.  Lack of 
improvement (or worsening) within [ADDRESS_21280] is considered 
eligible to resume IP administration or to continue in 
the trial. 
It is agreed that, for reasonable cause, the investigator 
may terminate the trial at his/her site or the Sponsor 
may decide to terminate the trial.  Bile Duct Stricture 
Investigational product may be interrupted  at the 
discretion of the Investigator if a subject develops a 
stricture requiring intervention (eg , drainage, ERCP, 
stent) in order to re -establish bile flow .  If the 
investigational pr oduct has been interrupted and 
the subject does not show improvement within 
[ADDRESS_21281] administration or to continue in the trial.  
Pruritus 
Pruritus is a common symptom in  PBC but less 
common in  PSC (Chapman 2011 ).  Investigator  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 159 
Confidential and Proprietary    Section Original Text Revised Text  
guidance for pruritus  management strategies  are 
outlined in  Section [IP_ADDRESS] of this protocol.  
Subjects who experience one or more epi[INVESTIGATOR_22044] , despi[INVESTIGATOR_22045] [IP_ADDRESS], should be discontinued from the 
trial. 
Section 9.[ADDRESS_21282] 12 weeks of the DB phase, subjects will be instructed to administer two tablets daily:  one  1.5 mg 
(small) tablet and one 5 mg (big) tablet.  Investigational product will be dispensed in bottles 
of [ADDRESS_21283] 12 weeks of the DB phase, 
subjects will be instructed to administer 2 tablets 
daily with water :  one 1.5 mg (small) tablet and one  
5 mg (big) tablet. 
Section 9.2 
Concomitant 
Medications Relevant information about all concomitant drugs 
(including prescribed, over the counter, or herbal 
preparations) taken prior to (ie, within 30 days of Day 
0) and during the trial must be recorded in the source 
documents and CRF , as well as any dose or dose 
regimen changes that occur during the trial. Relevant information about all concomitant drugs 
(including prescribed, over- the-counter, or herbal 
preparations) taken prior to (ie, within 30 days of 
Screening ) and during the trial must be recorded in 
the source documents and CRF , as well as any dose 
or dose regimen changes that occur during the trial. 
Section 9.2.1 
Ursodeoxycholic Acid Subjects taking UDCA  at Day 0 should maintain this 
dose and the timing of administration  of UDCA for 
the duration of the DB phase of the trial (24 weeks).  
Subjects who were unable to tolerate  UDCA prior to 
participating in  the trial should not initiate UDCA 
therapy at any time during their participation in the DB phase of trial . Subjects taking UDCA  at Day 0 should maintain this 
dose and the timing of administration of UDCA for 
the duration of the DB phase of the trial (24 weeks).  Subjects who are not taking UDCA  on entry into  
the trial should not initiate UDCA therapy at any time 
during their participation in the DB phase of the  trial. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 160 
Confidential and Proprietary    Section Original Text Revised Text  
Section 9.2.3 
Prohibited Medications â€¢ Systemic or enteral therapy for pruritus in 
the month prior to Screening.  A subject may remain in the study if they require 
systemic or enteral therapy for pruritus 
after the initiation of investigational 
product administration 
â€¢ Administration of antibiotics within [ADDRESS_21284] been on a stable dose for â‰¥3 months prior 
to, and including, Screening  and remain on a stable 
dose throughout the trial:  
â€¢ Anti-TNF and anti-integrin antibodies 
â€¢ Immunosuppressants (eg, azathioprine, 
colchicine, cyclosporine, methotrexate, 
mycophenolate mofetil, pentoxifylline) 
â€¢ Corticosteroids  â€¢ Systemic or enteral therapy for pruritus in 
the [ADDRESS_21285] administration. 
â€¢ Administration of antibiotics within 1 month of Day 0 (unless subject is on a 
stable prophylaxis dose for at least 
3 months prior to Day 0) , except if 
administered for acute cholangitis 
whereby [CONTACT_22086] 
[ADDRESS_21286] been on a stable dose for â‰¥3 months prior 
to, and including, Day  0 and remain on a stable dose 
throughout the trial:  
â€¢ Anti-TNF and anti-integrin antibodies 
â€¢ Immunosuppressants (eg, azathioprine, colchicine, cyclosporine, methotrexate, 
mycophenolate mofetil, pentoxifylline) 
â€¢ Corticosteroids  
â€¢ Statins 
Protocol 747-207 Version 5:   [ADDRESS_21287] the 
scientific integrity of the study or data.  No Text 
Section 9.4.2 Unblinding Procedures â€“ 
Emergency Unblinding No Text 
9.4.2  Unblinding Procedures â€“ Emergency 
Unblinding  
For the DB phase of the trial, treatment 
assignment will be made available to the Investigator for emergency use only through the 
IWRS.  When possible, the Medical Monitor should be consulted in the event that a medical emergency necessitates unblinding (i e, in 
situations where knowledge of the blinded treatment is necessary for further medical management of the subject).  If it is not reasonable 
to inform the Medical Monitor in advance of unblinding, the Investigator must promptly 
document in the subjectâ€™s  source record and 
should subsequently contact [CONTACT_22147] (such as accidental unblinding or 
unblinding due to an SAE).  Procedures for 
unblinding a subjectâ€™s treatment will be provided separately to the Investigator.  Similarly, if the 
Medical Monitor breaks the blind for the purpose 
of evaluating an emergent safety issue, the Medical Monitor will document within trial 
documentation the rationale, circumstances, and 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 162 
Confidential and Proprietary    Section Original Text Revised Text  
the person or persons b eing informed about the 
unblinding.  
The DSMC (refer to Section 13.6.2) will have 
access to the IWRS and will be able to unblind 
individual subjects.  Refer to Section  13.6.2 for 
further details regarding DSMC access to blinded 
and unblinded data.  The DSMC  will document, in 
the closed session DSMC minutes (which will be 
made available to the Sponsor only after the 
database is locked and the trial is unblinded), 
details about any unblinded subject data reviews.  Cases of premature unblinding (as noted above)  
will be reviewed by [CONTACT_6802].  
Access to treatment assignments will also be made available through the IWRS to the appropriate, 
named individual(s) responsible for reporting 
SAEs and suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) to the regulatory authorities.  
Section 9.6.1 Visit 
Windows All trial visits during the DB period are relative to 
Day 0 (eg, if the Week 6 visit occurs 4 days late, the 
Week 12 visit should still be 12 weeks from Day 0).  
The Screening visit should occur â‰¤30 days prior to 
the Day 0 visit.  All visits during the DB treatment 
period should occur within Â± 1 week of the indicated time.  The exception to this is the Week 2 visit, which 
should occur within Â± 3 days of the indicated time.  
During the LTSE period, visits are relative to LTSE Day 1 (which is also the DB Week  24 visit) and all 
visits during this  period should occur within All trial visits during the DB period are relative to 
Day 0 (eg, if the Week 6 visit occurs 4 days late, the 
Week 12 visit should still be 12 weeks from Day 0).  
The Screening visit should occur â‰¤30 days (ie, Day -30 to Day -1) prior to the Day 0 visit.  All visits 
during the DB treatment period should occur within 
Â±1 week of the indicated time.  The exception to this 
is the Week 2 visit, which should occur within 
Â±3 days of the indicated time.  
During the LTSE period, visits are relative to LTSE 
Day 1 (which is also the DB Week  24 visit) and  all 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 163 
Confidential and Proprietary    Section Original Text Revised Text  
Â± 2 weeks of the indica ted time, except for the 
Follow-Up visit, which should occur within 
Â± 1 week.   visits during this  period should occur within 
Â±[ADDRESS_21288] which sh ould occur within 
Â±3 days and the Follow-Up visit, which should occur 
within Â±1 week.  
Section 9.6.3 
Screening Procedures (Within 
30 Days of Day 0) The Screening V isit assessm ents must be performed 
within â‰¤[ADDRESS_21289] be perfor med 
within â‰¤30 days (ie, Day -30 to Day -1) prior to 
Day [ADDRESS_21290] meets all the 
inclusion criteria and none of the exclusion criteria.  
Section 9.6.3 
Screening Procedures (Within 
30 Days of Day 0) Screening V isit procedures are as follows:  
â€¢ The subject is to review  the PIS and sign 
the ICF.  Written informed consent must 
be obtained from the subject before 
performing any trial related procedures, 
including Screening procedures. (Note:  
Collection of AEs commences from the 
point the subject signs the consent form.)  
â€¢ Assign subject number 
â€¢ Collect medical  history 
â€¢ Record prior (within 30 days of Day 0 ) 
and current concomitant medications  
â€¢ Verify inclusion and exclusion criteria for eligibility  
â€¢ Perform a physical examination, including 
height (Screening Visit only)  and weight.  
See Section 12.2.2 for physical 
examination requirements. Screening v isit procedures are as follows:  
â€¢ The subject is to review  the PIS and sign 
the ICF.  Written informed consent must 
be obtained from the subject before 
performing any trial related procedures, 
including Screening procedures.  (Note:  
Collection of AEs commences from the 
point the subject signs the consent form.) 
â€¢ Assign subject number . 
â€¢ Collect medical  history. 
â€¢ Record prior (within 30 days of 
Screening ) and current concomitant 
medications . 
â€¢ Verify inclusion and exclusion criteria for eligibility . 
â€¢ Perform a physical examination, including 
height and weight .  See Section 12.2.2 for 
physical examination requirements. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 164 
Confidential and Proprietary    Section Original Text Revised Text  
â€¢ Record vital signs  
â€¢ Perform a standard 12- lead 
electrocardiogram (ECG) 
â€¢ For subjects with UC:  provide the diary 
and request subject completes this for 
each of the 7 consecutive days prior to the 
next scheduled visit.   
â€¢ For subjects with CD:  provide the diary 
and request subject completes this for 
each of the 7 consecutive days prior to the 
next scheduled visit.   
â€¢ Obtain blood samples for s erum chemi stry 
and hematology   
Note:  
If a subject has an ALP value â‰¤2x ULN, a 
further sample may be taken during the 
Screening period (at least 14 days after the initial sample was taken), and provided 
the mean ALP is â‰¥2x ULN, the subject 
will have met inclusion criterion 4 (ALP 
at Screening â‰¥2x ULN) â€¢ Record vital signs . 
â€¢ Perform a standard 12- lead 
electrocardiogram (ECG). 
â€¢ Perform hepatic ultrasound to  assess 
bile duct patency . 
â€¢ For subjects with UC:  provide the diary 
and request subject completes this the day 
prior to the Day [ADDRESS_21291] their 
symptoms since the Screening visit.  
â€¢ For subjects with CD:  provide the diary 
and request subject completes this for 
each of the 7 consecutive days prior to the 
Day 0 visit.   
â€¢ Obtain blood samples for s erum 
chemistry , hematology, and coagulation. 
Note:  
If a subject has an ALP value <2x ULN, a 
further sample may be taken during the 
Screening period (at least 14 days after the 
initial sample was taken), and provided 
the mean ALP is â‰¥2x ULN, the subject 
will have met inclusion criterion 4 (ALP 
at Screening â‰¥2x ULN) . 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 165 
Confidential and Proprietary    Section Original Text Revised Text  
Section 9.6.4 Day 0 
Procedures, Bullets 5, 6 & 15 â€¢ For subjects with UC:  obtain partial 
Mayo scor e (excluding endoscopy).  See 
Appendix B for details.  
â€¢ For subjects with CD:  complete CDAI 
assessments and assign CDAI score.  See 
Appendix F for details.  
â€¢ Subjects with UC or CD:   provide the 
diary and request  this is completed for 7 
consecutive d ays prior to their next 
scheduled visit.  â€¢ For subjects with UC:  obtain partial Mayo scor e (excluding endoscopy)  using 
the data from the diary card provided 
at the Screening visit.  See Appendix B 
for details.  
â€¢ For subjects with CD:  complete CDAI 
assessments using the data from the 
diary card provided at the Screening 
visit.  See Appendix F for details.  
â€¢ Subjects with UC or CD:   provide the 
appropriate  diary card  and request this is 
completed for the  7 consecutive days 
prior to their next scheduled visit (for 
subjects with CD) and the day prior to 
their next scheduled visit (for UC 
subjects) . 
Sections 9.6.4â€“
9.6.12, Sections 9.6.16â€“9.6.19, 9.6.21â€“9.6.22 Visit Procedures â€¢ Obtain blood samples for s erum 
chemistry and hematology â€¢ Obtain blood samples for serum 
chemistry, hematology, and coagulation  
Sections 9.6.5, 
9.6.6, 9.6.7, 9.6.8, 9.6.9 Visit 
Procedures â€¢ Subjects with UC or CD: provide the 
diary and request  this is completed for 7 
consecutive days prior to their next 
scheduled visit.  
 â€¢ Subjects with UC or CD:  provide the 
appropriate  diary card  and request this is 
completed for the  7 consecutive days 
prior to their next scheduled visit (for 
subjects with CD) and the day prior to 
their next scheduled visit (for UC 
subjects) .  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 166 
Confidential and Proprietary    Section Original Text Revised Text  
Sections 9.6.5, 
9.6.6, 9.6.8, 9.6.9 Visit Procedures  â€¢ Record the visit in IWRS  and dispense 
indicated bottles of IP  â€¢ Record the visit in IWRS  
Section 9.6.7 Week 12 (Titration Visit) Procedures â€¢ For sites and subjects participating in PK 
sampling:  obtain samples for PK analysis 
(see Section 11.5 for sampling schedule)  â€¢ For sites and subjects participating in PK 
sampling:  obtain samples for PK analysis (see Section 11.5 for sampling schedule) .  
Subjects undergoing PK sampling 
should take the currently assigned dose 
(ie, lower dose); the titrated dose should 
be taken by [CONTACT_22148]. 
Section 9.6.10 
Week 24/LTSE Day 1 Procedures ; 
Subjects Participating in the LTSE â€¢ Unblind the subjectâ€™s treatment allocation 
in IWRS (as detailed in the study 
reference manual)  and document the dose 
of OCA on which the subject will commence the LTSE.  â€¢ Unblind the subjectâ€™s treatment allocation in IWRS (as detailed in a separate trial 
document ) and document the dose of 
OCA on which the subject will commence the LTSE.  
Sections 9.6.10, 
9.6.11, 9.6.16, 9.6.17, 9.6.18, 9.6.19, 9.6.20, 9.6.21 Visit Procedures â€¢ Subjects with UC or CD: provide the 
diary and request  this is completed for 7 
consecutive days prior to their next 
scheduled visit.  â€¢ Subjects with UC or CD:  provide the 
appropriate  diary card  and request this is 
completed for the  7 consecutive days 
prior to their next scheduled visit (for 
subjects with CD) and the day prior to 
their next scheduled visit (for UC 
subjects) .  
Protocol 747-207 Version 5:   [ADDRESS_21292] will be contact[CONTACT_22149] 2 weeks after the start of the LTSE phase to 
assess safety.  
Sections 9.6.20, 
9.6.21 Visit 
Procedures â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry and hematology  
âˆ’ FGF-19  
âˆ’ CRP 
âˆ’ ELF markers and other analytes 
âˆ’ Plasma bile acids and C4  
âˆ’ Apolipoprotein and NMR lipoprotein 
panel 
âˆ’ Genetics study (if subject has consented 
to provide a sample for RNA analysis)  â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry , hematology, and 
coagulation  
âˆ’ FGF-19  
âˆ’ CRP 
âˆ’ ELF markers and other analytes 
âˆ’ Plasma bile acids and C4  
âˆ’ Genetics study (if subject has consented 
to provide a sample for RNA analysis)  
Section 9.6.22 
Follow-Up Visit: 
LTSE â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry and hematology 
âˆ’ Apolipoprotein and NMR lipoprotein 
panel â€¢ Obtain blood samples for: âˆ’ Serum chemistry and hematology 
Protocol 747-207 Version 5:   [ADDRESS_21293] Administration  Subjects will be instructed to begin dosing on the day after the Day 0 visit (ie, on Day 1).  IP  administration 
should occur at approximately the same time of day throughout the duration of the trial.  Subjects must be 
instructed to swallow the indicated number of tablets whole; they must not chew, divide, or crush the tablets. Subjects will be instructed to begin dosing on the day 
after the Day 0 visit (ie, on Day 1).  Investigational product administration should occur at 
approximately the same time of day throughout the duration of the trial.  Subjects must be instructed to swallow the indicated number of tablets whole  with 
water; they must not chew, divide, or crush the 
tablets. 
Section 10.4.[ADDRESS_21294] compliance and 
eligibility.  At the 12 Week V isit during the DB 
phase of the clinical study, subjects will receive 4 bottles of IP  (see Table 6).  At the [ADDRESS_21295] enrolled in the trial, general medical supportive measures should be provided, including observation and follow-up (eg, serum chemistry) as appropriate.  Due to the extensive enterohepatic recirculation of OCA it is likely that it 
will take s everal days before blood (and organ) 
concentrations of the drug will decrease.  Treatment with cholestyramine (eg, Questranâ„¢), colesevelam (eg, Welcolâ„¢) and other BAS  is recommended given 
that they should bind and eliminate the drug in feces.  The maximum dose of OCA that has been given to humans is [ADDRESS_21296] enrolled in the trial, general medical supportive measures should be provided, including observation and follow-up (eg, serum chemistry) as appropriate.  Due to the extensive enterohepatic recirculation of OCA it is likely that it 
will take several days before blood (and organ) concentrations of the drug will decrease.  Treatment with cholestyramine (eg, Questranâ„¢), colesevelam (eg, Welcolâ„¢) and other BAS  is recommended given 
that they should bind and eliminate the drug in feces.  
The Sponsor should be notified immediately in the 
Protocol 747-207 Version 5:   [ADDRESS_21297]â€™s medical records for SDV and retain the diary cards.  
Pertinent aspects of these data will be recorded in the CRF.  Disease-Specific Symptoms 
To assist sites with recording and calculating the 
partial Mayo score and the CDAI , subjects with UC 
will be asked to co mplete a diary the day prior to 
the next scheduled visit, recording details since their last visit; and subjects with CD should complete the diary in the [ADDRESS_21298] â€™s medical records for 
SDV and retain the diary cards.  Pertinent aspects of 
these data will be recorded in the CRF.   Data from 
the Screening period diary card will be recorded at Day 0. 
Section 11.5 Pharmacokinetics and Bile Acid Assessments Following collection of the fasted laboratory samples ([ADDRESS_21299]) at Week 12 and Week 24 (as noted in Table 1 ), subjects who are participating in 
the PK/bile acid assessment will each receive a single dose of their allocated IP with approximate ly [ADDRESS_21300]-dose.  The trial specific laboratory 
manual will include details of the volume of blood 
required to be drawn during each sampling timepoint as well as other logistical details and sample handling Following collection of the fasted laboratory samples ([ADDRESS_21301]) at Week 12 and Week 24 (as noted in Table 1 ), subjects who are participating in 
the PK/bile acid  assessment will each receive a 
single dose of their allocated investigational product with approximately 240 mL of water.  At 
Week 12, subjects will receive their dose assigned prior to titration (ie, the lower dose of 
investigational product).  Serial blood samples will 
be obtained for measurement of OCA and its 
conjugates prior to dosing and at 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 hours postdose.  The trial -specific 
laboratory manual will include details of the volume of blood required to be drawn during each sampling 
timepoint as well as other logistical details and 
Protocol 747-207 Version 5:   [ADDRESS_21302]-dose, subjects will be fed a standardized 
meal consisting of a Nutridrinkâ„¢ (Nutricia).  sample handling requirements.  
Subjects should not drink additional water for [ADDRESS_21303] .  
After approximately 1 hour postdose, subjects will be 
fed a meal replacement drink .  
Section [IP_ADDRESS] Severity of Pruritus  Pruritus was the most common AE seen in the Phase [ADDRESS_21304] 
experienced within â‰¤1 month of Screening , moderate 
to severe pruritus requiring systemic or enteral 
treatment, or any history of severe pruritus (as 
defined in Table 9 ) are excluded from participating  
this trial.  Pruritus was the most common AE seen in the Phase 
[ADDRESS_21305] 
experienced within â‰¤ 3 months of Screening , pruritus 
requiring systemic or enteral treatment are excluded 
from participating  in this trial.  
Section [IP_ADDRESS] 
Reporting of SAEs In agreeing to the provisions of this protocol, the investigator accepts all legal responsibilities for 
immediate reporting of SAEs to the medical monitor.  
The medical monitor for this trial is:  
Roya Hooshmand-Rad, MD, PhD 
Telephone:  +[PHONE_354] (Pacific time zone)  
Mobile:  +[PHONE_353] (Pacific time zone) 
Email: rhooshmand- [EMAIL_382]  
SAE Fax:  + [PHONE_352]  
SAE Email:  [EMAIL_380]   
All SAEs must be reported to the medical monitor 
immediately (ie, within 24  hours) after the 
investigator identifies the SAE.  SAEs are reported 
by [CONTACT_22150] (EDC) system.  Entering the SAE data into In agreeing to the provisions of this protocol, the Investigator accepts all legal responsibilities for 
immediate reporting of SAEs to the Sponsor .  
Immediate reporting implies within [ADDRESS_21306] be reported to the Sponsor.  SAEs are 
reported by [CONTACT_22151].  Entering the SAE data into the 
EDC system will automatically notify the Sponsor of the event.  In the event that the EDC system is 
inaccessible, an SAE may reported by : 
â€¢ E-mail to the SAE email address:  
[EMAIL_380]  
â€¢ Fax using a paper SAE report form:  
+[PHONE_352] 
â€¢ Telephone:  [PHONE_357] 6398 
Protocol 747-207 Version 5:   [ADDRESS_21307] also be completed in the EDC system as soon as the EDC system is accessible At a minimum the following information should be 
provided at the time of the initial report:  subject 
number and initials, a description of the event, at 
least one criterion classifying the event as serious and 
the name [CONTACT_22168].  
Additionally, judgment of causality by [CONTACT_22152](s).  Following the initial 
report, any additional information obtained by [CONTACT_22153].  Any supporting 
source documentation should be faxed to [PHONE_358] 
8521 or emailed to sae@interceptpharma .com as 
soon as possible. 
The investigator will assess whether the event is 
causally related to the IP.  The Sponsor, Intercept, 
will also assess whether the event is causally related 
to the IP in addition to assessing the overall safety 
profile of the IP .  The Sponsor will notify the 
appropriate regulatory agencies as well as all participating investigator s of investigational new 
drug (IND) s afety reports/expedited s afety reports If an SAE is reported by [CONTACT_12221], an SAE 
Report form must also be completed in the EDC 
system as soon as the EDC system is accessible.  At a minimum, the following information should be provided at the time of the initial report:   
â€¢ Subject number  
â€¢ Event term  
â€¢ At least 1 criterion classifying the event 
as serious  
â€¢ Name [CONTACT_22169]   
â€¢ Causal relationship to the 
investigational product 
The Investigator will assess whether the event is 
causally related to the investigational pr oduct.  The 
Sponsor, will also assess whether the event is 
causally related to the investigational product in 
addition to assessing the overall safety profile of the investigational product.  The Sponsor will notify the appropriate regulatory agencies as w ell as all 
participating Investigators of investigational new 
drug (IND) Safety Reports/Expedited S afety Reports 
that occur during the trial within the time frames required by [CONTACT_22105].  An SAE 
assessed with possible, probable, or definite ca usal 
relationship to the investigational product and unexpected according to the IB Reference Safety Information (RSI), is known as a suspected 
unexpected serious adverse reaction (S[LOCATION_003]R).  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 172 
Confidential and Proprietary    Section Original Text Revised Text  
that occur during the trial within the time frames 
required by [CONTACT_22105].  
The investigator is responsible for submitting 
information on IND s afety reports/expedited s afety 
reports received from the Sponsor to her/his local 
IRB/IEC.  Documentation of the submissions to 
IRBs/IEC and health authorities  must be retained in 
the appropriate trial file(s).  As instructed by [CONTACT_429], IND s afety reports/expedited s afety reports 
should be retained with the current IB.  The Investigator must report S[LOCATION_003]Rs using the 
SAE reporting method described above.  
Following the initial report, any addition al 
information obtained by [CONTACT_941] I nvestigator about 
the SAE must be reported promptly to the 
Sponsor in the same manner as described above for the initial SAE report.  Any supporting source document ation should be faxed to +[PHONE_352] 
or emailed to [EMAIL_380] as soon as possible.   
The Investigator is responsible for submitting Safety 
Reports/Expedited S afety Reports received from the 
Sponsor to her/his local IRB/IEC , in compliance 
with the local country requirements.  For the 
European Union, the Sponsor will notify the regulatory agencies and report S[LOCATION_003]Rs via the Eudra Vigilance database within 7 calendar days of a S[LOCATION_003]R involving death or a life- threatening 
S[LOCATION_003]R, and all other S[LOCATION_003]Rs within 15 calendar 
days.  Documentation of the submissions to 
IRBs/IEC s and health authorities  (as applicable) 
must be retained in the appropriate trial file(s).  As instructed by [CONTACT_1034], S afety Reports/Expedited 
Safety Reports should be retained in the appropriate 
Investigator site trial files, or with the IB.  
Section 12.1.5 Anticipated Serious Adverse Events Associated with PSC There are a number of events which are commonly 
associated with PSC and for the Sponsorâ€™s 
Regulatory reporting purposes, these events are considered to be â€˜Expectedâ€™ in this patient population 
and are listed below.   There are a number of events which are commonly 
associated with PSC and for the Sponsorâ€™s 
Regulatory reporting purposes, these events are considered to be â€˜Expectedâ€™ in this patient population 
and are listed in the IB.   
Protocol 747-207 Version 5:   [ADDRESS_21308]â€™s AE CRF.  Other supporting documents such as radiology reports, 
hospi[INVESTIGATOR_22046], when appropriate.  Additionally, upon request by [CONTACT_7195], 
the investigator should provide input into the SAE 
narrative and provide timely information to ensure 
prompt follow up and closure of the SAE report. The safety data recorded in the CRF represent the 
official record of all AEs and SAEs reported in the trial.  The Investigator  should comply with requests 
by [CONTACT_22154]â€™s AE CRF.  Other supporting documents such as radiology reports, 
hospi[INVESTIGATOR_8838] , and autopsy reports 
should also be provided, when appropriate.  
Additionally, upon request by [CONTACT_19457], the 
Investigator  should provide input into the SAE 
narrative and provide timely information to ensure prompt follow -up and closure of the SAE report. 
Section 12.1.[ADDRESS_21309]-Trial SAEs  If an investigator becomes aware of an SAE that may 
be attributable to the IP  at any time after the end of 
the trial, the  medical monitor should be notified 
immediately (ie, within 24 hours).  If an Investigator becomes aware of an SAE that may 
be attributable to the investigational product  at any 
time after the end of the trial, the Sponsor should be 
notified immediately (ie, within 24 hours). 
Section 12.1.8 Follow-Up of AEs and SAEs  No Text All subjects showing possible drug -induced liver 
injury should be followed until all abnormalities 
return to normal or to the baseline state.  Drug -
induced liver injury may develop or progress even 
after the causative drug has been stopped.  Results should be recorded in the CRF.  Note that longer 
follow-up can sometimes reveal an off -drug 
repetition of what had appeared to be drug -
induced liver injury, indicating that liver injury was related to underlying liver disease.  
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 174 
Confidential and Proprietary    Section Original Text Revised Text  
Section 12.2.5 
Laboratory Assessments All subjects with laboratory tests containing clinically 
significant abnormal values are to be followed regularly until the values return to normal ranges; 
until a valid reason, other than test -article related AE, 
is identified; or until further follow -up is deemed 
medically unnecessary.   Subjects testing positive for 
urine drug sc reen will be excluded from the trial.  
Urine based Î²-hCG pregnancy tests will be 
performed in female subjects of childbearing 
potential per protocol specified visits.  If a urine 
pregnancy test is positive, a serum pregnancy test must be performed to confirm the result.  If positive, 
the Sponsor must be notified and the subject will be 
followed as outlined in Section  12.1.9 until 
pregnancy outcome.  All subjects with laboratory tests containing clinically significant abnormal values are to be followed regularly until the values return to normal ranges; 
until a valid reason, other than test -article related AE, 
is identified; or until further follow -up is deemed 
medically unnecessary.  
Urine based Î²-hCG pregnancy tests will be performed in female subjects of childbearing potential per protocol specified visits.  Additionally, in 
accordance with local country or site requirements, additional urine pregnancy tests 
may be performed.   If a urine pregnancy test is 
positive, a serum pregnancy test must be performed 
to confirm the result.  If positive, the Sponsor must be 
notified and the subject will be followed as outlined 
in Section  12.1.9 until pregnancy outcome.  
Section 13.6.1 
Interim Analysis An unblinded interim analysis will be conducted after 
approximately 50% of subjects have completed the 
initial 12-weeks of blinded treatment.  The trial will 
not be terminated early for futility.  The interim 
analysis will compare at Week 12, the same variable 
as will be analyzed for the primary endpoint, the change from Baseline in ALP, between OCA 
treatment groups and placebo.  No adjustments to the 
alpha level will be made.  An unblinded interim analysis will be conducted after 
approximately 50% of subjects have completed the 
initial 12-weeks of blinded treatment.  The trial will 
not be terminated early for futility.  The interim 
analysis will compare at Week 12, the same variable 
as will be analyzed for the primary endpoint, the change from Basel ine in ALP, between OCA 
treatment groups (1.5 mg and 5 mg)  and placebo 
using an analysis of covariance (ANCOVA) model with fixed effects for treatment group and 
randomization strata and Baseline as a covariate .  
No adjustments to the alpha level will be made. 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 175 
Confidential and Proprietary    Section Original Text Revised Text  
Section 13.6.2 D ata 
and Safety 
Monitoring Committee  An independent DSMC will review safety data at 
periodic intervals from this trial.   The DSMC  
includes internationally recognized hepatologists, 
pharmaceutical physicians and statistician (s). All 
have considerable experience with clinical trial 
conduct and DSMCs , prior to joining the OCA 
DSMC.  Candidates are screened for conflicts of interest and any candidate found to have such a conflict is not offered membership.  Conflicts of 
interest are assessed regularly, and if members are 
found to have a new conflict of interest they would be 
replaced.  The DSMC meets approximately quarterly 
at scheduled meetings and ad hoc meetings are 
convened, as appropriate.  The DSMC reviews all Intercept sponsored Phase [ADDRESS_21310] 
every 6 months .  The DSMC  includes internationally 
recognized hepatologists, pharmaceutical physicians and statistician (s).  All have considerable experience 
with clinical trial conduct and DSMCs, pr ior to 
joining the OCA DSMC .  Candidates are screened for 
conflicts of interest and any candidate found to have 
such a conflict is not offered membership.  Conflicts 
of interest are assessed regularly, and if members are found to have a new conflict of interest they will be 
replaced.  The D SMC meets approximately quarterly 
at scheduled meetings, and ad hoc meetings are convened, as appropriate.  The DSMC reviews all 
Intercept-sponsored Phase 2 and 3 studies.  Members 
of the DSMC will no t be allowed to participate as 
Investigator s in this trial and will not otherwise 
consult for the Sponsor.   
SAE information will be provided to the DSMC on 
an ongoing basis as SAEs occur.  Adhoc (closed) 
DSMC meetings for review of unblinded data from subjects who experience SAEs, as requested 
by [CONTACT_6802] , will be arranged.  The DSMC will 
review data on a periodic basis to ensure the safe and 
proper treatment of subjects.  Based on review of 
these data, the DSMC will advise the Sponsor on the 
validity and scientific merit of continuing the trial.   
Protocol 747-207 Version 5:   [ADDRESS_21311] their origin in the Declaration of Helsinki (Seoul Revision, 2008) and are consistent 
with ICH/GCP, applicable regulatory requirements.  The trial will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki ( 64
th WMA General Assembly, Fortaleza, 
Brazil, October 2013) and are consistent with 
ICH/GCP, applicable regulatory requirements.  
Section 17.[ADDRESS_21312] or discovered by [CONTACT_22155].  In agreeing to the provisions 
of this protocol, the Investigator accepts all legal 
responsibilities for immediate reporting of SAEs to 
the Sponsor . 
Section 18 
Publication Policy  The Sponsor intends to publish the results of all of 
the clinical trials that it sponsors consistent with the 
Declaration of Helsinki ( Seoul Revision 2008, 
[http://www.wma.net/en/30publications/10policies/b3
/index.html, accessed May 22, 2013] ). Consistent 
with the recommendations of the editors of several 
leading medical journals, the International Committee of Medical Journal Editors (ICMJE), authorship of 
publications resulting from Intercept sponsored 
studies should fairly recognize the activities of those that have made a significant contribution to the trial 
(http://www.icmje.org/ethical_1author.html, accessed 
May 22, 2013).  Thus, it is anticipated that authorship will reflect the contribution made by [CONTACT_22156], the Investigator s, and others involved, 
such as statisticians.   The Sponsor intends to publish the results of all of 
the clinical trials that it sponsors consistent with the 
Declaration of Helsinki ( 64th WMA General 
Assembly, Fortaleza, Brazil, October 2013). 
Consistent with the recommendations of the editors 
of several leading medical journals, the International 
Committee of Medical Journal Editors (ICMJE), authorship of publications resulting from Intercept 
sponsored studies should fairly recognize the 
activities of those that have made a significant contribution to the trial 
(http://www.icmje.org/ethical_1author.html, accessed 
May 22, 2013).  Thus, it is anticipated that authorship will reflect the contribution made by [CONTACT_22156], the Investigator s, and others involved, 
such as statisticians.   
Protocol 747-207 Version 5:   [ADDRESS_21313] with the farnesoid X receptor (FXR) agonist 
INT-747 restores hepatic enos activity and lowers 
portal pressure in cirrhotic rats. Hepatology. 
2009;50(4 Supplement):336A- 7A. Chapman R. Primary sclerosing cholangitis. 
Autoimmune Liver Disease. 2011; 39(10):558-591. 
Mookerjee RP, Mehta G, Balasubramaniyan V, 
et al, Hepatic dimethylarginine -
dimethylaminohydrolase1 is reduced in cirrhosis 
and is a target for therapy in portal hypertension. 
J Hepatol. 2015 Feb; 62(2):325-331. 
Appendix A List of 
Planned Laboratory Analytes Hematology 
prothrombin time (PT and INR) 
partial thromboplastin time (PTT)  Coagulation Parameters 
prothrombin time (PT and INR)  
partial thromboplastin time (PTT) 
 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 178 
Confidential and Proprietary    APPENDIX I. PROTOCOL VERSION 4  â€“ SUMMARY OF CHANGES  
Background:   Protocol 747-207 has been prepared as a Phase 2 trial to evaluate the potential 
clinical benefit of obeticholic acid (OCA) in PSC.  
Rationale:   Version 4 of the protocol includes changes to clarify eligibility criteria.  
Summary of Changes:   The following revisions were made to the Protocol Version 3 in 
Protocol Version 4.  (Note:  Deletions are stricken and additions are indicated in bol d font.)  
Minor grammatical changes are not detailed unless included with other changes (eg, 
capi[INVESTIGATOR_602], punctuation).
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 179 
Confidential and Proprietary    Section Original Text (Version 3) Revised Text (Version 4) 
Title Page  Original Version:  06 Jun 2014 
Version 2:  24 September 2014 Version 3:  [ADDRESS_21314] 2015 Original Version:  06 Jun 2014 Version 2:  24 September 2014 Version 3:  [ADDRESS_21315] 2015 
Version 4:  08 February 2016 
Synopsis, 
ExclusionCriterion # 5 Clinical evidence of dominant stricture ( as evidenced 
by [CONTACT_22157] 12 months prior to Day 0) or 
current biliary stent  Current clinical evidence of dominant stricture s 
that are considered clinically relevant in the 
opi[INVESTIGATOR_22047], 
ExclusionCriterion #6 Current cholec ystitis or gallstones (identified by [CONTACT_22158]) Current cholecystitis or evidence of current 
biliary obstruction due to gallstones. Asymptomatic gallstones that are not 
considered a safety risk in the opi[INVESTIGATOR_22048], 
ExclusionCriterion #10 Known Gilbertâ€™s syndrome or elevations in 
unconjugated (indirect) bilirubin >ULN Known Gilbertâ€™s syndrome or history  of 
elevations in unconjugated (indirect) bilirubin >ULN or unconjugated (indirect) bilirubin 
>ULN at Screening  
8.3. Subject Exclusion 
Criteria, ExclusionCriterion #5 Clinical evidence of dominant stricture ( as evidenced 
by [CONTACT_22159] 12 months prior to Day 0) or 
current biliary stent  Current clinical evidence of dominant stricture s 
that are considered clinically relevant in the 
opi[INVESTIGATOR_22049] 
8.3. Subject Exclusion 
Criteria, ExclusionCriterion #6 Current cholecystitis or gallstones (identified by [CONTACT_22158]) Current cholecystitis or evidence of current 
biliary obstruction due to gallstones. Asymptomatic gallstones that are not 
considered a safety risk in the opi[INVESTIGATOR_22050] 747-207 Version 5:   18 Mar 2016 
 Page 180 
Confidential and Proprietary    Section Original Text (Version 3) Revised Text (Version 4) 
8.3. Subject Exclusion 
Criteria, 
ExclusionCriterion 
#10 Known Gilbertâ€™s syndrome or elevations in 
unconjugated (indirect) bilirubin >ULN  Known Gilbertâ€™s syndrome or history  of 
elevations in unconjugated (indirect) bilirubin >ULN or unconjugated (indirect) bilirubin 
>ULN at Screening 
12.2.5 Laboratory 
Assessments  Lp(a)  
Appendix A  Lp(a)  
Appendix A  Samples will be assessed for the presence/absence of 
Lipoprotein X   
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 181 
Confidential and Proprietary    APPENDIX J. PROTOCOL VERSION 5 â€“ SUMMARY OF CHANGES  
Background:   Protocol 747-207 has been prepared as a Phase 2 trial to evaluate the potential 
clinical benefit of obeticholic acid (OCA) in P SC. 
Rationale:   Version 5 of the protocol includes changes to clarify eligibility inclusion criterion #3 
and #9, investigational product storage instructions , clarification for titration adjustments , and 
clarification for summarizing ECG results.   The inte ntion for inclusion criterion #3 is to define 
the evidence required for diagnosis of PSC, which is, as already stated in inclusion criterion #3, 
by [CONTACT_22160].  The requirement for a mandatory 12-month 
cholangiogram to diagnose PSC was included in error in the previous version.  Inclusion 
criterion # [ADDRESS_21316] examples of barrier methods in the protocol. 
Summary of Changes:   The following revisions were made to Protocol Version 4 in Protocol 
Version 5.  (Note:  Deletions are crossed out and additions are indicated in bold font.)  Minor 
grammatical changes are not detailed unless i ncluded with other changes (eg, capi[INVESTIGATOR_602], 
punctuation). 
Protocol 747-207 Version 5:   18 Mar 2016 
 Page 182 
Confidential and Proprietary    Section Original Text (Version 4) Revised Text (Version 5) 
Title Page  Original Version:  06 June 2014 
Version 2:  24 September 2014 
Version 3:  [ADDRESS_21317] 2015 
Version 4:  08 February 2016 Version 5:  18 March 2016 
 
Synopsis, Methodology  Doses of OCA should be titrated as follows, unless 
clinically indicated:  1.5 mg to 3 mg, 3 mg to 5 mg, and 5 mg to 10 mg. Doses of OCA should be titrated as follows, unless 
clinically indicated:  1.5 mg to 3 mg, 3 mg to 5 mg, and 5 mg to 10 mg.  Intermediate doses (eg, 6.5 
mg) may be considered as deemed appropriate by 
[CONTACT_737].   Dose should not exceed 10 mg .
 
Synopsis, Inclusion 
Criterion #[ADDRESS_21318] a diagnosis of PSC (based on cholangiography at any point in time) and must have 
had a cholangiography within the past [ADDRESS_21319] a diagnosis of PSC (based on 
cholangiography at any point in time). 
 
Synopsis, Inclusion 
Criterion # 9 â€¢ Double barrier method, ie, (a) condom (male or 
female) or (b) diaphragm, with spermicide; or  Barrier method, ie, (a) condom (male or female) 
with spermic ide or (b) diaphragm with 
spermicide; or  
Synopsis, 
Investigational Product, Dosage and Mode of Administration  LTSE Phase:  All subjects will receive open -label OCA 
at a starting dose that is dependent upon their dose at 
completion of DB phase, as well as safety and 
tolerability.  Doses may be 1.5 mg, 3 mg, 5 mg, or 10 
mg, ie, 1 or 2 tablets, once daily.   LTSE Phase:  All subjects will receive open -
label OCA at a starting dose that is dependent 
upon their dose at completion of DB phase, as well as safety and tolerability.  Doses may be 
1.5 mg, 3 mg, 5 mg, or 10 mg, ie, 1 or 2 tablets, 
once daily.  Intermediate doses (eg, 6.5 mg) 
may be considered as deemed appropriate by 
[CONTACT_737].   Dose should not exceed 
10 mg. 
 
Synopsis, Safety 
Analyses Laboratory  parameters , vital signs , and 
electrocardiograms (ECGs)  will be summarized by 
[CONTACT_22161] 747-207 Version 5:   18 Mar 2016 
 Page 183 
Confidential and Proprietary    Section Original Text (Version 4) Revised Text (Version 5) 
and at each scheduled post -Baseline visit .  The change 
from Baseline will also be summarized.   scheduled post -Baseline visit .  The change from 
Baseline will also be summarized.  
Electrocardiograms (ECGs) will be 
summarized by [CONTACT_22162].  The shift from 
baseline will also be summarized.   
7.4.2, LTSE Phase  â€¦Doses of OCA should be titrated as follows, unless 
clinically indicated:  1.5 mg to 3 mg, 3 mg to 5 mg, and 5 mg to 10 mg.   Doses of OCA should be titrated a s follows, 
unless clinically indicated:  1.5 mg to 3 mg, 3 mg to 5 mg, and 5 mg to 10 mg.  
Intermediate doses (eg, 6.5 mg) may be 
considered as deemed appropriate by [CONTACT_3786].   Dose should not exceed [ADDRESS_21320] Inclusion 
Criteria, Inclusion 
Criterion #[ADDRESS_21321] a diagnosis of PSC (based on 
cholangiography at any point in time) and must have 
had a cholangiography within the past [ADDRESS_21322] a diagnosis of PSC (based on 
cholangiography at any point in time) . 
8.[ADDRESS_21323] Inclusion 
Criteria, Inclusion 
Criterion # 9 â€¢ Double barrier method, ie, (a) condom (male or 
female) or (b) diaphragm, with spermicide; or  Barrier method, ie, (a) condom (male or female) 
with spermicide  or (b) diaphragm with 
spermicide; or  
10.[ADDRESS_21324] should be stored in the 
containers in which they are received from the Sponsorâ€™s supplier, at controlled room temperature , and 
protected from excess humidity . The investigational product should be stored in 
the containers in which it is received from the 
Sponsorâ€™s supplier, at 15 Â°C to 25Â°C. 
12.2.4, 
Electrocardiogram  These ECGs must be clearly labeled with the  subjectâ€™s 
initials, Subject ID number, date and time . These ECGs must be clearly labeled with the 
Subject ID number, date and time . 
13.5.3, Additional 
Safety Analyses  Additional safety assessments include vital signs and 
ECGs.  Vital signs and ECGs will be summarized by 
[CONTACT_22163] -Baseline visit.  The change 
from Baseline will also be summarized.   Additional safety assessments include vital signs 
and ECGs.  Vital signs will be summarized by [CONTACT_22164] -Baseline 
visit.  The change from Baseline will also be summarized.  ECGs will be summarized by 
[CONTACT_22165] 747-207 Version 5:   18 Mar 2016 
 Page 184 
Confidential and Proprietary    Section Original Text (Version 4) Revised Text (Version 5) 
visit.  The shift from baseline will also be 
summarized.   
 